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Introduction: Sensory inputs from the kidney induce sympatho-excitation, and are 
integrated in brainstem regions receiving protective sensory inputs from high- and 
low-pressure baroreceptors. Blunted baroreflex control of renal sympathetic nerve 
activity (RSNA) was revealed in hypertension models that involve renal inflammation. 
Suppression of inflammation restored the normal baroreflex control of RSNA in some 
of these models, suggesting that renal inflammation impairs baroreflex control of 
blood pressure through the disruption of renal afferent nerve signalling. Renal 
oxidative stress and inflammation are evident following exposure to chronic 
intermittent hypoxia (CIH) in addition to blunted baroreflex control of heart rate. 
However, little information is available about the baroreflex control of RSNA. In 
addition, because kidney injury disrupts renal afferent nerve signalling, changes in the 
reno-renal reflex control of sympathetic outflow may occur following exposure to 
CIH. Therefore, understanding the stage at which baroreflexes and the reno-renal 
reflex are altered is required to explore the mechanisms that contribute to the early 
CIH-induced sympathetic hyperactivity and the onset of hypertension. 
Methods: Following exposure to CIH or normoxia, baroreflexes were examined under 
anaesthesia. Kidney excretory function was measured during the assessment of low-
pressure baroreflex by volume expansion (VE). Baroreflexes were assessed before and 
after blockade of renal TRPV1 channels. Moreover, to investigate if the excitatory 
reno-renal reflex contributes to sympathetic over-activity in CIH, renal afferent nerves 
located in the renal pelvic wall were chemically stimulated by bradykinin and 
capsaicin, or inhibited by bradykinin receptor type 1 (BK1R) and/or 2 (BK2R) 
blockers, and cardiovascular and RSNA responses were measured. Renal histology, 
inflammation and oxidative stress biomarkers were assessed.  
Results: CIH-exposed rats were hypertensive with elevated RSNA, with no evidence 
of glomerular hypertrophy or renal inflammation and oxidative stress. Water and 
sodium excretion were increased following CIH exposure. However, diuresis and 
natriuresis during VE were attenuated in CIH-exposed rats despite preservation of the 
progressive decrease in RSNA during VE, suggesting that altered kidney excretory 
function in CIH was independent of neural control. The increase in atrial natriuretic 
xix 
 
peptide during VE was attenuated in CIH. Assessment of the high-pressure baroreflex 
revealed decreased slope in CIH-exposed rats with substantial hypertension, but not 
when hypertension was modest. Diuresis and natriuresis during VE were enhanced in 
CIH-exposed and sham rats following the intra-renal blockade of TPRV1 channels, 
suggesting a role for renal TRPV1 in the control of renal excretory function. However, 
TRPV1 protein expression in the kidney was unchanged and TRPV1 activation by 
intra-renal pelvic infusion of capsaicin induced a similar sympatho-excitation in sham 
and CIH-exposed rats. Moreover, sympatho-excitation during intra-renal pelvic 
infusion of bradykinin was suppressed in CIH-exposed rats. This was associated with 
53% decreased expression of BK2R in the renal pelvic wall of CIH-exposed rats 
compared with sham rats. Inhibition of renal bradykinin receptors did not affect 
cardiovascular parameters or RSNA in sham and CIH-exposed rats.  
Conclusion: Our findings show no evidence of an excitatory reno-renal reflex driving 
sympathetic hyperactivity and the onset of hypertension in CIH. This was revealed by 
the absence of renal pathology despite the presence of a hypertensive phenotype. 
Moreover, the findings indicate suppressed rather than exacerbated sympatho-
excitation in CIH-exposed rats in response to bradykinin. In addition, the baroreflex 
control of RSNA was maintained in CIH-exposed rats with modest hypertension, 
indicating that blunted baroreflex control is not obligatory for the onset of 
hypertension in CIH. Overall, renal injury appears to develop after the progressive 
elevation of blood pressure, although it may also develop in circumstances of exposure 
to severe CIH, suggesting that chronic kidney disease, frequently observed 
concomitant with obstructive sleep apnoea (OSA), may be mitigated if OSA is 
controlled at an early stage. 
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Chapter 1. Introduction: The role of renal afferent signalling 
in baroreflex regulation and sympathetic activity: Potential 
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NF-κB Nuclear factor kappa B 
NK1 Neurokinin 1 receptor 
NO Nitric oxide 
eNOS Endothelial nitric oxide synthase 
NOX NADPH oxidase 
NTS Nucleus tractus solitarius 
O2
.- Superoxide 
OSA Obstructive sleep apnoea 
PG Prostaglandin 
PKA Phosphokinase A 
PKC Phosphokinase C 
PLC Phospholipase C 
PVN Paraventricular nucleus 
RAAS Renin-angiotensin-aldosterone system 
RBF Renal blood flow 
ROS Reactive oxygen species 
RPP Renal perfusion pressure 
RSNA Renal sympathetic nerve activity 
RVC Renal vascular conductance 
RVLM Rostral ventrolateral medulla 
RVR  Renal vascular resistance 
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SFO Subfornical organ 
SHR Spontaneous hypertensive rat 
sLTF Sensory long-term facilitation 
SNA Sympathetic nerve activity 
SNS Sympathetic nervous system 
SOD Superoxide dismutase 
SON Supraoptic nucleus 
SP Substance P 
TGF-β Transforming growth factor- beta 
TNF-α Tumour necrosis factor- alpha 
TRPV1 Transient receptor potential cation channel subfamily 





















1.1. Chronic intermittent hypoxia as a model for obstructive sleep 
apnoea-induced hypertension 
Individuals with sleep apnoea experience periodic interruption of ventilation during 
sleep epochs accompanied by arterial hypoxaemia, hypercapnia and sleep 
fragmentation. Recurrent apnoeas (pauses in breathing) can arise from occlusions of 
the upper airway giving rise to obstructive sleep apnoea (OSA) or periodic suppression 
of central respiratory drive causing central sleep apnoea (150, 281). During apnoea, 
hypoxaemia stimulates arterial chemoreceptors in the carotid bodies, which transduce 
afferent signals to hindbrain regions primarily to nucleus tractus solitarius (NTS) 
which are then conveyed to the rostral ventrolateral medulla (RVLM), nucleus 
ambiguous and dorsal and ventral respiratory groups located in the medulla oblongata 
(91). Central integration of these afferent inputs enhances sympathetic discharge to 
peripheral organs (221). Reflex sympatho-excitation increases cardiac output, which 
facilitates oxygen supply to essential organs. Individuals with OSA experience 
nocturnal hypertension (159). Hypertension accompanied by elevated sympathetic 
nervous activity persists even during normal oxygenation giving rise to diurnal 
hypertension (248, 318, 376). Indeed, OSA is an independent risk factor for 
hypertension and is associated with high incidence of cardiovascular co-morbidities 
such as ischaemic heart disease, heart failure, arrhythmia and angina (119, 177, 317). 
Clinical trials addressing the relationship between OSA and hypertension estimate that 
30-70% of individuals with OSA are hypertensive (12). The combined evidence points 
to a strong causal relationship between OSA and hypertension.  
Exposure to recurrent intermittent hypoxia (IH) of varying severity and duration is 
considered the primary stimulus causing autonomic dysregulation in OSA. 
Furthermore, experimental animal models of IH consistently demonstrate persistent 
increases in arterial blood pressure (74, 98, 217, 226, 258, 273, 318, 392, 415). Indeed, 
animal models of chronic IH (CIH) are widely used in the study of pathophysiological 
processes associated with sleep apnoea. Exposure of animals to IH increases 
sympathetic outflow as evidenced by observations of IH-induced increases in muscle, 
renal, and splanchnic sympathetic nerve activity and increased vascular tone (251, 
269, 324, 332). Ganglion blockade results in a greater reduction of blood pressure in 
CIH-exposed animals compared with controls, which highlights that sympatho-
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excitation is the primary cause of  high blood pressure in this model (416). This was 
revealed by increased catecholamine release from the adrenal medulla, the major end 
organ of the SNS (279). Duration of exposure to CIH has a major impact on blood 
pressure, which correlates with elevated sympathetic activity and increased levels of 
catecholamine. For a given duration, increased hypoxia intensity or increased number 
of hypoxia cycles also correlate with increased blood pressure (15).  
Exposure to CIH of mild severity (9 cycles/hr) for 3 days resulted in enhanced basal 
sensory activity of carotid bodies during normoxic breathing phase (i.e. during 
wakefulness) that reached its maximum following 10 days of exposure (271). 
Meanwhile, elevated blood pressure was shown after 5 days of exposure to a severe 
protocol of CIH (48 cycles/hr), indicating that augmented firing of carotid bodies are 
involved in the initiation of hypertension (202). Consistent with this, selective ablation 
of carotid bodies prevented blood pressure elevation and catecholamine release from 
the adrenal medulla (279). Meanwhile, deceased cardiac baroreflex sensitivity was 
revealed after 17 days of exposure to the same CIH protocol (202). Furthermore, three 
days of exposure to a severe protocol of CIH (30 cycles/hr) was associated with 
increased level of endothelial injury biomarkers (342), suggesting endothelial 
dysfunction to occur during the early phase of CIH-induced hypertension. In addition, 
decreased renal oxygen tension was shown after 14 days of exposure to a moderate 
protocol of CIH (12 cycles/hr) (258). Exposure to 3 weeks of CIH was associated with 
central neural inflammation (263), while upregulation of central N-methyl-D-aspartate 
receptors and enhanced neuronal excitability were shown after 7 days of exposure to 
CIH (73). Overall, this indicates that a variety of CIH protocols utilizing different 
hypoxic durations and intensities evoke different mechanisms associated with the 
development and maintenance of hypertension, which are related to IH itself and 
indirectly related to sympathetic hyperactivity (15).  
Similar to ischemia-reperfusion, during the reoxygenation phase of IH, reactive 
oxygen species (ROS) are produced (280). ROS are detected in the carotid bodies 
following exposure to CIH and are associated with augmented firing of carotid bodies 
and enhanced respiratory drive (282, 283). Moreover, increased ROS generation 
following exposure to IH was revealed centrally and in the adrenal medulla, causing 
increased levels of plasma catecholamine and increased sensitivity of adrenal medulla 
to hypoxia (283). Consistent with this, the administration of a superoxide dismutase 
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(SOD) mimetic prevented blood pressure elevation and abolished the enhanced 
activity of carotid bodies (282). The cellular mechanism involved in ROS generation 
during exposure to IH is related to the inhibition of the mitochondrial complex I of the 
electron transport chain and the upregulation of NADPH oxidase (NOX), mainly 
NOX2 (283). Additionally, exposure to IH was shown to be associated with an 
increase in the expression of hypoxia-inducible factor (HIF)-1 and a decrease in the 
expression of HIF-2, where HIF-1 encodes the transcription of oxidative enzymes and 
HIF-2 regulates the expression of anti-oxidants (316). HIF is composed of hypoxia 
sensitive α subunit and constitutively expressed β subunit. Proline hydroxylases 
require aerobic conditions to hyroxylate HIF-1α subunit and degrade HIF 
heterodimers (316). Therefore, exposure to IH stabilizes HIF-1 while HIF-2 
degradation is enhanced through the activation of calpain proteases (316). This 
imbalance in HIF-1/HIF-2 ratio eventually lead to oxidative dysregulation, NOX 
activation, loss of SOD and ROS generation. In support of this, a mouse model of 
partial HIF-2α+/- deficiency had augmented activity of carotid bodies and breathing 
instability in addition to decreased expression of SOD (316). This was normalized 
when HIF-2α+/- mice were treated with a superoxide scavenger. Meanwhile, mice with 
partial HIF-1α+/- deficiency that were exposed to IH had no increased levels of ROS 
and catecholamine, and the basal activity of carotid bodies was not augmented (274). 
Overall, pathophysiological changes induced by IH are related to oxidative stress and 
the generation of ROS. This is mainly caused by the stabilisation of HIF-1 followed 
with the upregulation of NOX, in conjunction with the degradation of HIF-2 followed 










1.2. Baroreflex control of blood pressure 
Under physiological conditions, short-term changes in blood pressure stimulate 
mechanoreceptors known as high- and low-pressure baroreceptors (163, 260). In 
response to an increase in blood pressure, sensory inputs from both class of receptors 
are integrated in the NTS in the dorsal medulla of the brainstem, with resultant 
inhibition of the sympathetic nervous outflow and activation of the parasympathetic 
nervous system to restore blood pressure to normal (10).  
 
1.2.1. Anatomy and physiology of high-pressure baroreceptors 
High-pressure baroreceptors are stretch-sensitive receptors classified, according to 
their location, into aortic baroreceptors (in the tunica adventitia of the aortic arch) and 
carotid sinus baroreceptors, which are found in the wall of a dilation in the internal 
carotid artery superior to the carotid bifurcation (162). They are also classified based 
on nerve fibre myelination as type 1 (A-fibres) and type 2 (C-fibres) baroreceptors. 
These receptors stimulate a feedback mechanism that buffers short-term fluctuations 
of arterial blood pressure (55, 162, 350). Type 1 receptors, but not type 2 receptors, 
are involved in the acute resetting mediated by the fast conducting A-fibres (350). 
Meanwhile, some studies have highlighted a significant role for high-pressure 
baroreflex in the long-term regulation of blood pressure (291, 350).  
Changes in mean arterial pressure (MAP) and/or pulse pressure causes an alteration in 
transmural pressure and dimensional change in the arterial wall (162). Consequently, 
baroreceptors send afferent information to the brainstem through the glossopharyngeal 
nerve originating from carotid sinus nerve and/or through the vagus nerve from the 
aortic arch. Inputs are transmitted to the NTS of the dorsal medulla, which acts as a 
relay centre of the baroreflex arc and sends inputs to the paraventricular nucleus 
(PVN), which is one of the sites of renal afferent nerve projections. Neurons of the 
NTS send inputs to other regions responsible for autonomic nervous system and 
cardiovascular regulation, including the caudal ventrolateral medulla (CVLM) and 
subsequently, the RVLM; both involve preganglionic sympathetic neurons. The NTS 
is also connected to the nucleus ambiguous, which comprises parasympathetic 
preganglionic neurons that synapse with postganglionic parasympathetic nerves to the 
9 
 
heart (Figure 1.1). Afferent discharges from the baroreceptors to the NTS cause 
reciprocal changes in sympathetic and parasympathetic outputs to maintain stable 
blood pressure (162, 291).   
 
Figure 1. 1. Central and peripheral circuits of the baroreflex arc. Figure illustrates 
afferent signals arising from carotid sinus and aortic arch baroreceptors. Signals are 
transmitted through the glossopharyngeal nerve (IX) and vagus nerve (X) to medullary 
regions followed by modulation of efferent outputs (sympathetic and parasympathetic) 
to different organs. NTS, nucleus tractus solitarius; RVLM, rostral ventrolateral 





1.2.2. High-pressure baroreflex control of heart rate 
An increase in blood pressure activates the baroreflex feedback mechanism, which 
causes an increase in the efferent preganglionic parasympathetic discharge. This is 
followed by an increase in the firing of vagal nerve innervating the sinoatrial node. 
This is accompanied by an activation of the CVLM neurons and an inhibition of the 
RVLM neurons, which decreases the activity of pre-sympathetic neurons projecting 
to the spinal cord (Figure 1.1). It is worth mentioning that the heart rate response to 
vagus nerve firing (latency period of 200-600ms) is quicker than its response to the 
sympathetic outflow (latency period of 2-3s). This is due to the variability of the 
adrenergic and cholinergic postsynaptic mechanisms involved (162). However, 
response of heart rate to baroreflex-mediated alterations in the sympathetic and 
parasympathetic arms of the autonomic nervous system is likely different to responses 
seen in other organs. This has been reported in previous studies where the RSNA 
response to high-pressure baroreflex is notably different from heart rate response in 
the same physiological model as in exercise (243), or pathophysiological models, such 
as in renal wrap Grollman and two-kidney one-clip hypertension models (133, 363). 
In rats, an increase in the maximum gain of the RSNA baroreflex was observed during 
exercise. However, no change in the baroreflex gain of heart rate was observed (243). 
In renal wrap Grollman hypertension, baroreflex regulation of RSNA after 
development of hypertension was maintained, but the baroreflex sensitivity of heart 
rate was decreased (363). Moreover, in rabbits, a renal hypertension model exhibited 
attenuated baroreflex regulation of heart rate and a normal baroreflex regulation of 
lumbar sympathetic nerve activity (LSNA) (363). There are different reasons for the 
differential baroreflex regulation between the kidney and the heart. For example, heart 
rate results from compound changes in the parasympathetic and the sympathetic 
neuronal activities. Meanwhile, the kidney is mainly controlled by the sympathetic 
nervous system (SNS) with no evidence of parasympathetic innervation. On the other 
hand, in the two-kidney one-clip model in rabbits, cardiac sympathetic nerve activity 
(CSNA) was measured instead of heart rate during baroreflex function assessment. 
However, the CSNA response to baroreflex was comparable to control animals, while 
an increase in the baroreflex gain of RSNA was observed (133). This suggests 
differential responses of sympathetic nerves in hypertension, which could be due to 
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dissimilar alteration of interpretation of afferent baroreflex inputs and/or alteration in 
descending medullary neurons accompanied with regional variability in the delivery 
of sympathetic signals. In support of this notion, it was shown that the PVN, a region 
involved in the integration of baroreceptor afferent information, has a greater influence 
on RSNA compared with CSNA in normal and heart failure sheep (294). Nevertheless, 
the vagal parasympathetic segment of the baroreflex loop is overlooked in the 
literature.  
 
1.2.3. High-pressure baroreflex control of RSNA 
The implication of baroreflex regulation of RSNA and renal function in long-term 
blood pressure control has been illustrated previously in the literature (26). Most of 
the prior investigations show the importance of high-pressure baroreceptors in 
moment-to-moment regulation of SNA and blood pressure, while being of less 
significance in long-term regulation (350). This suggestion was based on reports that 
showed rapid re-setting of the arterial baroreflex during sustained blood pressure 
elevation, but no alteration in blood pressure following sinoatrial denervation (67). 
This was opposed however by a study conducted by Thrasher et al. (351), where 
baroreceptors in the aortic arch and one carotid sinus were denervated while 
baroreceptors in the other carotid sinus were left intact. The intact baroreceptors were 
activated using a common carotid artery ligation procedure, which caused an increase 
in the arterial blood pressure over 7 days after ligation. This was accompanied by an 
increase in heart rate, renin levels, and a decrease in sodium excretion, indicating an 
increase in RSNA. These physiological alterations were restored to normal after the 
removal of the ligation, suggesting no baroreflex resetting. Alternatively, a sustained 
decrease in RSNA has been reported for 7 days in rabbits with Ang II-induced 
hypertension (26). It was found that in the presence of unilateral renal denervation, 
Ang II infusion increased sodium excretion from the innervated kidney compared with 
the denervated one, suggesting a sustained reduction in RSNA (220). However, 
following denervation of the baroreceptors, sodium excretion decreased from the 
innervated kidney during Ang II infusion, indicating that RSNA decrease and sodium 
excretion increase, before sinoaortic denervation, were baroreflex-mediated. Besides, 
the RSNA baroreflex did not reset during the 7 days of Ang II infusion despite 
sustained blood pressure elevation and heart rate baroreflex resetting (26). This 
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provides further evidence about differences in the baroreflex-mediated organ 
responses, but it also indicates that the high-pressure baroreflex has a significant long-
term effect on RSNA and blood pressure regulation. The dispute about the role of the 
baroreflex in short-term vs. long-term blood pressure regulation has gained significant 
attention supported by multiple commentaries on this topic (79, 328, 350). Moreover, 
the utilisation of renal denervation as a promising treatment for resistant hypertension 
in humans, provides evidence of the importance of baroreflex control of RSNA in 
long-term regulation of blood pressure (158, 197, 376).  
 
1.2.4. Altered baroreflex function in hypertension 
Inadequate control of SNA destabilizes blood pressure and causes poor cardiovascular 
outcomes. Baroreflex function parameters that are usually studied in experimental 
models include midpoint pressure (A3) and sensitivity (A2) or maximum gain. The 
midpoint pressure reflects the operating pressure at which baroreceptors have the 
highest capability to buffer blood pressure fluctuations. A change in the operating 
pressure range and/or a change in threshold pressure over a range of change in holding 
pressure is called resetting of baroreceptors. The latter occurs when the operating point 
moves away from the centre of the baroreflex curve and closer to threshold pressure, 
at a site of reduced sensitivity. Resetting allows the baroreflex to control blood 
pressure efficiently at higher levels of blood pressure caused by the sustained elevation 
of arterial blood pressure (296). This maintains reflex inhibition of RSNA at the new 
resting levels of arterial blood pressure. If the baroreflex does not reset after sustained 
elevation of blood pressure, RSNA and heart rate responses remain at the lower 
plateau of the curve with lessened control of RSNA or heart rate during arterial blood 
pressure fluctuation around the new operating pressure (363). Resetting can occur at 
a peripheral level due to increased threshold pressure of baroreceptors; thus, decreased 
sensitivity to a defined stimulus. In addition, central resetting can be associated with 
neuro-hormonal mechanisms such as increased levels of Ang II, or enhanced afferent 
peripheral inputs that causes altered coupling between afferent signals and efferent 
nerves activities (53). Indeed, blunted baroreflex mechanism is associated with long-
term elevation of resting SNA, which eventually leads to hypertension (132). In many 
hypertensive disease models, differential alterations of baroreflex control of SNA was 
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observed (133, 354, 363). For example, in the renal wrap hypertension model, an 
attenuation of heart rate baroreflex with normal RSNA and LSNA baroreflexes was 
illustrated, in addition to a resetting of the midpoint pressure at which the 
baroreceptors operate (363).  
Alteration in the baroreflex mechanism is associated with peripheral modulation in 
receptor function and/or alterations in the central loop. The latter includes alteration 
of the medullary centres receiving afferent information from baroreceptors, and 
modulation of efferent medullary sympathetic pathways going to peripheral organs. 
However, mechanisms involved in peripheral or central changes in the baroreflex arc 
could differ among hypertensive disease models. These mechanisms involve hormonal 
and/or structural changes that develop during hypertension such as Ang II, renin and 
aldosterone. Moreover, kidney injury, through a reno-renal reflex mechanism, causes 
blunted baroreflex control through excessive sympathetic over-activity, which 
eventually leads to blood pressure elevation (6).  
In the two-kidney one-clip model in rabbits, resetting of heart rate and RSNA 
baroreflexes was observed after 3 and 6 weeks of kidney clipping along with a decline 
in baroreflex sensitivity after 3 weeks. However, after 6 weeks, RSNA baroreflex 
sensitivity was restored to sham levels with continued attenuation of heart rate 
baroreflex (133). This suggests that the RSNA baroreflex is sensitive to hormonal 
changes that happen in the beginning of hypertension, such as angiotensin, which 
lessen at a later stage of the disease. Meanwhile, after 6 weeks, structural changes 
begin such as cardiac and vascular hypertrophy, which could be related to blunted 
heart rate baroreflex. Conversely, the same model in sheep exhibited increased 
sensitivity of the RSNA baroreflex along with no change in the baroreflex control of 
CSNA and heart rate after 3 weeks of clipping (354). This is similar to the Ang II-
induced hypertension model during which RSNA decreases after 7 days of Ang II 
infusion, but increases after a longer duration of Ang II infusion or by combining 
another stressor such as high-sodium diet (26, 124). Ang II has been described as a 
sympatho-excitatory mediator that acts on different central regions such as PVN, area 
postrema, subfornical organ (SFO) and the A5 region of the pons (124). In fact, 
administration of a low dose of Ang II with high-sodium diet resulted in upward shift 
in the RSNA response to blood pressure increase i.e. augmented excitatory RSNA. 
Moreover, high-sodium diet was associated with resetting of baroreflex control of 
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RSNA after 21 days of Ang II administration. However, the increase in RSNA 
occurred at later stage of the study and after hypertension was established (124). In 
addition, high-sodium diet and Ang II infusion alone was not associated with an 
increase in blood pressure or RSNA over the 7 day period (124). Therefore, it might 
be that the increase in RSNA in this model is a consequence of the development of 
hypertension and endogenous Ang II release rather than a cause of it. In addition, 
blood pressure elevation at later stages of the disease evoke renal damage, which in 
turn can activate renal afferent nerves and contribute to increased RSNA activity.  
 
1.2.5.  Up to date evidence of high-pressure baroreflex changes in intermittent 
hypoxia 
In one study of the effects of exposure to CIH, it was shown that elevated ROS 
centrally was associated with a decrease in nitric oxide (NO) levels in the brain, mainly 
the PVN (390). The injection of a NO donor into the PVN decreased blood pressure 
and RSNA following exposure to CIH (142). It was shown that the enhanced 
baroreflex sensitivity mediated by the central activation of angiotensin II type 2 (AT2) 
receptors was reversed by NO blockade (4). Similarly, central inhibition of 
angiotensin II type 1 (AT1) receptors resulted in increased sensitivity of RSNA and 
heart rate baroreflexes. This increase in the baroreflex sensitivity was reversed when 
NO production was inhibited (4). The injection of apocynin into the RVLM attenuated 
the pressor response caused by Ang II, suggesting that ROS generation is associated 
with Ang II-AT1 receptor dependent mechanism (240). Of note, it was shown that the 
generation of central ROS is regulated by an increase in the activity of NOX and 
uncoupling of nitric oxide synthase (NOS), both were revealed following exposure to 
CIH (22, 240). Oxygen free radicals bind to NO to produce highly toxic peroxynitrite 
anions, causing protein nitration and DNA damage (265). In addition, CIH exposure 
is associated with decreased expression of neuronal NOS in the PVN and SFO regions 
(142). Normally, NO controls the responsiveness of arterial and cardiopulmonary 
baroreflexes to blood pressure changes (4, 5). Indeed, impaired baroreflex control of 
heart rate was reported in CIH-exposed rats after 17 days of exposure to IH (202). On 
the other hand, exposure to IH for 7 days was associated with a resetting of RSNA 
baroreflex with no changes in baroreflex gain (392). This is consistent with a previous 
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IH study that illustrated increased expression of pro-inflammatory cytokines in some 
brain regions, but not in the RVLM and NTS, after 7 days of exposure to CIH (330). 
However, longer exposure to CIH was associated with inflammation in the NTS and 
RVLM, which might underpin blunted baroreflex control of heart rate observed during 
the later stages of CIH (202, 263). Bilateral carotid body ablation restored the mid-
point operating pressure to levels similar to sham rats; however, blunted baroreflex 
gain of heart rate was not restored (74). This suggests the presence of other aberrant 
afferent inputs to the NTS in CIH models contributing to blunted baroreflexes. In 
contrast, ten days of exposure to IH (6% O₂ for 40 seconds every 9 minutes) in juvenile 
male rats was enough to cause hypertension and enhance the sensitivity of the 
sympathetic and parasympathetic baroreflex regulation of blood pressure (416). 
Moreover, Moraes et al. (246) reported increased gain of the high-pressure baroreflex 
during expiration using the in situ rat preparation after 10 days of exposure to IH. This 
was associated with CIH-mediated respiratory modulation and enhanced inhibitory 
responses of RVLM presympathetic neuronal activity. In patients with OSA and 
hypertension, an impaired baroreflex response to hypotension induced by sodium 
nitroprusside was reported. Interestingly, this was observed even when blood pressure 
is within the normal range (49), suggesting that derangements are present before the 
onset of hypertension in OSA. Viewed together, a full understanding of high-pressure 
baroreflex changes in CIH-exposed animals has not yet been achieved and there is still 











1.3. Low-pressure baroreflex  
1.3.1. Anatomy and physiology of low-pressure baroreceptors 
Cardiac and pulmonary receptors are described in the literature as a united population 
known as cardiopulmonary receptors or low-pressure baroreceptors although there is 
evidence that each induce particular response patterns (110). Atrial receptors mainly 
located in the left atrium, monitor blood volume changes and initiate a reflex 
mechanism to change urine volume, thereby regulating body fluid homeostasis (129). 
The receptors present as unencapsulated nerve endings and are classified into type A 
receptors that are activated during atrial contraction, type B receptors that are 
stimulated during atrial filling, and intermediate receptors with both A and B activities 
(129). Studies point toward afferent inputs from the left side of the heart as the major 
sensors for the cardiopulmonary reflex (110). Cardiac receptors are innervated by 
myelinated and non-myelinated afferent fibres that travel through the vagus nerve 
carrying afferent impulses to the NTS to regulate sympathetic outflow. From the NTS, 
signals travel to the hypothalamus, mainly to the supraoptic nucleus (SON) and PVN 
to regulate antidiuretic hormone (ADH) secretion (Figure 1.2). There is evidence of 
some afferent nerves that travel through sympathetic rami and are activated by 




Figure 1. 2. Cardiopulmonary baroreflex arc. Afferent sensory signals travel from 
different cardiac regions to the NTS followed by their projection to higher brain 
centres within the hypothalamus. This modulates efferent sympathetic outflow to 
different organs and antidiuretic hormone release from the pituitary gland. Activation 
of cardiopulmonary receptors inhibits preganglionic renal sympathetic neurons and 
activates preganglionic cardiac sympathetic neurons through different projection 
pathways. NTS, nucleus tractus solitarius; RVLM, rostral ventrolateral medulla; 
CVLM, caudal ventrolateral medulla; PVN, paraventricular nucleus; NO, nitric oxide; 
OXY, oxytocin pathway; ADH/GLU, antidiuretic hormone/glutamate pathway. 
 
An increase in blood volume increases atrial pressure and activates atrial receptors. 
This triggers a negative-feedback loop that causes a decrease in ADH hormone 
secretion and RSNA. This eventually causes an increase in urine flow and restoration 
of blood volume. In contrast, this reflex includes an increase in CSNA with no changes 
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in LSNA (63, 156). Interestingly, the increase in heart rate (known as the Bainbridge 
effect) reported in the literature was not accompanied by an increase in cardiac 
contractility or changes in peripheral vascular resistance except for the renal 
vasculature, where an increase in renal blood flow was observed (129). Therefore, the 
SNS responds to cardiac afferent inputs in a non-uniform fashion, which is due to 
discrete pathways within the hypothalamus that differentially regulate the activity of 
renal and cardiac sympathetic preganglionic nerves (63). The PVN is the central 
command site that regulates the RSNA response within the reflex arc of the 
cardiopulmonary receptors. Destruction of PVN neurons significantly attenuates the 
RSNA response to saline overload (63). PVN ADH/glutamate neurons projecting to 
the spinal cord elicit an excitatory effect on renal preganglionic sympathetic nerves. 
ADH nerves are inhibited by GABA interneurons within the PVN. This central 
network was found to be dependent on NO, as inhibition of NO synthase attenuates 
RSNA sympatho-inhibition mediated by the volume reflex. There is also a group of 
ADH/glutamate neurons travelling from the PVN to the RVLM that regulates 
sympathetic outflow through vasomotor nerves (63). Interruption of cardiac afferent 
inputs by pericardial lidocaine or by bilateral vagotomy totally abolished the renal 
sympatho-inhibitory response to volume expansion. Importantly, lidocaine eliminated 
sensory inputs from the heart, not the lungs, which indicates that pulmonary receptors 
do not contribute to the renal sympatho-inhibitory response (245). On the other hand, 
CSNA is mainly regulated by the PVN oxytocin pathway projecting to the spinal cord, 
which influences preganglionic cardiac sympathetic nerves. The cardiac arm of the 
volume reflex is independent of ADH or GABA (63).  
Multiple physiological conditions can activate intra-thoracic mechanoreceptors such 
as positive- and negative-pressure breathing. Positive-pressure breathing causes a 
decrease in intra-thoracic blood volume, which eventually causes a reflex increase in 
plasma ADH and a decrease in urine volume (110). In contrast, negative-pressure 
breathing was associated with an increase in intra-thoracic blood volume, an increase 
in urine volume and a decrease in ADH secretion (110). This suggests that renal 
function alterations and ADH secretion were reflex-regulated by intra-thoracic 
mechanoreceptors including cardiac receptors. However, other cardiovascular and 
haemodynamic changes occur during positive- and negative-pressure breathing that 
could mediate renal responses. For example, a decrease in arterial blood pressure and 
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an increase in central venous pressure were reported during positive-pressure 
breathing. In addition, bilateral cervical vagotomy did not abolish completely the 
increase in ADH secretion and the decrease in water diuresis that had happened during 
positive-pressure breathing in rats and dogs (110). Thus, the putative presence of 
mechanisms other than the cardiac volume reflex that might be attributed to reflex 
alterations in renal function and plasma ADH levels cannot be excluded.  
Other studies that involved balloon inflation at different regions of the left side of the 
heart supported the presence of a cardiac receptor-mediated reflex. These studies 
include balloon inflation in the left atrium near the mitral valve or at the junction of 
the pulmonary vein and the atrium, or at the left and right atrial appendages. In relation 
to that, an increase in diuresis and a decrease in plasma ADH was reported during 
atrial balloon distension (110). Balloon inflation in the left atrium was associated with 
haemodynamic changes such as an increase in heart rate, which mediates, at least 
partly and in conjugation with ADH, the diuretic response. In addition, infusion of 
pitressin (ADH analogue) caused attenuation but not elimination of the diuretic 
response. Interestingly, damaging the appendages of the left and right atria eliminated 
the renal response to balloon inflation, which suggests that the response is mediated 
by stretching of these appendages. Mechanical distension of the right atrial 
appendages was associated with an increase in urine flow. This suggests that right 
atrial receptors in addition to the left atrial receptors can influence renal function (110). 
Importantly, however, pressures or forces used in balloon inflation do not necessarily 
reflect physiological pressure changes.  
Atrial distension was shown to be associated with sodium excretion, which also can 
be mediated by a decrease in RSNA, an inhibition of the renin-angiotensin-aldosterone 
system (RAAS), and an increase in the release of atrial natriuretic peptide (ANP) 
(109). ANP is stored in atrial granules as an inactive pro-hormone and its release is 
stimulated by cardiac stretch. It plays a physiological role in renal sodium excretion 
acting on ANP-A receptors that exist on renal tubules (378). It boosts natriuresis and 
diuresis through different mechanisms that include the decrease of aldosterone 
secretion and the inhibition of apical sodium channels and the basolateral Na+/K+ 
ATPase pump in the inner medullary collecting duct. There is evidence that ANP 
inhibits Ang II-induced release of ADH from the posterior pituitary gland (378). 
Moreover, ANP increases glomerular filtration rate (GFR) through afferent arteriolar 
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vasodilation, the inhibition of renin release and the relaxation of the contractile 
mesangial cells. Indeed, the administration of atrial tissue extracts to anaesthetised rats 
was associated with natriuresis and diuresis (109). Moreover, volume expansion in 
anaesthetised rats resulted in diuresis and natriuresis concomitant with increased 
plasma levels of ANP (308). The prevention of ANP increase during saline overload 
in anaesthetised rats abolished renal diuretic and natriuretic responses (308). However, 
in dogs, cardiac denervation during volume expansion eliminated the natriuretic effect 
despite a fourfold increase in the plasma levels of atrial peptides (111). Overall, 
volume expansion studies suggest that ANP contributes to diuresis and natriuresis 
observed during the stimulation of the cardiopulmonary reflex.   
 
1.3.2. Altered low-pressure baroreflex function in hypertension 
There is less focus on low-pressure baroreflex control of blood pressure in 
hypertension compared with the high-pressure baroreflex. Blunted cardiopulmonary 
reflex is observed in many hypertensive disorders that involve cardiac hypertrophy, 
such as renovascular hypertension and aortic stenosis (107). Interestingly, 
normotensive athletes with thickened heart walls also showed a decreased response to 
cardiopulmonary reflex stimulation (107). In spontaneously hypertensive rats (SHR), 
acute volume expansion caused a 25% decrease in RSNA compared with a 45% 
decrease in control rats. In addition, these SHR rats had a blunted bradycardic response 
to chemical stimulation of the cardiopulmonary receptors and higher left ventricular 
to body weight ratio (357). It is therefore suggested that distension of the left atrium 
due to hypertrophy in these rats resets the cardiopulmonary receptors.  
Studies on obese rats and in the cisplatin-induced renal injury model showed blunted 
RSNA response to volume expansion accompanied by decreased diuresis and 
natriuresis (3, 120, 169). However, unilateral and or bilateral denervation of the kidney 
in these rats restored the normal baroreflex and kidney function response to volume 
expansion (120, 168). In relation to that, elevation of renal transforming growth factor 
beta (TGF-1β) in cisplatin-induced renal failure animals, and tumour necrosis factor-
α (TNF-α) and interleukin 6 (IL-6) in kidneys harvested from obese rats was also 
reported (120, 170). Therefore, immunosuppression using tacrolimus restored the 
blunted RSNA baroreflex response of either obese or cisplatin-induced renal failure 
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rats (2, 170). In this regard, it is proposed that kidney inflammation activates afferent 
renal nerves which cause a reflex sympatho-excitation and the attenuation of the low-
pressure baroreflex function.  
Studies in humans showed that increased venous return due to leg raising in athletes 
was associated with attenuated cardiopulmonary reflex function as demonstrated by a 
lesser decrease in forearm vascular resistance and plasma norepinephrine (NE) 
compared with controls (107). Similar findings were reported in response to a decrease 
in venous return by lower body negative pressure in athletes (107). Moreover, mild-
to-moderate hypertensive individuals showed slightly decreased forearm vascular 
resistance in response to leg raising, while it was markedly attenuated in patients with 
more severe hypertension and cardiac hypertrophy (232). The vasoconstrictor 
response to cold pressor test was similar in athletes vs. controls, and in patients with 
mild-to-moderate hypertension vs. patients with severe hypertension and cardiac 
hypertrophy. Therefore, it was suggested that impaired cardiopulmonary reflex is 
associated with changes in the neural arc of the loop rather than diminished effector 
sensitivity (107, 232). Overall, the cardiopulmonary reflex might be maintained in the 
beginning of hypertension and impaired as cardiac structural changes develop (232). 
This suggests that blunted cardiopulmonary reflex is not a cause of hypertension rather 
it is a consequence of it, and it increases sympathetic activity and contributes to a 
vicious cycle of hypertension. Interestingly, in one study, normotensive individuals 
with OSA showed increased left ventricular wall thickness and left atrial size 
compared with normotensives individuals with no OSA (86). However, the 








1.4. Renal sensory afferent nerves 
1.4.1. Distribution and projection to brain 
Renal sensory receptors are present as free nerve endings in the kidney that project to 
thoracolumbar region of dorsal root ganglia primarily from T12 to L3 (372). Afferent 
fibres synapse with interneurons within the ipsilateral dorsal horn in laminae I and 
laminae III to V. They project to brain sites including NTS, RVLM, SFO and PVN 
(151).  
The location of the renal sensory nerve fibres has been identified using highly specific 
wheat germ agglutinin horseradish peroxidase nerve tracing (237). 
Immunohistochemistry has also been implemented to explore renal sensory nerves by 
tracking calcitonin gene-related peptide (CGRP) and substance P (SP) as specific 
neurotransmitters of sensory neurons (115, 179, 186, 247). In the kidney, the sensory 
fibres travel parallel to the renal vein, renal artery and ureter entering the kidney at the 
hilus. The nerve endings of these sensory fibres are predominantly found in the ureter 
and the muscular layer of the renal pelvic wall with some located in the uroepithelial 
layer of the renal pelvis (237). This is evidenced by the presence of SP in the space 
between the muscular layer and the epithelial cells of renal pelvic wall (96) indicating 
the presence of sensory nerves in the renal pelvis. Similarly, CGRP was identified in 
the renal pelvic wall in previous studies in rat and sheep (37, 101) and was utilised to 
examine the validity of renal denervation in these studies. Marfurt and Echtenkamp 
(237) identified renal afferent nerves in the renal cortex by labelling these fibres with 
wheat germ agglutinin-horseradish peroxidase. However, labelling was not detected 
in the renal medulla or papilla. Immuno-labelling by the same group indicated the 
presence of afferent fibres in the interlobular and arcuate arteries. Some of these 
afferent sensory fibres were stimulated when the renal artery and renal vein were 
obstructed (36, 389). Similarly, an elevation in renal venous pressure resulted in an 
increase in urinary sodium excretion and urine flow. This response was not attenuated 
when lidocaine, a local anaesthetic, was injected into the renal pelvis (195), providing 
evidence for the presence of sensory nerves in the renal vein separate from those 
present in the renal pelvis. In rats, around 76% of afferent nerves are unmyelinated 
slowly conducting axons while some 19% are thin myelinated and only 5% are rapidly 
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conducting myelinated fibres (176). In general, sensory nerve endings in the kidney 
are of two types: mechanoreceptors and chemoreceptors (338).  
The mechanoreceptors are sensitive to stretch induced by volume expansion, capsaicin 
or any stimulus that increases SP and CGRP formation. However, a group of renal 
sensory nerves were found to be responsive to ischaemia due to renal artery occlusion 
or due to cyanide, but not to pelvic pressure elevation (298). These sensory nerves that 
were sensitive to ischaemia, were not activated by mechanical stretch and were 
therefore referred to as chemoreceptors, which are classified to R1 and R2 receptors. 
R1 chemoreceptors are silent under resting conditions and are innervated by the non-
myelinated slow conducting nerve fibres, which elicit action potentials of long 
duration when activated (298). In contrast, R2 chemoreceptors are active in the resting 
state and are slowly-adapting insofar as their firing continues 15-20 minutes after 
death. They are activated by renal ischaemia and by backflow of hypertonic or 
hyperosmotic urine (118, 297). Studies pointed toward a role for chemoreceptors in 
initiating an excitatory reno-renal reflex, which contributes to sympatho-excitation 
and blood pressure elevation (44, 118, 298). To distinguish the role of 
mechanoreceptors from that of chemoreceptors, an increase in renal pelvic pressure 
over a physiological range (2.5–10 mmHg) was utilised to activate the 
mechanoreceptors while a solution of 450mM NaCl was used to stimulate the 
chemoreceptors (189, 364). However, there is still a scarcity in the literature of studies 
that differentiate between mechanoreceptors and chemoreceptors in terms of structure 
and function.  
 
1.4.2. The physiological activity of renal afferent and efferent sensory nerves 
Efferent nerves travelling into the kidneys are sympathetic in nature and are mainly 
located in the corticomedullary region and to a lesser extent, in the renal pelvic wall. 
The renal efferent nerves are intertwined with afferent nerves in the same nerve fibre 
bundle (178, 186). Efferent sympathetic stimulation increases NE release, which binds 
to α1 and α2 adrenoreceptors in the renal pelvic wall (186). NE stimulates renin release 
followed by RAAS activation, which results in increased renal sodium and water 
reabsorption (126). This causes an increase in ureter and renal pelvic pressure that 
activates mechanosensitive receptors through the opening of transient receptor 
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potential cation channel subfamily V member 1 (TRPV1) and release of SP and 
CGRP, which in turn enhances afferent renal nerve activity (ARNA). Renal afferent 
nerve stimulation provides a negative feedback mechanism that causes reflex 
natriuresis and diuresis i.e. a fall in efferent renal sympathetic nerve activity (ERSNA) 
(180). This is known as the inhibitory reno-renal reflex, which protects against 
sympathetic over-activity and blood pressure elevation (Figure 1.3).   
 
Figure 1. 3. Renal afferent and efferent sympathetic nerves. Blue lines represent 
afferent signals and red lines represent efferent sympathetic discharge. Afferent 
signals, mediated by the release of substance P (SP) and calcitonin gene-related 
peptide (CGRP), are integrated in the paraventricular nucleus (PVN) and nucleus 
tractus solitarius (NTS) to activate the rostral ventrolateral medulla (RVLM), 
increasing sympathetic nerve activity to different organs including the kidneys. An 
increase in efferent renal sympathetic nerve activity enhances the release of 
norepinephrine (NE) and activates the renin-angiotensin-aldosterone system (RAAS). 
This decreases sodium and water excretion and increases renal pelvic pressure, 
causing stimulation of the mechanoreceptors of the afferent pathway (15).  
 
SP natriuretic and diuretic response is associated with two mechanisms. First, SP 
activates an inhibitory reno-renal reflex to decrease sympathetic outflow, thus, 
increasing water and sodium excretion. Second, SP induces pelvic contractions that 
facilitate urine movement into the bladder (182). The role of CGRP in renal sensory 
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nerve endings is not extensively studied, but there is convincing evidence that CGRP 
stimulates renal afferent nerves and increases renal sodium excretion (114, 115, 385). 
Of high interest, the effect of CGRP and SP together on ARNA is greater than the 
effect of each neuropeptide alone. In addition, CGRP infusion into the pelvis causes a 
greater increase in ARNA induced by an increase in renal pelvic pressure (116). 
Although neurokinin 1 (NK1) receptor antagonism blocks CGRP-mediated effect on 
ARNA, CGRP receptor blockade was not associated with a similar effect on SP-
mediated activation of afferent renal nerves (116). Therefore, it was suggested that 
CGRP action is mediated via a mechanism which involves inhibition of SP 
metabolism, thus, augmenting SP-mediated activation of ARNA. 
On the other hand, previous studies have shown that the intra-renal infusion of 
ischaemic mediators such as adenosine or backflow of urine into the renal pelvis, 
causes reflex sympatho-excitation and a decrease in sodium and water excretion (59, 
161). Moreover, the infusion of hypoxic blood into the kidney induces reflex 
sympatho-excitation, which was greatly attenuated by the inhibition of adenosine and 
bradykinin synthesis (18). This is known as the excitatory reno-renal reflex which was 
frequently observed in different models of hypertension. Receptors involved in the 
activation of the excitatory reno-renal reflex are not clearly illustrated. However, it 
was shown that the infusion of bradykinin and capsaicin into the kidney induces 
contralateral renal sympatho-excitation (101, 391, 397), indicating that renal 
bradykinin receptors and TRPV1 channels are involved in the excitatory reno-renal 
reflex. Studies of hypertension and the excitatory reno-renal reflex are described in 
section 1.4.4.2.  
 
1.4.3. Activation pathways of renal afferent sensory nerves 
Signalling pathways involved in sensory mechanoreceptor activation have been 
extensively studied by Kopp et al. (180) employing pharmacological agents and direct 
recording of renal afferent nerve signals in rats. Activation pathways of 
mechanoreceptors are via two main routes: NK1 activation by SP and/or stimulation 
of TRPV1 as illustrated in Figure 1.4. These pathways result in the release of SP and 
CGRP, primary neurotransmitters for ARNA and/or increase intracellular calcium 
with subsequent depolarization through TRPV1 channels. Some signalling pathways 
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require the presence of cyclooxygenase (COX) enzyme and prostaglandins (PGs) as 
previously reported (194). The pathway involves PGE2 binding to its receptors 
resulting in the activation of the cAMP/PKA signalling cascade and this ultimately 
causes SP and CGRP production (185). Detailed information is provided in sections 
1.5 and 1.6 regarding TRPV1 and bradykinin receptors.  
 
Figure 1. 4. A representation of possible pathways that enhance renal afferent 
nerve activity in a renal afferent nerve ending. B2, Bradykinin receptor type 2; 
PKC, protein kinase C; NE, norepinephrine; ET1, endothelin 1; ETA and ETB, 
endothelin receptor type A and type B; PKA, phosphokinase A; SP, substance P; 
CGRP, calcitonin gene related peptide; NK1, neurokinin receptor 1; TRPV1, 
Transient receptor potential cation channel; NMDA, N-methyl-D-aspartate receptors; 
ARNA, afferent renal nerve activity. Solid lines represent excitatory pathways and 
dashed lines represent inhibitory pathways. Chronic intermittent hypoxia may evoke 
aberrant renal afferent signalling contributing to hypertension through action on one 
or more of the above signalling mechanisms (15). 
 
1.4.4.  Renal afferent nerves and hypertension 
Renal afferent nerve hyperactivity is associated with derangement of reno-renal reflex 
control, contributing to blood pressure elevation by suppression of the pre-mentioned 
inhibitory reflex and/or activation of an excitatory reno-renal reflex (180). 
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Sympathetic over-activity, and sodium and water retention associated with high blood 
pressure was reported in different models of hypertension such as the two-kidney one-
clip Goldblatt model (198), SHR (149), high fat diet-induced hypertension (169), and 
CIH-induced hypertension (320, 416). In the CIH model for example, a neurogenic 
mechanism is activated early in the disease process and is dependent on increased 
sympathetic tone (318). It is not known, however, if renal afferent signalling has a 
contributory role in mediating increased sympathetic nerve activity in CIH and OSA. 
 
1.4.4.1. Suppression of the inhibitory reno-renal reflex 
In the SHR, elevation of peripheral sympathetic nerve activity is eliminated when the 
injured kidney is denervated (182), with almost a 50% decrease in blood pressure 
observed 10 minutes after denervation. In addition, renal denervation is associated 
with a decrease in renal cortical NE levels (104). Therefore, it has been suggested that 
part of the decrease in blood pressure following renal denervation is due to a reduction 
in NE release from the postganglionic efferent nerves. It is also suggested that the 
decrease in blood pressure following denervation is due to interruption of renal 
afferent neuronal signalling. Janssen et al. (149) utilised selective renal afferent nerve 
denervation to demonstrate the significant influence of renal afferents on SNS activity 
and baroreflex sensitivity in SHR. Renal afferent denervation in the latter study did 
not elicit a blood pressure lowering effect, and had no effect on urine volume or 
sodium excretion. Relevant to these findings, an increase in renal pelvic pressure or 
an intra-renal pelvic injection of bradykinin, neither caused an increase in ARNA, nor 
an increase in SP release (182, 190). Moreover, there was a decreased responsiveness 
of NK1 receptors to SP in SHR (182). These studies collectively provide evidence for 
suppression of the inhibitory reno-renal reflex in the SHR, which contributes to 
sympathetic over-stimulation in this model. 
 
1.4.4.2. Activation of the excitatory reno-renal reflex  
Activation of the excitatory reflex is proposed to play a major role in renovascular 
hypertension and hypertension associated with chronic kidney disease (46, 149, 169, 
383). In the two-kidney, one-clip model of hypertension, the clipped kidney undergoes 
ischaemic damage compared with the non-clipped kidney. While renal denervation of 
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the non-clipped kidney caused a decrease in sodium excretion, renal denervation of 
the clipped kidney resulted in an increase in ipsilateral and contralateral sodium 
excretion along with a fall in contralateral ERSNA (181). Likewise, dorsal rhizotomy 
followed by clipping of the renal artery resulted in a significant partial decrease in 
blood pressure in the one-kidney, one-clip model. However, contralateral dorsal 
rhizotomy of the nephrectomised kidney did not cause any change in blood pressure 
(383). This confirms the presence of excitatory afferent signals from the clipped 
kidney due to ischaemic insult. Furthermore, previous studies suggested that 
ischaemia induces adenosine release, which in turn stimulates afferent nerves (18, 
212). Therefore, based on these studies, it was suggested that adenosine, in addition to 
bradykinin and prostaglandin E2, which are mediators released during ischaemia, are 
associated with the activation of renal chemoreceptors (18).  
The effect of renal deafferentation was also studied in the 5/6 nephrectomy model and 
was shown to attenuate hypertension and decrease NE turnover in the brain (46). 
Moreover, renal afferent denervation decreased forebrain Ang II, AT1 receptors, c-fos 
in RVLM and tyrosine hydroxylase levels. Similarly, at the level of the kidney, 
macrophage count, fibrosis markers and NOX expression were reduced following 
denervation (48). In deoxycorticosterone acetate (DOCA) hypertensive rats, renal 
denervation decreased arterial blood pressure by 50% together with a decrease in 
plasma NE. Interestingly, the same effect was observed after selective afferent 
denervation using capsaicin. Importantly, renal afferent denervation was performed 
prior to DOCA initiation, which supports a key role for afferent nerves in the 
development of hypertension in this model (101). Based on these studies, it is possible 
that blood pressure reduction is attributed to an interruption of renal afferents, in 
addition to the effect of removal of efferent nerves to the kidneys. 
Ischaemia-reperfusion injury is another disease model associated with elevated blood 
pressure and heart rate. In this model, oxidative stress and inflammatory cytokines are 
elevated in the systemic circulation, SFO, hippocampus, corpus callosum and cerebral 
cortex. Overexpression of NOX2 and NOX4 in the kidney, SFO and hippocampus was 
reported in this model (47, 155, 326). In a renal ischaemia-reperfusion injury model, 
deafferentation by intra-renal capsaicin decreased blood pressure, and renal and 
central oxidative and inflammatory mediators (47). Ma et al. (229) reported an 
impaired release of SP and downregulation of NK1 receptors in the post-ischaemic 
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kidney. In the latter study, selective stimulation of mechanoreceptors by an increase 
in intra-pelvic pressure impaired renal excretory function. It can be suggested from 
the above studies that ischaemia as characterized by increased NOX, activates 
chemoreceptors in the kidney, which contribute to the enhanced sympathetic activity 
seen in hypertension. 
 
1.4.4.3. Kidney inflammation, excitatory reno-renal reflex and baroreflex 
dysregulation 
Baroreflex regulation of blood pressure is impaired in several models of hypertension 
including some animal models of CIH (202, 392). Indeed, failure of the baroreflex 
mechanism is associated with long-term elevation of resting SNA (132). In different 
models of hypertension, it was reported that impairment of the normal baroreflex 
mechanism is secondary to afferent renal nerve activation (6). Kidney injury, through 
reno-renal reflex mechanisms, causes a blunted baroreflex through excessive 
sympathetic over-activity, which eventually leads to blood pressure elevation.  
As mentioned above, studies of cisplatin-induced renal injury and a high-fat diet model 
of obesity in rats demonstrated that it is the excitatory reno-renal reflex that is 
dominant in these models, responsible for blunted baroreflex control of blood pressure 
(168, 170). The dysregulation of the baroreflex in cisplatin or high-fat diet models is 
attributed to renal inflammation that initiates excitatory afferent neural signals, a 
suggestion supported by the increase in renal and systemic inflammatory cytokines 
such as TNF-α and IL-6 (170). Treatment of rats in both models by tacrolimus, an anti-
inflammatory agent, restored the low- and high-pressure baroreflex, in addition to 
decreased renal tissue levels of TNF- and IL-6 in these rats (2, 170). Together, the 
involvement of inflammation and renal nerves in mediating the derangement of the 
baroreflex control of blood pressure in these studies was evident when bilateral renal 
denervation and/or the administration of an anti-inflammatory agent restored the 
sensitivity of low- and high-pressure baroreflexes to changes in blood volume and 




1.4.4.4. A possible link between renal afferent nerves and CIH-induced 
hypertension: Role of inflammation and oxidative stress 
OSA is a known inflammatory disease that activates inflammatory signalling 
molecules in the systemic circulation and kidney tissue. This can cause renal fibrosis 
and apoptosis as indicated by studies of CIH-exposed animals (11, 223, 382). Chronic 
kidney disease is often diagnosed in patients with OSA. Therefore, molecular 
mechanisms underlying OSA-induced kidney damage are currently of interest. 
Inflammation plays a major role in the pathogenesis of CIH-induced hypertension as 
reported by a number of studies (9, 146, 224, 342). In addition, in response to oxidative 
stress, HIF-1 stimulates the translocation of nuclear factor kappa B (NF-B), which 
increases the expression of genes that encode TNFα, interleukin 1β (IL-1β) and IL-6 
(76, 146, 263).  Chronic treatment of CIH-exposed carotid bodies with ibuprofen in a 
previous study decreased cytokine levels and attenuated the enhanced ventilatory 
response to hypoxia, and prevented the development of hypertension (76). An anti-
inflammatory treatment was associated with a decrease in c-fos levels in the NTS 
indicating a role for cytokines in neurogenic hypertension in agreement with a number 
of previous reports (76, 154, 321, 336). However, ibuprofen failed to decrease 3-
nitrotyrosine levels and did not impede the augmented sensitivity of the carotid bodies 
to hypoxia (76). Meanwhile, anti-oxidant treatment abolished enhanced 
responsiveness of peripheral chemoreceptors and the ventilatory response to hypoxia 
along with a decrease in cytokine levels in carotid bodies (76). Thus, it is likely that 
inflammation and increased cytokine levels are secondary to oxidative stress in the 
vasculature associated with exposure to CIH. Similar increases in inflammatory and 
oxidative stress markers were reported in the kidneys of CIH-exposed animals as 
shown by a number of studies in the literature (Appendix 1, Table 8.1) (224, 330, 382, 
409).  
Based on previous studies, it appears that exposure to CIH induces a temporal response 
such that short-term or mild IH initiates an early renal response during which cellular 
defence anti-oxidative mechanisms are activated to elicit a compensatory response 
(Table 1.4). However, long-term or severe IH induces inflammation, apoptosis and a 
decrease in the levels of antioxidant enzymes and anti-inflammatory cytokines (de-
compensatory response) (80, 164, 224, 277, 380, 382). Although some studies 
reported compensatory responses for up to 3 weeks of exposure to IH, other studies 
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reported renal morphological damage and attenuation of antioxidant enzymes after 
just 2 weeks of exposure to more frequent cycles of IH (277). Moreover, short-term 
IH exposure (3 days) was sufficient to induce lipid peroxidation, release of adhesion 
molecules and fibrogenetic factors (342). This indicates that IH might induce early 
renal changes as indicated by lipid peroxidation and activation of endothelial 
dysfunction markers (277, 342). 
Furthermore, exposure to IH for 28 days and for 8 weeks was accompanied by HIF-1 
upregulation in renal tissue (164, 224). HIF-1α expression was also observed in NTS 
and RVLM after exposure to CIH (273). HIF-1 upregulation is a ROS-dependent 
process mediated by NOX. NOX4 is located in renal pelvic wall (216), and NOX4 
overexpression in the kidney was reported after exposure to CIH accompanied by a 
decrease in SOD levels (223). It has been shown that renal denervation and anti-
oxidant treatment significantly decrease renal oxidative stress and blood pressure in 
CIH models (164, 224, 384). In addition, treating CIH-exposed rats with N-acetyl 
cysteine restored renal tissue SOD levels and decreased RSNA and blood pressure 
(223). This proposes a clear link between oxidative stress and renal nerves contributing 
to sympatho-excitation and hypertension. Additionally, metallothionein knockout 
mice exhibited renal fibrosis after 3 weeks of exposure to IH, but 8 weeks of exposure 
was needed to induce fibrosis in wild-type mice (380). Moreover, SOD was 
downregulated while NOX2 was upregulated in the NTS and RVLM after 10 days of 
exposure to IH (273). When viewed together, these findings highlight an important 
interaction between oxidative stress and sympatho-excitation either at the level of the 
peripheral organs (carotid bodies and kidneys) and/or within the higher control 
centres.  
TRPV1 is sensitised by hydrogen peroxide (H2O2) administration leading to SP release 
in renal mechanoreceptors. The impact of H2O2 on TRPV1 is inhibited by catalase. Of 
interest, renal NOX4 is upregulated after exposure to CIH and is co-localized with 
TRPV1 receptors in renal sensory nerve endings. (216). Likewise, it was shown that 
ROS mediates TRPV1 signalling in peripheral sensory nerves and in carotid bodies 
(174, 218). Increased ROS in carotid bodies was due to HIF-1-mediated NOX2 
upregulation and it was associated with enhanced sympatho-excitatory response to 
hypoxia. (200). These studies led to the one of hypotheses of this thesis, that early 
changes in renal oxidative and/or inflammatory signalling sensitizes renal TRPV1 
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receptors and contributes to afferent renal nerve hyperactivity, similar to the role of 
TRPV1 in sensitizing the carotid bodies following exposure to CIH (235), contributing 























1.5. TRPV1 channels  
1.5.1. Location and activation pathways 
TRP (Transient receptor potential) channels are polypeptides composed of six helices 
with intracellular C- and N-terminals. Subunits join each other to form a tetramer and 
the functional channel is composed of a non-selective cationic permeable pore. 
TRPV1 channels are predominant in nociceptors in addition to trigeminal and nodose 
ganglia (160). They are also distributed throughout the tubules of the renal cortex, 
outer medulla and juxtaglomerular apparatus. In addition, TRPV1-positive sensory 
nerves were identified in renal pelvic wall and in the ureter (96).  
TRPV1 channels are more selective to Ca2+ and Mg2+ compared with Na+. In addition 
to mechano-stimulation, they are also activated by heat (>43°) and acidic pH (<5.9), 
relevant to inflammation or ischaemia (160, 211). Endogenous activators of TRPV1 
channels are mainly arachidonic acid metabolite derivatives known as endovanilloids 
such as anandamide, in addition to lipoxygenase (LOX) products, which are 
subdivided into endocannabinoids and eicosanoids (160, 211). The most commonly 
used exogenous activator of TRPV1 channels is capsaicin. Resiniferatoxin is another 
TRPV1 agonist with markedly greater potency than capsaicin (211). Of note, agonist 
binding was found to induce allosteric changes and to lower the rate binding energy 
required for other agonists (144). Accordingly, protons enhance the binding of 
capsaicin to TRPV1 channels which increases TRPV1 response current to protons and 
temperature.  
Furthermore, TRPV1 activity is mediated by the phosphorylation of kinases, such as 
phosphokinase A (PKA), PKC, calcium calmodulin-kinase II and Src kinase (211). 
Inflammatory mediators such as prostaglandins activate PKA, which sensitizes the 
TRPV1 response to capsaicin and temperature. Similarly, other inflammatory 
mediators such as bradykinin activates, via its binding to bradykinin type 2 (BK2R) 
receptors, PKC which phosphorylates TRPV1 (211, 276). This lowers the threshold 
required to evoke TRPV1 response when stimulated by heat, protons or capsaicin 
(340). However, continuous activation of PKA, PKC or intracellular calcium causes 
desensitisation of TRPV1 (187, 211, 234).  
It was shown that local inflammation of peripheral sensory neurons stimulates BK2R 
to phosphorylate TRPV1 channels by a Gq/11 dependent mechanism (337). In 
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nociceptive receptors, bradykinin stimulates phospholipase C (PLC), which activates 
phosphatidylinositol 4, 5-bisphosphate to release inositol triphosphate (IP3) and 
diacylglycerol. IP3 in turn enhances the release of intracellular calcium and 
depolarizes sensory neurons (51). Bradykinin, through PLA2, releases arachidonic 
acid which is a precursor for LOX products that are endogenous agonists for TRPV1 
(187). Therefore, BK2R activation of sensory neurons might partially be mediated by 
TRPV1 channels or by stimulating the release of intracellular calcium. As in 
nociceptive neurons, it is expected that a cross talk exists between BK2R and TRPV1 
channels in the renal sensory afferent neurons of the renal pelvic wall. Figures 1.4 and 
1.5 illustrate the mechanisms of TRPV1 activation of renal afferent nerve endings 
whether direct via increasing intracellular calcium or indirect by stimulating the 
release of CGRP and SP neurotransmitters, the latter of which acts on NK1 receptors 
and stimulates ARNA. 
It has been suggested that TRPV1-mediated modulation of the reno-renal reflex either 
due to capsaicin or resiniferatoxin binding to TRPV1 can be abolished when an NK1 
receptor antagonist was injected into the renal pelvis (385). However, CGRP receptor 
blockade did not eliminate capsaicin-mediated activation of renal afferent sensory 
nerves. On the other hand, TRPV1 blockade in the renal pelvis by capsiazipine (CPZ) 
abolished CGRP-mediated stimulation of ARNA (385). There is evidence that 
capsaicin activation of renal afferent nerves occurs through PLC, which is the main 
second messenger for CGRP receptors. Therefore, it is suggested that PLC inhibition 
is responsible for the elimination of CGRP receptor-dependent effect on ARNA 
following TRPV1 blockade (385). However, it is also plausible that CGRP might 
mediate part of the TRPV1 effect on renal afferent sensory nerves, as CGRP has been 
shown to decrease SP metabolism (116).  
An increase in the efferent RSNA causes the release of NE and the activation of the 
RAAS, which causes a decrease in sodium and water excretion. The release of NE is 
often accompanied with increased release of endothelin-1 (ET-1) that induces 
vasoconstriction, leading to decreased blood flow to the kidney and decreased GFR 
(188). Endothelin type A (ET-A) receptors are found in the smooth muscle cells of the 
renal pelvis and ET-B receptors are located near to unmeylinated schwann cells of 
renal sensory nerve fibers in the renal pelvic wall (188). ET-1 binds to endothelin type 
B (ET-B) receptors located in the renal pelvic wall which increases ARNA and 
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facilitates the inhibitory reno-renal reflex to induce sodium and water excretion (188). 
On the other hand, it has been shown that rats fed with low sodium diet had increased 
expression of ET-A receptors in the renal pelvic wall (183). The binding of ET-1 with 
ET-A receptors inhibits PGE2-mediated activation of ARNA and supresses the 
inhibitory reno-renal reflex, causing sodium and water retention (183). TRPV1 
receptors was found to mediate ET-B receptor-induced activation of afferent renal 
nerves and diuresis and natriuresis that follow the infusion of ET-1 into the renal 
pelvis. ET-B blockade did not affect capsaicin-induced activation of ARNA (386). 
Furthermore, ET-A receptor-mediated suppression of ARNA in wild-type mice 
disappeared in TRPV1-/- mice, indicating a cross talk between ET-A and TRPV1 
receptors (386). Interestingly, infusion of a PKC inhibitor into the renal pelvis 
suppresses ET-B receptors-mediated sensory nerves activation but did not affect 
capsaicin-mediated activation of these nerves (386). Enhancement and suppression of 
ARNA were associated with a corresponding increase and decrease of the release of 
SP and CGRP, respectively. Together, there is considerable evidence that TRPV1 
channels have a central role in mediating renal afferent nerves activity directly or as 
part of other receptor signalling pathways, making TRPV1 a possible candidate in the 




Figure 1. 5. Interaction of TRPV1 with other receptors in the renal pelvic wall. 
TRPV1 plays a central role in mediating afferent renal nerve activity (ARNA). 
Putative cross talk between bradykinin type 2 (B2) receptors and TRPV1 is evident in 
peripheral sensory neurons (276), but is yet to be confirmed in the renal sensory 
mechanism. LOX, lipooxygenase; PKC, phosphokinase C; ET-A, endothelin receptor 
type A; ET-B, endothelin receptor type B; TRPV1, transient receptor potential cation 
channel member 1; PLC, phospholipase C; SP, substance P; CGRP, calcitonin gene-
related peptide; NK1, neurokinin 1 receptor. 
 
1.5.2. TRPV1: physiological role in the kidney 
In renal pelvic wall, TRPV1 channels function as baroreceptors that regulate the 
release of neuropeptides including SP and CGRP in response to stretch (414). 
Unilateral TRPV1 activation stimulates an ipsilateral and contralateral inhibitory reno-
renal reflex, which causes an increase in sodium and water excretion (386, 413). The 
latter was blocked following ipsilateral TRPV1 blockade and ipsilateral renal 
denervation (96, 413). Enhanced ARNA induced by an increase in renal pelvic 
pressure was abolished following NK1 receptor blockade, but not CGRP receptor 
antagonism (191).  
Due to the wide distribution of TRPV1 channels in different parts of the kidney, they 
play a significant role in modulating renal haemodynamic function. Studies in the 
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literature point towards a role for TRPV1 channels in endothelium-dependent 
vasorelaxation and therefore their protective effect on different organs (57, 411). In 
the kidney, TRPV1 activation causes an increase in GFR, natriuresis and diuresis. 
Following increased perfusion pressure by phenylephrine injection, TRPV1 activation 
resulted in an attenuated perfusion pressure and increased GFR, mediated by 
decreased renal vascular resistance (210). The latter indicates that TRPV1 channels 
cause larger vasodilation in afferent compared with efferent arterioles. It was also 
reported that TRPV1 activation increases the absolute but not fractional sodium 
excretion so receptor activation does not alter proximal tubular sodium reabsorption 
(412). Importantly, the effect of TRPV1 activation on GFR and water/sodium 
excretion was completely abolished after the infusion of SP and CGRP receptor 
blockers Spantide II and CGRP8–37, which indicates a major role for SP and CGRP in 
TRPV1-mediated vasodilation (210).  
Further evidence of TRPV1-mediated vasorelaxation was proposed by Zygmunt et al. 
(418) who showed that vanilloid receptors located within the perivascular sensory 
neurons mediate vasodilation induced by anandamide ex vivo in small mesenteric 
arteries and hepatic arteries isolated from the rat. The application of CPZ abolished 
anandamide and capsaicin-mediated vasodilation, which was associated with 
suppression of CGRP release. Furthermore, CGRP receptor antagonism blunted the 
vasodilator effect of anandamide. Conversely, pre-treatment with a high dose of 
capsaicin, sufficient to desensitise vanilloid receptors, did not alter vasodilation 
produced by exogenous CGRP administration (418). Similar findings were reported 
by Ralevic et al. (290) who studied the vasodilator effect of methanandamide on rat 
mesenteric arterial bed and small mesenteric arteries. In the latter, pre-treatment with 
high dose capsaicin or CPZ or CGRP antagonism blocked the methanandamide-
dependent vasodilation effect.  
 
1.5.3. The putative role of renal TRPV1 channels in hypertension 
Several studies have investigated the role of renal TRPV1 receptors in sympathetic 
modulation and hypertension, with reports showing variable effects of TRPV1 
receptor activation and suppression on the SNS, and therefore blood pressure 
regulation. Kopp et al. (192), Zhu et al. (413), Feng et al. (96) and Ditting et al. (82) 
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reported renal sympatho-inhibition without significant changes in blood pressure in 
response to intra-renal pelvic or intra-renal arterial infusion of an agonist dose of 
capsaicin. This was associated with contralateral increase in sodium and water 
excretion. The effect of intra-renal pelvic infusion of capsaicin on RSNA and kidney 
function was abolished by an infusion of CPZ (82). In contrast, Ye et al. (397) showed 
clear evidence of a role for renal TPRV1 receptors in mediating an excitatory reno-
renal reflex and high blood pressure. Intra-renal infusion of an agonist dose of 
capsaicin caused an increase in blood pressure and contralateral RSNA, and increased 
c-fos labelling in the PVN. This excitatory effect was abolished by intra-renal infusion 
of CPZ and by the denervation of the same kidney, pre-infused with capsaicin (287, 
397). Interestingly, intra-renal infusion of an agonist dose of capsaicin caused an 
increase in superoxide production in the PVN (287). Tempol, N-acetyl cysteine and 
apocynin (an NOX inhibitor) applied to the PVN before intra-renal infusion of 
capsaicin caused a decrease in basal RSNA and blood pressure, and prevented the 
intra-renal capsaicin-mediated sympatho-excitatory response. On the other hand, the 
administration of an Ang II receptor blocker or the inhibition of the release of Ang II 
in the PVN abolished the excitatory effect of intra-renal capsaicin and reduced 
superoxide production in the PVN (287). This suggests that renal TRPV1 activation is 
associated with sympatho-excitation and can contribute to blood pressure elevation 
through the Ang II-AT-1 receptor-NADPH oxidase-ROS production pathway in the 
PVN. This is similar to the symaptho-excitatory effect of capsaicin mediated via the 
adipose afferent reflex (70). In this regard, capsaicin injected into white adipose tissue 
caused an increase in c-fos in the posterior region of the PVN and SON (70).  
In the cisplatin-induced renal failure model, intra-renal infusion of CPZ restored the 
blunted high-pressure baroreflex control of RSNA to normal. Moreover, the blunted 
renal sympatho-inhibitory response to volume expansion during low-pressure 
baroreflex stimulation was normalized following blockade of renal TRPV1 channels 
by CPZ (1). This points to a contributing role of TRPV1 in the sympathetic 
hyperactivity in hypertension disease models that involve kidney inflammation and 
injury. These findings are in agreement with a previous study on two-kidney, one-clip 
renovascular hypertension model (261). In the latter, activation of renal afferent nerves 
caused an increase in blood pressure, with concomitant increased lumbar, splanchnic 
and renal SNA. Application of a high dose of capsaicin on the renal artery was 
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associated with complete elimination of TRPV1 as revealed by immunofluorescence 
and a significant reduction in blood pressure after clipping of the kidney (261). On the 
contrary, another study using the same experimental model in mice showed that a low 
amount of capsaicin in the diet for 6 weeks significantly decreases blood pressure 
(313). Administration of L-NAME, NO synthase inhibitor, abolished the blood 
pressure lowering effect of systematic administration of capsaicin. Moreover, dietary 
capsaicin has been associated with upregulation of phosphorylated endothelial NO 
synthase (eNOS). This indicates that the blood pressure lowering effect of capsaicin 
in renovascular hypertension was partly mediated by a NO-vasorelaxation effect 
through TRPV1 channels. Thus, one can propose that the activation of kidney TRPV1 
receptors activates SNS distinctively from other sites activated by systematic 
administration of capsaicin, which cause a lowering of blood pressure, as shown in the 
two-kidney, one-clip model. Meanwhile, dietary capsaicin in sham rats was associated 
with a similar increase in eNOS phosphorylation, but with no alteration in blood 
pressure levels (313). Therefore, in sham rats fed with capsaicin, blood pressure was 
not altered because capsaicin activates SNS through TPRV1 receptors which 
compensates for the blood pressure decrease that occurs in response to vasodilation. 
On the other hand, in the two-kidney, one-clipped mouse model, the basal SNA is 
greater than shams, and diet mixed with capsaicin did not cause further activation of 
sympathetic nerves, which resulted in a decrease in blood pressure mediated by NO 
synthase-mediated vasodilation. Therefore, it is suggested that capsaicin mediates dual 
effects: a blood pressure lowering effect through TRPV1/NO synthase pathway 
producing an effect on the vasculature (313); and a sympatho-excitatory effect through 
TRPV1 receptors in other sites, such as carotid bodies, kidneys and adipose tissue (70, 
307, 397).  
Protective effects of TRPV1 activation on the cardiovascular system have been also 
reported and characterised by lowering of blood pressure, an improvement in cardiac 
and renal function following ischaemic injury (57, 360, 401, 411). In the DOCA-salt 
hypertension model, glomerulosclerosis, glomerular hypertrophy, tubular 
proliferation and tubulointerstitial fibrosis were more severe in TRPV1-/- mice 
compared with wild-type mice (368). Furthermore, renal macrophage infiltration and 
8-isoprostane levels in urine (a marker of oxidative stress) were significantly less in 
DOCA-salt-treated wild-type mice compared with DOCA-salt-treated TRPV1-/- mice, 
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which suggest anti-inflammatory and anti-oxidative properties of TRPV1 (368). Of 
interest, TRPV1 were highly expressed in DOCA-salt-treated mice, which suggests 
that TRPV1 upregulation in this model is adaptive and may limit renal injury (368). 
This is supported by a previous report that showed TRPV1 upregulation in renal 
cortex, medulla and mesenteric arteries following high sodium intake in Dahl salt-
resistant rats (369). In contrast, TRPV1 expression was greatly reduced following 
high-sodium diet in Dahl salt-sensitive rats (369). Down regulation of CGRP was also 
revealed in dorsal root ganglion of Dahl salt-sensitive rats, but not in Dahl salt-
resistant rats, both groups fed with high-sodium diet (369). Therefore, it is suggested 
that attenuated blood pressure elevation observed in Dahl salt-resistant rats is partly 
attributed to the protective effect elicited by the increased expression of TRPV1. In 
addition, however, the salt-induced blood pressure elevation in Dahl salt-sensitive rats 
is partly due to an impairment in the sensory autonomic mechanism, which involves 
TRPV1 in the kidney. This notion is further supported by studies involving 
intravenous capsaicin administration which caused a greater lowering of blood 
pressure in Dahl salt-resistant rats compared with Dahl salt-sensitive rats both fed with 
high sodium-diet (369). Similarly, intra-pelvic infusion of capsaicin was associated 
with lesser activation of afferent renal nerves accompanied with lower release of SP 
and CGRP in Dahl salt-sensitive rats following high-sodium diet, which was followed 
by impaired contralateral diuresis and natriuresis (387). Therefore, in salt-sensitive 
models, protective regulatory mechanisms against renal injury are lost due to TRPV1 
downregulation, which contributes to blood pressure elevation in a mechanism that 
involves suppression of the sympatho-inhibitory reno-renal reflex. These results are 
consistent with previous findings obtained after high-salt diet in rats with renal 
ischaemia-reperfusion injury. In this regard, subcutaneous administration of a low 
dose of capsaicin prior to ischaemia was associated with a significant decrease in blood 
pressure, oxidative stress markers and inflammatory cytokines, accompanied with an 
upregulation in renal TRPV1 (401, 402). This was also associated with an increase in 
ARNA and CGRP release while RSNA was decreased, along with an improvement in 
kidney function. Additionally, high dose of subcutaneous capsaicin prior to ischaemia, 
was associated with down-regulation of TRPV1 in the kidney and a decrease in 
ARNA, in addition to deterioration in renal and cardiovascular parameters following 
high-sodium diet (402). Systemic administration of capsaicin 30 minutes prior to 
ischaemia-reperfusion injury attenuated serum creatinine levels, tubular injury and 
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decreased inflammatory macrophages. However, CPZ treatment did not alter kidney 
injury or function in the ischaemia-reperfusion model (57). Altogether, TRPV1 
channels modulate SNS activity and blood pressure regulation. There is a dual role 
however, and the modulation can be excitatory or inhibitory and thus, detrimental or 
protective to kidney function, such that the influence of TRPV1 channels remains 
controversial.  
 
1.5.4. TRPV1 receptors and hypoxia 
Recent evidence has shown that TRPV1 contributes to afferent-mediated sympatho-
excitation in carotid bodies and NTS following intermittent hypoxia (175, 307). 
Exposure to CIH increases spontaneous postsynaptic excitatory currents in the NTS 
and decreases tractus solitarii evoked postsynaptic excitatory firing, which alter the 
synaptic activity between afferent neurons and second level neurons of the NTS.  
Interestingly, synaptic transmission changes elicited by exposure to CIH in wild-type 
mice were absent in TRPV1-/- mice. Furthermore, the application of CPZ to NTS slices 
harvested from CIH-exposed mice reduced the enhanced spontaneous and 
asynchronous postsynaptic excitatory activity (175). The mechanism by which 
TRPV1 mediates CIH-induced enhanced NTS synaptic transmission is still unknown. 
It was suggested that exposure to CIH activates calcium/calmodulin-protein kinase II 
which phosphorylates TRPV1 channels. In addition, it is proposed that inflammation, 
observed during and after exposure to CIH, activates LOX that produces endovanilloid 
by-products, which are endogenous agonists for TRPV1 channels (175). The latter 
explanation has been supported by in vitro studies conducted on HEK293T cells in 
which exposure to 3% O2 increased the amplitude of TRPV1 currents with no reported 
changes in TRPV1 protein expression, indicating the possibility that hypoxia increases 
the production of TRPV1 activators (172). It is also suggested that hypoxia might 
induce TRPV1 membranous translocation, a phenomenon that was reported in rat 
pulmonary artery smooth muscle cells exposed ex vivo to 1% O2 for 48 hours (266). 
In addition, hypoxia-mediated activation of TRPV1 was inhibited by CPZ and tiron, a 
ROS scavenger that is membrane permeable (172). This suggests that ROS increases 
the activity of TRPV1 channels through an intracellular pathway. In HEK293T cells, 
desensitization of TRPV1 channels was reduced under hypoxic and high glucose 
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conditions (304). In this regard, hypoxia alone caused a greater reduction in TRPV1 
desensitization compared with high glucose conditions (304). 
On the other hand, TRPV1 activation and subsequent release of intracellular calcium 
cause ROS production which leads to mitochondrial depolarization and DNA damage 
(343). It was also found that challenging H9C2 rat cardiac myoblasts with hypoxia 
and reoxygenation increased apoptosis. Capsaicin treatment further decreased cell 
viability, which was later attenuated when TRPV1 was blocked by CPZ. Of interest, 
after ischaemia-reperfusion injury (40 minutes of no flow in Langendorff heart 
preparation followed by 30 reperfusion) and during concomitant inhibition of CGRP, 
TRPV1-/- mice had improved cardiac function compared with wild-type mice (343). 
This suggests that TRPV1 activation produces detrimental consequences through 
calcium release, whereas it can elicit cardio-protective effects through the release of 
SP and CGRP as reported in other studies of ischaemia-reperfusion injury (360).  
Exposure to acute intermittent hypoxia supplemented with bouts of hypercapnia 
causes sensory long-term facilitation (sLTF) of the carotid bodies i.e. increased basal 
firing of carotid bodies in addition to their exacerbated responsiveness to acute 
challenges such as hypoxia. This is mediated by P2X2/3 and TRPV1 receptors located 
at the postsynaptic afferent nerve fibres through a mechanism that is dependent on 
PKC phosphorylation (307). It has been shown that TRPV1 blockade causes 50% 
attenuation in carotid body sLTF (307). Similarly, TRPV1 located in renal sensory 
nerve endings might mediate enhanced firing of afferent renal nerves in the CIH model 
of hypertension (15). In support of this possibility, immunofluorescence confirmed 
co-localisation of TRPV1 channels with NOX4 in renal pelvic wall (216). Molecular 
analysis showed that NOX4 stimulates the release of hydrogen peroxide (H2O2) which 
activates TRPV1 to increase calcium entry and/or to enhance the release of SP and 
CGRP, with resultant activation of renal afferent nerves. In further support of this 
potential mechanism, H2O2 perfusion to the renal pelvis was associated with increased 
ARNA, an effect that was inhibited by CPZ and catalase infusion (216). On the basis 
of the above evidence, hypoxia can induce changes in TRPV1 activity which can alter 





1.6. Renal kallikrein-kinin system 
1.6.1. Bradykinin formation and localisation  
Kallikrein-kinin systems are either composed of high molecular weight kininogens 
and found only in liver tissue or low molecular weight kininogens, found in a variety 
of cells (309). Kinins are biologically active peptides that result from the hydrolysis 
of kininogens by a kallikrein enzyme from serine proteases family. In the kidney, 
kinins are formed within groups of cells at the terminal part of the distal nephron: 
collecting duct cells and connecting tubule cells (117, 309). At this site, kininogen is 
stored in the collecting duct cells and when the kallikrein enzyme is released from the 
connecting tubule cells, it converts kininogen to the kinins: bradykinin, lys-bradykinin 
and met-lys-bradykinin at the luminal and basolateral sides of the collecting duct. 
Bradykinin is formed either directly from kininogen by kallikrein or from lys-
bradykinin by aminopeptidase. Inactive kininogen represents 10% of human urinary 
protein (1.6-6.2 mg/L, respectively) and presents at a higher amount in renal medulla 
(2.4 mg/g protein) (113, 117). Kinins are degraded to inactive metabolites mainly by 
neutral endopeptidases (NEP) or angiotensin converting enzyme (kininase II). They 
are also converted by kininase I (carboxypeptidases) to Arg9-bradykinin and des-
Arg10-lys-bradykinin, which are both bradykinin receptor type 1 (BK1R) agonists 
(276, 309). The kallikrein-kinin system is also found in the cerebral cortex, 
hypothalamus, thalamus and choroid plexus (335). 
 
1.6.2. Renal bradykinin receptors: location and transduction pathways 
There are two types of bradykinin receptors: bradykinin receptors type 2 (BK2R) that 
are constitutively expressed and mediate the majority of physiological functions of 
bradykinin and BK1R that are absent in healthy conditions and are activated by 
kininase II hydrolysis products of bradykinin. Nevertheless, BK1R mRNA expression 
is rapidly stimulated in response to inflammation (367). Inflammatory cytokines 
including IL-6, TNF-α, IL-1β and growth factors trigger BK1R expression and 
augments its effects (117, 335). In addition, the BK1R gene activates the transcription 
sequences of NF-κB and activation protein-1 factor (335). BK1R mRNA expression 
is also stimulated by lipopolysaccharides (LPS) especially in the efferent arterioles, 
thin ascending and descending loop of Henle and distal tubules (117). In addition, 
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observations from functional studies indicate the localisation of BK1R in the afferent 
arterioles and mesangial cells (309). In response to inflammation, BK1R are also 
expressed in neurons, microglia and astrocytes of the spinal cord and the brain, which 
illustrate their role in neuroinflammation. Of interest, there is weak homology (~36%) 
between BK1R and BK2R, and high variability regarding BK1R between humans and 
rodents (335).  
Different methods were used to determine the location of BK2R in the kidney, such 
as the binding of micro-labelled bradykinin to nephron dissected segments, 
immunohistochemistry and RT-PCR (117). It was reported that BK2R are located in 
proximal tubules, thick ascending loop of Henle and connecting tubule cells. They are 
also located in the cortical and outer medullary collecting ducts and in the afferent 
arterioles. In relation to that, BK2R were identified using RT-PCR in the distal tubules. 
Moreover, BK2R were detected in the interstitial space of the renal medulla. BK1R 
and BK2R have been also localised in renal afferent sensory nerve endings and the 
lamina propria of the renal pelvic wall (151). 
Bradykinin is a well-known physiological pro-inflammatory mediator involved in pain 
sensation and inflammatory responses. Therefore, bradykinin receptors are also found 
in nociceptive small unmyelinated and thinly myelinated sensory fibres and nerve cell 
bodies of dorsal root ganglia, trigeminal ganglia and nerve terminations in the 
superficial parts of the spinal cord. They are also located in cardiac afferent fibres and 
stellate ganglia (339).  
Studies showed that both BK2R and BK1R are G-protein coupled receptors with seven 
transmembraneous helices. In the kidney, the BK2R transduction pathway is coupled 
to Gαq and Gαi subunits, which stimulate PLC, PLA2, PLD and PKC intracellular 
pathways (113, 117, 309). PLC activates second messengers such as diacylglycerol 
and IP3 which stimulate the release of intracellular calcium. Moreover, PKC 
phosphorylation activates sodium entry in distal nephron in addition to phosphatidyl 
inositol-mediated intracellular calcium stores mobilisation (105, 117). Cytosolic 
calcium in turn activates the release of prostaglandins, c-AMP/PKA-mediated 
inhibition of potassium efflux, in addition to an increase in SP and CGRP release 
(105). In a similar pathway in nociceptive nerve terminals, BK2R activation inhibits 
potassium efflux and causes nerve ending depolarization (105). BK2R, through PLA2 
45 
 
activation, increases the formation of arachidonic acid, which is a precursor for 
prostaglandin synthesis (105). Meanwhile, in renal sensory afferent nerve endings, the 
identified BK2R signalling pathway involves PKC-mediated activation of 
prostaglandins formation, which in turn activates the cAMP/PKA pathway and 
enhances the release of SP and CGRP (15, 187), as shown in Figure 1.4. Overall, 
bradykinin binding to BK2R directly activates ion channels causing depolarization 
and/or induces the release of neuropeptides that act on other receptors such as NK1 
receptor causing the activation of sensory nerve endings.  
For BK1R, there is a lack of information about its transduction pathway as it is not 
highly expressed under normal conditions. However, BK1R are Gαq and Gαi coupled 
receptors which activate PLC and stimulates IP3 and diacylglycerol to increase 
intracellular calcium (335). In addition, it is suggested that the BK1R transduction 
pathway involves P38 mitogen-activated protein kinase (MAPK) activation and 
extracellular signal-regulated kinase (ERK) phosphorylation (276, 335). Previous 
studies have shown that BK2R are desensitized following acute stimulation by 
bradykinin, which is due to receptor internalisation and ligand-receptor dissociation 
i.e. decreased binding affinity. However, there is no evidence of BK1R desensitisation 
after activation, rather than reports showing their upregulation in the presence of an 
agonist through the activation of NF-κB (105, 335).  
 
1.6.3. Physiological role of bradykinin in the kidney 
Endogenous bradykinin activates the renal mechanosensory afferent nerves through 
BK2R-mediated SP release. This is associated with a decrease in ipsilateral and 
contralateral RSNA i.e. an inhibitory reno-renal reflex (137, 180). In addition, 
bradykinin, through BK2R, enhances diuresis and natriuresis independent of the reno-
renal reflex by a glomerular-mediated action and a direct effect on the tubule (309). 
Furthermore, bradykinin stimulates the release of PGE2 from the collecting ducts, 
which results in inhibition of sodium reabsorption (117). It was also reported that 
bradykinin, through BK2R, inhibits sodium chloride reabsorption in the thick 
ascending limb of loop of Henle by cytochrome P450 and cyclooxygenase-2 (COX2)-
dependent mechanism (309). Indeed, BK2R are co-localised with COX2 as 
demonstrated by immunohistochemistry (305). Interestingly, infusion of bradykinin 
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into the renal medulla was associated with enhanced diuresis and natriuresis, an effect 
that was abolished after NO synthesis blockade (244). This effect of bradykinin is 
partially mediated by a reduction in ADH-enhanced water permeability and sodium 
reabsorption in the collecting ducts. In support of this notion, it was shown, using Fab 
fragments of antibodies, that a decrease in kallikrein activity by 80% and kinin release 
by 77% were associated with a 30% decrease in diuresis and 20-40% decrease in 
natriuresis, without alteration in blood pressure. This was confirmed by enhanced 
water and chloride reabsorption in the collecting ducts after the administration of 
HOE140, a selective BK2R antagonist (117). Of note, an increase in sodium intake 
was associated with an increase in urinary bradykinin levels, leading to inhibition of 
endothelial sodium channels (ENaC) in the distal tubules (231). In a transgenic rat 
model of excess bradykinin in the proximal tubules, RAAS alteration was observed, 
in addition to a decrease in mRNA expression of ADH A1 receptors and a decrease in 
ENaC expression in the distal nephron (27). RAAS changes involved increased Ang 
II levels and decreased plasma concentration of renin.  
Bradykinin, through BK2R, results in vasodilation in the afferent and efferent 
arterioles and vasa recta. However, there is also contraction of the glomerular 
mesangium leading to a decrease in filtration surface area and glomerular filtration 
coefficient. Therefore, bradykinin enhances diuresis but without changing GFR (309). 
In rabbits and rats, bradykinin’s vasodilator effect on afferent arterioles was found to 
be mediated by prostaglandins. In addition, bradykinin causes a dose-dependent 
vasodilation in the efferent arterioles mediated by cytochrome P450 in rabbits (299). 
Bradykinin at high concentration however can cause vasoconstriction that was found 
to be related to thromboxane. As previously mentioned, BK1R are not detected in 
tissues under healthy conditions, which indicates their minor physiological role. 
Nonetheless, results from isolated perfused rat kidneys showed increased renal 
vascular resistance in response to a BK1R agonist infusion. In rabbits, “BK1R-
mediated” vasoconstriction was abolished by HOE140, a BK2R antagonist. 
Conversely, activation of BK1R and BK2R in anaesthetised dogs resulted in an 
increase in renal blood flow (309). These conflicting results could be due to different 
roles of BK1R and BK2R in different species. 
Bradykinin triggers variable effects on the reno-renal reflex depending on the route of 
administration. Intra-renal bradykinin elevates RSNA, decreases natriuresis and 
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diuresis in the contralateral kidney with an immediate increase in heart rate, blood 
pressure and vascular resistance. This effect was abolished by renal denervation or by 
ganglionic blockade (3, 29, 329). However, intravenous injection of the same dose of 
bradykinin did not induce any significant changes in blood pressure or heart rate (101), 
but it produced mesenteric vasodilation (329). Moreover, intra-pelvic infusion of 
bradykinin was associated with the activation of afferent renal sensory nerves that 
stimulate an inhibitory reno-renal reflex and a contralateral natriuresis (190). 
Contrariwise, bradykinin infusion into the renal artery was associated with enhanced 
firing of ADH cells in SON, increased plasma ADH levels, and increased blood 
pressure and vascular resistance (101, 391). The sympatho-excitatory effect was 
abolished after the denervation of the kidney that was infused by bradykinin, strongly 
suggesting an excitatory reflex resulted from bradykinin activation of sensory afferent 
renal nerves (151, 391).  
 
1.6.4. The kallikrein-kinin system changes in hypertension 
BK1R and BK2R activation contributes to many physiological and pathophysiological 
elements of cardiovascular dysfunction. Both receptors mediate inflammatory 
responses as BK2R are involved in the acute phase of inflammation and BK1R are 
involved in the chronic inflammatory phase (335). Decreased levels of kallikrein was 
observed in hypertensive individuals (309). In addition, kininogen deficient rats, 
BK2R-/- deficient mice and control mice subjected to BK2R blockade, each exhibited 
salt-sensitive hypertension (244). Intra-renal infusion of a BK2R blocker increased 
blood pressure in rats with normal sodium intake (353). Moreover, transgenic mice 
with overexpression of BK2R were hypotensive and BK2R blockade restored their 
blood pressure back to normal (244). Therefore, considerable evidence related to the 
protective role of kallikrein-kinin system, in particular through BK2R signalling, has 
been proposed.  
One of the protective mechanisms of BK2R is linked to the pressure natriuretic 
response to elevation in arterial blood pressure. When blood pressure increases, it 
induces preglomerular vasoconstriction as part of the autoregulatory mechanism. This 
induces shear stress and the release of endothelial humoral factors such as kinins and 
NO. Subsequently, bradykinin increases medullary and papillary blood flow (both lack 
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autoregulation), which causes pressure natriuresis. Bradykinin-mediated increase in 
papillary blood flow is dependent on NO production, rather than PGE2. This was 
further confirmed by the effects of HOE140, a BK2R antagonist, on lowering basal 
and pressure-induced increase in nitrate/nitrite urinary excretion (353).  
Bradykinin through BK2R decreases the expression of extracellular matrix (ECM) 
protein by increasing the activity of plasminogen and metalloproteinase 2 (310), which 
explains bradykinin-mediated decrease in cardiac and tubulointerstitial fibrosis. The 
latter has been observed in BK2R-/- deficient mice that exhibited exaggerated 
interstitial fibrosis after unilateral ureteral obstruction. Transgenic mice with 
overexpressed kallikrein gene had attenuated interstitial fibrosis in this model, which 
was blocked after BK2R inhibition (310). In general, ureteral obstruction is associated 
with increased mRNA expression of many fibrotic proteins and the differences 
between B2-/- receptor deficient and B2 overexpressed mice were related to changes 
in collagen III and IV expression (310).  
Importantly, suppression of the inhibitory reno-renal reflex mediated by impaired 
ARNA was observed in SHR. Kopp et al. (190) illustrated that suppressed ARNA is 
related to attenuated bradykinin. Intra-renal pelvic bradykinin that activates renal 
sensory nerve endings in control rats, failed to increase ARNA in SHR. Similarly, 
intra-renal pelvic infusion of 4β-phorbol 12,13-dibutyrate, a PKC activator, did not 
increase ARNA in SHR (190). Therefore, impaired inhibitory reno-renal reflexes in 
the SHR can be due to attenuated PKC activity that is necessary for mediating 
bradykinin effects. 
Increased expression of BK1R was observed in different disease models involving 
kidney injury. BK1R antagonism elicited a protective role in obstructive nephropathy, 
LPS-induced renal inflammation and glomerulonephritis (286). It has also been shown 
that BK1R disrupt blood brain barrier integrity and sustain arterial hypertension in 
SHR and Ang II-induced hypertension models (335). Intracerebroventricular (ICV) 
injection of Sar[D-Phe8]-desArg9-BK, a BK1R agonist, increases arterial blood 
pressure in normotensive and SHR, whereas a decrease in blood pressure and heart 
rate was observed after its blockade in SHR (90). Furthermore, BK1R antagonism in 
SHR was associated with a decrease in left ventricular hypertrophy and improvement 
in the ejection fraction. This was also associated with maintained mitochondrial 
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structure that is known to be disrupted in the SHR model (77). Enhanced activity of 
ERK1/2 and c-Jun N-terminal kinases (JNK) in SHR cardiovascular tissues was 
attenuated after BK1R antagonism (77). Conversely, in the two-kidney, one-clip 
model in BK2R -/- mice, BK1R induced opposing effects in response to antagonism 
such as an increase in blood pressure, in addition to a decrease in blood pressure after 
their stimulation. It was suggested that BK1R overexpression in the clipped kidney of 
BK2R -/- mice exhibits BK2R-like haemodynamic changes (88).  
In Ang II-induced hypertension, BK1R inhibition abolishes inflammatory cytokines 
and the expression of oxidative stress biomarkers. Furthermore, it was found that AT1 
and BK1R form heterodimers in hypertensive individuals. This suggests a cross talk 
between BK1R and RAAS. Therefore, as AT1 receptor activation by Ang II mediates 
neuroinflammation in hypertension, it is suggested that BK1R are also involved in the 
pathogenesis of neuroinflammatory features of hypertension (335). Indeed, BK1R are 
upregulated in the hypothalamus of SHR and DOCA-induced hypertension models, as 
well as in the spinal cord and brain of Ang II-induced hypertensive rats, and in the 
PVN of hypertensive mice expressing pro-inflammatory cytokines. Moreover, BK1R 
inhibition attenuates blood pressure and neuroinflammation observed in salt-sensitive 
hypertension (335). It has also been shown that BK1R activation enhances inducible 
NO synthase and induces superoxide production by NADPH oxidase (335). NO 
interaction with superoxide produces peroxynitrite anions that cause nitrosative stress, 
inflammation and DNA damage (335). Of interest, these pathological features were 
detected in kidneys harvested from CIH-exposed rats (224). BK1R receptor activation 
induces neutrophil degranulation, leukocyte migration and the release of matrix 
metalloproteinase 9 through ERK1/2 and P38-MAPK pathway (335). MAPK 
enhanced phosphorylation of ERK1/2 and P38 apoptotic pathways were also detected 
in renal tissues after exposing mice to 3 days of CIH (342, 380). BK1R inhibition was 
associated with a decrease in proteinuria, renal inflammation (CCL2 and CCL7 
chemokines), CD4+ T cells, renal macrophages and attenuation of blood pressure in 
lupus nephritis and obstructive nephropathy. In addition, BK1R antagonism was also 
associated with a decrease in renal fibrosis in obstructive nephropathy and a reduction 
in renal inflammation in LPS, cisplatin models and ischaemia-reperfusion injury 
(286). Of importance, BK1R antagonism decreased blood pressure in glucose-fed rats, 
which was accompanied by decreased superoxide levels in the renal medulla (78). 
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Therefore, there is conclusive evidence that BK1R expression and/or activation are 
involved in the pathogenesis of hypertension. 
 
1.6.5. The role of the kallikrein-kinin system in baroreflex regulation 
Intra-renal bradykinin infusion disrupts the autonomic control of blood pressure, 
resulting in decreased high-pressure baroreflex sensitivity. Moreover, it was 
associated with 13% decrease in RSNA sympatho-inhibitory response to volume 
expansion compared with 58% RSNA sympatho-inhibition following intra-renal 
infusion of saline (167). Furthermore, intra-renal bradykinin was associated with 
increased contralateral ERNSA and decreased diuresis and natriuresis (28). Renal 
stenosis in addition to 50% decrease in renal blood flow was associated with R2 
chemoreceptor stimulation, which caused a decrease in baroreflex sensitivity and a 
reflex increase in vascular resistance i.e. renal sympatho-excitatory reflex (230). In 
addition, systemic administration of aprotinin, an inhibitor of tissue kallikrein, caused 
33% decrease in vascular resistance, which suggests partial contribution of kinins in 
the chemoreceptor-mediated renal pressor reflex (230). In support of these findings, 
Abdulla et al. (3) investigated the role of renal bradykinin receptors in the modulation 
of the baroreflex in a cisplatin-induced renal failure model. In renal failure rats, 
blockade of BK2R, but not BK1R, markedly restored arterial baroreflex regulation of 
RSNA and heart rate to near control levels. In addition, BK1R blockade enhanced the 
RSNA sympatho-inhibitory response to volume expansion (3). Unexpectedly, BK1R 
blockade blunted RSNA sympatho-inhibitory response to volume expansion in control 
rats. In contrast with the aforementioned results, impaired baroreflex control of heart 
rate has been reported in transgenic mice lacking BK2R (244). Nevertheless, the renal 
kallikrein-kinin system potentiates the excitatory reno-renal reflex observed in some 
hypertension disease models that involve kidney injury, which have been shown to 
impair baroreflex homeostasis. However, there is insufficient evidence regarding the 
subtype of bradykinin receptors involved in the excitatory vs. inhibitory reno-renal 
reflexes, and this requires further investigation.   
Together, these studies support the presence of an excitatory reno-renal reflex that is 
activated with contributions from a number of receptors such as TRPV1 and 
bradykinin. As in CIH-induced hypertension, inflammatory mediators such as TNF-α 
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and IL-6 were found to be highly expressed in the kidney in several models of renal 
injury and hypertension which showed BK1R upregulation (131, 224, 333, 335, 382). 
This points to a possible role of these mediators in initiating a sympatho-excitatory 
response leading to impaired blood pressure homeostasis. 
 
1.6.6. Kallikrein-kinin system during hypoxic injury 
Individuals exposed to acute hypoxia (10% O2 and 12% O2) showed an increase in 
renal blood flow, with no changes in GFR or plasma and urine bradykinin 
concentration (17). In relation to that, the action of kinins on BK1 and BK2 receptors 
exhibited both protective and deleterious effects during ischaemia-reperfusion injury. 
Wang et al. (367) reported pathological changes in the kidney in response to 45 
minutes of renal ischaemia followed by reperfusion. BK2R-/- mice in this study had 
higher serum creatinine concentration 24 hours following ischaemia-reperfusion 
compared with wild-type mice. However, serum creatinine was lower in mice lacking 
BK1R at 4, 24, 48 and 120 hours following injury. Furthermore, BK1R antagonism 
pre-treatment in wild-type mice elicited a similar decrease in serum creatinine as in 
BK1R-/- deficient mice. In support of the functional improvement associated with BK1 
receptor antagonism, BK1R-/- mice exhibited an increase in mRNA expression of anti-
apoptotic Bcl-2 and an attenuation of gene expression of Bad and caspase-3, which 
are apoptotic factors. Moreover, following ischaemia-reperfusion, in BK1R-/- mice 
and wild-type with BK1R antagonism, increased mRNA expression of anti-
inflammatory mediators (IL-4, IL-10 and GATA-3) and decreased pro-inflammatory 
mediators including IL-1β and T-bet transcription factor were observed (367). BK1R 
inhibition was also associated with increased heme oxygenase-1 (HO-1) and decreased 
expression of monocyte chemoattractant protein-1 (MCP-1) (367). This highlights the 
deleterious consequences of BK1R activation in hypoxic injury. In another study of 
renal ischaemia-reperfusion injury, BK2R-/- mice showed decreased serum creatinine 
compared with wild-type mice. This was associated with a decrease in TNF-α, ROS, 
apoptosis and MCP-1 expression (367). However, the elimination of BK1R and BKR2 
together elicited greater pathological deterioration. Kakoki et al. (153) reported 
exaggerated renal ischaemia-reperfusion injury in BK1R-/- /BK2R-/- mice compared 
with BK2R-/- mice. This was associated with low NO production as reflected by lower 
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plasma nitrite/nitrate ratio in BK1R-/- /BK2R-/- mice compared with BK2R-/- mice and 
wild-type mice (153). Moreover, tubular damage, growth factors (TGF-β1, CTGF and 
endothelin-1) and 8-hydroxy-2'-deoxyguanosine were higher after ischaemia-
reperfusion injury in the BK1R-/- /BK2R-/- mice compared with either BK2R-/- or wild-
type mice (153).  
The findings from the above studies explain the superior effect of angiotensin-
converting enzyme inhibitors (ACEI) as anti-hypertensive agents compared with Ang 
II receptor blockers, because ACEI inhibit Ang II and decrease the degradation of 
bradykinin, which induces vasodilation through endothelial NO release (153). 
Bradykinin through BK2R induces relaxation of rat, dog and mouse carotid arteries 
and causes vasodilation in the middle cerebral arteries and coronary arteries (352). The 
protective role of BK2R was also revealed after myocardial ischaemic injury, as BK2R 
were upregulated at the zone between scar tissue and healthy myocytes (352). In 
addition, hypoxia (5% O2) exposure of rat cardiac microvascular endothelial cells and 
cultured human coronary artery endothelial cells was associated with increased mRNA 
expression of BK2R, which suggests a role for BK2R in mediating hypoxia-induced 
angiogenesis (352). Similarly, neuronal ischaemia-reperfusion injury was also 
associated with enhanced activation of inflammasomes, which causes cleavage of 
caspase-1 that converts IL-1β and interleukin-18 (IL-18) to their active form. This was 
accompanied by increased inflammatory cytokines and brain inflammation (347). 
These pathological consequences were decreased by bradykinin pre-treatment acting 
on BK2R, which were upregulated in response to ischaemia-reperfusion injury. 
Accordingly, HOE140, BK2R blocker, attenuated the neuroprotective effect elicited 
by bradykinin. In addition, bradykinin activation of BK2R was associated with a 
decrease in the percentage of apoptotic neurons that are triggered by hypoxia-
reperfusion injury (347). In primary cortical neuronal cultures, hypoxia-reoxygenation 
treatment was also associated with increased levels of gasdermin D (GSDMD) 
substrate of caspases by two-fold. Generation of the active form of GSDMD by 
activated caspase-1 induces apoptosis, which was suppressed by bradykinin pre-
treatment of neuronal cultured cells (347). Hypoxic-reperfusion injury induced by the 
obstruction of middle cerebral arteries, was associated with an increase in miR-200c 
expression and a decrease in syntaxin 1A. BK2R antagonism worsened brain function 
and increased miR-200c expression (348).  
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Post-conditioning is a protective phase following ischaemia that is defined by repeated 
cycles of obstruction and reperfusion. This phase involves the activation of many 
transduction pathways that include kinins-mediated activation of NO, c-GMP and  
mitochondrial K+ ATP channels, which induce ROS release (275). BK2R blockade 
during the reperfusion phase of isolated rat heart eliminated post-conditioning 
protection. This was also observed in response to antagonism of NO, PKG, 
mitochondrial K+ ATP channels and ROS scavengers such as N-acetylcysteine and 2-
mercapto-propionylglycine. Intermittent injection of diazoxide (activates K+ ATP 
channels) and bradykinin enhanced post conditioning protection (275). Importantly, 
exposure to chronic hypoxia (10% O2) for two weeks decreased kallikrein in renal 
tissue, which was associated with sodium retention. This elevates oxygen demand and 
worsens kidney hypoxia; thus, exacerbates hypertension. Therefore, it is unknown 
whether decreased kallikrein contributes to kidney hypoxia initiation or it occurs as a 
consequence of hypoxia, or both (362). Overall, hypoxia is associated with changes in 
kallikrein-kinin system that might involve BK2R or BK1R. BK2R can mediate a 
protective compensatory pathway through vasodilation and increased medullary blood 
flow whilst renal bradykinin can cause sympatho-excitation through the activation of 
renal sensor nerve endings. It is also suggested that BK1R activation plays a part in 
the pathological consequences of hypoxic injury. However, further studies are 
required to confirm the exact role of BK1R. 
Results from a previous study suggest that bradykinin acting through carotid bodies 
can induce a vasopressor response. Intra-carotid injection of bradykinin causes a 
biphasic effect; an early depressor phase, which was associated with decreased blood 
pressure and heart rate and a later pressor phase during which blood pressure and SNA 
were significantly elevated but with no change in heart rate. Interestingly, denervation 
of the carotid bodies abolished the pressor effect and exacerbated the early depressor 
effect (346). A similar biphasic response was also observed after ICV injection of 
bradykinin. Intra-carotid and/or ICV injection of indomethacin attenuated the pressor 
response of ICV-injected bradykinin (346). Similarly, intra-carotid infusion of 
arachidonic acid decreased the depressor effect and augmented the pressor response. 
This suggests that the bradykinin pressor reflex is dependent on PGE2 synthesis (346). 
Notwithstanding that the bradykinin pressor reflex is mediated by the carotid bodies, 
the possible role of bradykinin receptors in carotid body activation during hypoxia was 
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not studied. Exposure to CIH induces the expression  of inflammatory cytokines and 
profibrotic factors that are involved in the upregulation of BK1R (15). In addition, in 
renal tissue after exposure to different protocols of CIH, transduction signalling 
pathways of bradykinin receptors are activated such as MAPK and P38 pathways, 
peroxynitrite release and enhanced superoxide (382). However, the influence of 
exposure to CIH on renal expression and function of bradykinin receptors involved in 




















1.7. Renal functional changes during hypoxia  
Under normal conditions, the kidneys are supplied with 25% of the cardiac output. 
This makes blood and oxygen supply to the kidney greater than oxygen demand. The 
cortex receives high blood perfusion (~20% of cardiac output), which brings cortical 
PO2 levels to 50-60 mmHg. In contrast, the renal medulla is perfused with as little as 
10-15% of the total blood supplied to the kidney such that PO2 is relatively low at 10-
20 mmHg (327). It is known that the renal medulla is highly vulnerable to hypoxic 
damage due to low blood supply, lack of auto-regulatory mechanisms in deep regions 
and the arteriovenous shunt of vasa recta (66, 327). Kidney PO2 remains preserved in 
response to decreased renal blood flow (RBF) within the physiological range (up to 
30%). Preserved kidney oxygen tension is due to afferent arteriolar dilation and a 
decrease in filtered sodium load corresponding to the decrease in GFR, which 
maintains relatively constant oxygen supply to demand ratio (8). Meanwhile, another 
study has shown that cortical PO2 was preserved when RBF was decreased by ±30% 
as a result of stenosis and during the infusion of vasoactive agents. This was not 
conjugated with reduced medullary PO2. It was strongly proposed that the preserved 
PO2 levels in the cortex is related to decreased preglomerular oxygen shunt from 
arteries to veins when RBF is decreased (92, 108, 205). Specific preservation of PO2 
in the renal cortex during decreased renal blood flow was not conjugated with changes 
in the cortical oxygen consumption while medullary PO2 was reduced. It was strongly 
proposed that preserved PO2 levels in the cortex is related to decreased preglomerular 
oxygen shunt from arteries to veins (205).  Beyond these limits, hypoxia develops and 
the production of superoxide (O2
.-) and H2O2 is enhanced, which play a major role in 
regulating renal medullary blood flow and sodium excretion (66). It was also reported 
that superoxide radicals activate Na+/K+/2Cl- co-transporters and through the PKC-α 
pathway, they increase sodium reabsorption within the medullary thick ascending limb 
of the loop of Henle. Oxygen radicals produced from NOX, through NO suppression, 
enhance Na+/K+ ATPase activity in the renal medulla. Subsequently, oxygen demand 
is increased due to enhanced active reabsorption of sodium. Moreover, oxygen 
radicals produced from the mitochondria enhance phosphorylation of MAPK and 
increases the expression of COX-2. The latter activates cAMP/PKA pathway in renal 




It was shown that renal medullary blood flow is decreased after 3 weeks of 
hypertension in SHR and in Dahl salt-sensitive rats (66). Intra-medullary but not 
systemic infusion of captopril, an ACEI, enhanced renal medullary blood flow by 40% 
and attenuated blood pressure by 50% (222). Indeed, renal medullary infusion of tiron 
(O2
.- scavenger) increased renal medullary blood flow and enhanced sodium excretion. 
In addition, intra-medullary infusion of diethyldithiocarbamate (SOD inhibitor) 
reduced blood flow to the medulla and caused an anti-natriuretic effect (66). 
Interestingly, the latter was associated with the development of hypertension, which 
was abolished by intra-medullary infusion of catalase and tempol (SOD mimetic) (66). 
Moreover, apocynin (NOX inhibitor) infusion to the renal medulla attenuated salt-
induced hypertension by 50% in salt-sensitive rats (349). Thus, it was suggested that 
O2
.- and H2O2 play a synergistic role in reducing renal medullary blood flow and 
increasing sodium retention, contributing to the development and/or exacerbation of 
hypertension. Interestingly, a number of studies in the literature reported, using 
different hypoxia protocols, renal oxidative stress, accumulation of ROS and kidney 
injury (80, 224, 277, 342, 381).  
Furthermore, hypoxia is considered a mutual feature in acute kidney injury (AKI) and 
chronic kidney disease (CKD) (14). Ischaemic damage of the interstitium i.e. 
tubulointerstitial fibrosis, which is known as a cause and consequence of hypoxia, is 
a common feature in end-stage renal disease (262). In addition, epidemiological 
studies have shown a strong correlation between OSA and CKD (14, 215). An 
increased risk of hypertension by 46% has been reported in subjects that have sleep-
related oxygen saturation of less than 90% (14). On the other hand, increased filtration 
fraction and glomerular hypertrophy, a precursor for CKD, were detected in OSA 
patients (11). This is related to increased RSNA and enhanced renal RAAS. In relation 
to that, it was found that continuous positive airway pressure reverses the increase in 
glomerular pressure and the decrease in filtration fraction in OSA patients (403). 
Interestingly, however, altitudes of 159 m and higher showed a negative association 
with CKD prevalence, which suggests that renal changes might differ between 
intermittent and chronic hypoxia conditions (106). Other than OSA, several disease 
models such as renovascular hypertension, polycystic kidney disease and remnant 
kidney models reported a decline in kidney function concomitant with local renal 
hypoxia (8, 262, 327). However, the temporal contribution of hypoxia to the 
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development and progression of kidney malfunction is not fully established as most 
these of studies undertake assessments at just one time interval of the disease stage. 
This necessitates further studies to look at the time course of the disease process and 
add to our understanding of the effects of hypoxia on kidney functions. 
 
1.7.1. Effects of intermittent hypoxia on renal function 
Active transport in the medullary thick ascending limb of the loop of Henle is higher 
than in proximal tubules, with greater Na+/K+ ATPase activity. Accordingly, the thick 
ascending limb consumes 50% more energy per mg of tissue protein compared with 
proximal tubules (327). Thus, the oxygenation state of the kidney is profoundly 
controlled by a balance between sodium transport and oxygen supply on the one hand, 
and between sodium transport and oxygen consumption on the other hand. Disruption 
of this balance leads to a decline in renal PO2, a phenomenon that has been observed 
in a rat model of CIH (258). O’Neill et al (258) reported no change in diuresis and 
natriuresis in rats exposed to CIH (6.5% O2, 12 cycles/hr, 8 hr/day, 14 days). A 
decrease in RBF and GFR was reported along with an increase in renal vascular 
resistance (RVR) (258). This was accompanied by a fall in tissue NO levels, moderate 
proteinuria and an increase in kidney injury marker-1. Of note, another study using a 
different protocol of CIH (10% O2, 20 cycles/hr, 10 days) has shown increased cortical 
expression of adenosine type 2 receptors. Activation of these receptors causes efferent 
arteriolar vasodilation, which can explain decreased GFR in this model (173). Using 
the latter protocol, a decrease in RBF was detected in addition to a decrease in SOD1 
expression and an increase in IL-6 in the renal cortex (355). Importantly, the decline 
in GFR that was associated with a decrease in sodium load, was not associated with a 
reduction in oxygen consumption. Therefore, a shift in the linear relationship between 
transported sodium and oxygen consumption was observed, which indicates that for 
any amount of sodium reabsorbed, there is a higher oxygen consumption indicating a 
decrease in the efficiency of renal sodium transport mechanism. The altered balance 
could be due to lowering in NO bioavailability, as NO competes with oxygen for 
mitochondrial respiration leading to decreased oxygen consumption (258, 327). 
However, the type of NOS involved is unknown, but uncoupling of eNOS in response 
to a different CIH protocol has been reported (22). As a result, decreased cortical PO2 
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was observed following exposure to CIH, but interestingly medullary PO2 was normal 
(258), suggesting greater susceptibility in cortex compared with medulla in the CIH 
model. In another study, CIH-exposed rats had increased tissue IFN-γ and increased 
haematocrit level which indicates increased production of erythropoietin by HIF-1α 
(258). Similarly, a more severe protocol of CIH (20 cycles/hr, 5% O2, 8 hr/day, 6 
weeks) was associated with a decline in GFR and an increase in plasma creatinine 
(303). The latter suggests that intermittent hypoxia damaged medullary tubular 
epithelial cells and disrupted the integrity of the tight junction with a resultant back 
leak of creatinine into the bloodstream. Moreover, CKD rats that were exposed to the 
same CIH protocol had exacerbated hypertension. Medullary expression of HO-1, a 
gene that is regulated by Nrf2, was greater after exposure to CIH compared with the 
CKD group breathing normal air (303). It is well-known that HO-1 decreases the 
expression of vasodilatory enzymes. Therefore, the additive effect of CIH in terms of 
decreased ET-1 expression, suppressed NO bioavailability and increased expression 
of HO-1, augments endothelial dysfunction, which leads to further kidney hypoxia and 
hypertension in CKD animals. Overall, the current evidence shows that exposure to 
CIH induces renal hypoxia and kidney damage mainly through endothelial 
dysfunction in addition to the potential for tubular-dependent modulation as tubular 
transport efficiency is decreased (Figure 1.6). The possible role of renal nerves in 
mediating the reduction in RBF and GFR following exposure to CIH has not been 
studied. In addition, it is not determined whether renal alterations observed in CIH-
induced hypertension are due to hypoxia per se or secondary to blood pressure 
elevation. Friederich-Persson et al. (103) showed an a decrease in renal PO2 and 
proteinuria in the absence of other confounding variables such as hypertension or 
diabetes, after systemic administration of 2,4-dinitrophenol, a mitochondrial 
uncoupler to oxidative phosphorylation that increases oxygen consumption. 
Moreover, renal hypoxia was revealed 3 days after the initiation of type 1 diabetes 
mellitus lasting 15 days before the emergence of albuminuria (262). This suggests that 
renal hypoxia might precede and cause kidney injury. 
Patients with AKI who had cardiopulmonary bypass exhibited a fall in GFR and 
sodium reabsorption with no decrease in oxygen consumption, which also indicates a 
decrease in transport efficiency that led to renal hypoxia (262). Similarly, in the SHR 
model of hypertension, a decrease in RBF and a decline in sodium transport efficiency 
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(decreased transported sodium/oxygen consumption ratio) was observed (373). These 
changes occur despite the fact that CIH-exposed rats showed higher blood PO2 and 
lower PCO2, which arises due to long-term facilitation of breathing and persistent 
hyperventilation (258). A previous study has shown that forced breathing of normal 
air alters renal function and enhances diuresis and natriuresis (68). Therefore, further 
studies are needed to consider the complex effects of hypoxia on kidney function 
independent of renal functional fluctuations that are mediated by intrathoracic pressure 
changes or the suppressing effect that lowered PCO2 has on central chemoreceptors 
and SNA. 
 
Figure 1. 6. Suggested mechanisms of intermittent hypoxia-mediated renal 
functional changes. There is scarcity in studies that investigated kidney function in 
response to intermittent hypoxia. The available data suggest that endothelial 
dysfunction as a result of intermittent hypoxia causes renal functional changes. “?”, 
increased renal sympathetic nerve activity (RSNA) is another possible mechanism for 
the decline in glomerular filtration rate (GFR), which is yet unknown. A2 receptor, 
adenosine type 2 receptor; NO, nitric oxide; NOS, nitric oxide synthase; ET-1, 
endothelin-1; HO-1, heme oxygenase-1; ROS, reactive oxygen species; SOD, 
superoxide dismutase; KIM-1, kidney injury marker-1; KLF-2, Krüppel-Like Factor-
1; NGAL; Neutrophil gelatinase-associated Lipocalin; RBF, renal blood flow; RVR, 




1.7.2. Renal function alteration in acute hypoxia 
Previous studies have shown that exposure to acute hypoxia induces inconsistent 
changes in renal function, due to species differences and type of anaesthesia used. 
Moreover, the hypoxic ventilatory response can interfere with renal responses, which 
are modulated when mechanical ventilation is utilized (254). Furthermore, respiratory 
and cardiovascular changes during hypoxia further modulate renal function. 
Nevertheless, similar species exhibited variable renal function responses to acute 
hypoxia, which could be related to different hypoxia protocols with different severity 
levels of hypoxia and exposure i.e. systemic exposure vs. isolated organ exposure of 
the kidneys or carotid bodies (Figure 1.7). 
Acute exposure to hypoxia (12.5% O2 for 30 minutes) in conscious rats was associated 
with alterations in cardiovascular parameters (a decrease in blood pressure and an 
increase in heart rate), respiratory modulation (hyperventilation with consequential 
changes in blood PO2 and PCO2) and renal functional changes (decreased GFR and 
electrolyte retention) (31). These changes were also associated with a decrease in RBF 
(31, 366). It was suggested that the decreased GFR is responsible for decreased water 
excretion and decreased sodium load and therefore less sodium excretion. The 
decrease in blood pressure in the mentioned study (31) could be due to 
hyperventilation-induced hypocapnia, as a previous study showed no changes in blood 
pressure during exposure to isocapnic or hypercapnic hypoxia (366). However, 
exposure to hypercapnic hypoxia (8% O2 with 6% CO2 for 30 minutes) in conscious 
rats and dogs was associated with a similar decrease in RBF to that observed in 
poikilocapnic hypoxia (366). Therefore, in hypercapnic hypoxia, an increase in RVR 
was observed which was due to the decrease in RBF along with a relatively maintained 
blood pressure.  
In a similar acute poikilocapnic hypoxia exposure (12.5% O2 for 30 minutes) in 
anaesthetised rats, a decrease in GFR was reported along with 50-65% decrease in 
urine and sodium excretion. In contrast to conscious rats, this was associated with 
increased RBF and renal vascular conductance (RVC) (254). It is proposed that 
differences between conscious and anaesthetised rats could be due to a greater increase 
in SNA in response to chemoreceptor stimulation in the conscious state, with higher 
activation of certain brain areas that cause a decrease in RBF, which overcomes the 
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auto regulatory mechanisms. Meanwhile, respiratory modulation in response to acute 
hypoxia was similar in anaesthetised and conscious rats (254). The decrease in GFR 
and renal perfusion pressure (RPP) along with an increase in RVC indicates the 
presence of a vasodilatory mechanism on efferent, but not afferent arterioles. 
Adenosine is released in response to systematic ischaemia which can trigger 
vasodilation on the efferent arterioles through A2 receptors and vasoconstriction on 
the afferent arterioles through A1 receptors (334). Similar to conscious rats, the 
decrease in GFR could be responsible for the retention in water and sodium excretion 
i.e. decreased pressure diuresis. Interestingly, when the same hypoxia protocol was 
repeated after occluding the abdominal aorta distal to the renal artery, no changes in 
diuresis and natriuresis were observed in response to acute hypoxia despite a PO2 
decline to 40-45 mmHg (254). This was related to stabilisation of blood pressure and 
RPP during occlusion. This provides evidence that the anti-diuretic and anti-natriuretic 
effects were caused by the hypoxia-dependent decrease in RPP. Moreover, sustained 
RPP improves O2 supply to deeper regions of the kidney and therefore reduces the 
release of adenosine, which normally activates sodium-bicarbonate co-transporter 
causing sodium reabsorption (254). Indeed, other mechanisms mediated by the 
occlusion of abdominal aorta can contribute to kidney function alterations such as 
renin release, a decrease in baroreflex control of RSNA and the maintenance of 
adequate blood supply to carotid bodies; thus, decreasing their activity. The authors 
of the mentioned study excluded the possibility of altered ADH release because the 
PO2 level required to alter ADH secretion is less than the lowest PO2 level that was 
reached during the hypoxia protocol (254). Following renal denervation, acute 
hypoxia exhibited a similar decrease in urine and sodium excretion, which indicates 
that alterations in renal function were not mediated by changes in RSNA. However, 
renal denervation caused an increase in basal diuresis and natriuresis in addition to 
lower basal GFR (254).  
A study using a similar protocol (12% O2 for 20 minutes) in anaesthetised rats showed 
a 2.8 fold elevation in systemic renin activity (252). Nonetheless, it was illustrated that 
Ang II did not contribute to hypoxia-mediated anti-diuresis and anti-natriuresis, as 
losartan (Ang II receptor blocker) did not alter the magnitude of urine and sodium 
excretion during hypoxia. Maintenance of RPP by aortic occlusion decreased the anti-
diuretic and anti-natriuretic effects of hypoxia. This provides further evidence that 
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RPP contributes partially to hypoxia-mediated alterations in renal function and its 
decrease stimulates renin release, but not vice versa.  
In another study of acute hypoxia exposure in conscious rats (16.5% O2 for 4 hours) 
followed by measurement of kidney function under anaesthesia, GFR and RBF were 
increased with a tendency towards increased water and sodium excretion. The 
decrease in RVR indicates afferent vasodilation supported by elevated plasma and 
cortical NO bioavailability (258). However, these parameters were measured under 
anaesthesia during whilst animals were breathing normal air.  
Previous studies showed enhanced diuresis and natriuresis in response to acute 
hypoxia in conscious dogs, but the opposite was observed in anaesthetised dogs (40, 
365). Perfusion of the kidney with venous blood for 20 minutes in anaesthetised dogs 
was associated with 22% increase in renal plasma flow and 10% decrease in creatinine 
clearance; thus, increased RVR. However, there was a gradual increase in urine 
volume and sodium excretion in 6 out of 8 experiments and a significant increase in 
potassium excretion in 4 out of 8 dogs (314). Enhanced sodium excretion despite a 
decreased GFR was suggested to be related to impaired tubular electrolyte 
reabsorption. The increase in water excretion in response to hypoxia was attributed to 
either a decrease in ADH or another mechanism that impairs water reabsorption in the 
distal convoluted tubules. This is similar to observations from a hypoxia study in 
humans with blood PO2 of 50 mmHg (33, 314), where an increase in water and 
electrolyte secretion was seen despite decreased GFR. The increase in renal plasma 
flow in dogs was attributed to the possible release of adenine metabolites that mediate 
vasodilation. In relation to this, it was reported that anaesthetised dogs breathing 9 to 
14% O2 exhibited increased urine volume, while exposure to 5 to 7% O2 was 
associated with water retention (314). Similarly, experiments at high altitude of 5,486 
m in dogs showed increased renal plasma flow, whereas the opposite was observed at 
higher altitude of 7,315 m, indicating that severity of hypoxia might induce different 
modulation of kidney excretory function (165).  
Direct stimulation of carotid bodies in anaesthetised dogs by venous blood (PO2 ~27.4 
mmHg) was associated with an increase in blood pressure, and decreases in heart rate, 
RBF, GFR and filtration fraction, in addition to a decrease in water and absolute, but 
not fractional, sodium excretion (157). In the latter study, the carotid bodies were 
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isolated so there was no effect of perfusion on the brain. Moreover, dogs were 
artificially ventilated, their skeletal muscles were paralyzed and vagosympathetic 
nerves were sectioned to eliminate any effects from the cardiopulmonary or 
intrathoracic receptors on kidney function  (157).  
The role of renal nerves in hypoxia-induced renal functional changes is still unclear. 
It has been shown that renal denervation is associated with increased baseline water 
and sodium excretion, but it does not change the anti-diuretic and the anti-natriuretic 
response to acute hypoxia in rats (254). However, renal denervation abolished the 
decrease in RBF, GFR and water excretion resulted from direct stimulation of carotid 
bodies with hypoxic venous blood in anaesthetised dogs with intact nerves (157). 
Interestingly, ablation of renal nerves reversed the inhibitory effect of hypoxic carotid 
bodies on sodium excretion which resulted in enhanced natriuresis compared with 
sham-exposed dogs, suggesting that enhanced natriuresis is mediated by humoral 
factors (157). Indeed, renal excretory changes in response to hypoxic venous blood 
were abolished after destruction of the carotid bodies (157). 
Acute hypoxia in humans (12% O2) was associated with enhanced diuresis and 
natriuresis (344). Similar observations were reported in some other studies on 
mammals, whereas some other experiments have shown no changes in renal function 
(31, 254, 344). It has been suggested that natriuresis is related to direct hypoxic 
stimulation of the chemoreceptors, although exposure of isolated kidneys to hypoxia 
in animal studies was associated with diuresis and natriuresis (314). A positive 
correlation has been reported in humans between diuresis and natriuresis and the 
isocapnic hypoxic ventilatory response i.e. increased minute ventilation (344). 
Therefore, the induced natriuresis in hypoxia could be due to the activation of intra-
thoracic stretch receptors. Importantly, voluntary forced breathing of normal air for 45 
minutes was associated with an enhanced diuresis of similar magnitude to that 
observed during breathing 6% CO2 or 10% O2 (68). In addition, during hypoxia, a 
decrease in PCO2 induces respiratory alkalosis; thus, increasing bicarbonate and 
sodium excretion. However, bicarbonate excretion per se did not show any correlation 
with the hypoxic ventilatory response, while sodium-bicarbonate excretion showed an 
exponential rather than a linear relationship (344). This indicates that there is a higher 
sodium excretion for a given amount of bicarbonate excretion. Therefore, it is less 
likely that hyperventilation or bicarbonate excretion are predominantly responsible for 
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the natriuretic response during hypoxia. It is relevant to consider that hypocapnia 
decreases the activity of central chemoreceptors, which modulates hypoxic ventilatory 
responses that mediate renal excretory responses. Of note, no changes were detected 
in plasma ANP, aldosterone, angiotensin and renin, and no correlation has been found 
between measures of renal function and plasma levels of aforementioned humoral 
factors (344). Interestingly, since renal excretory responses were enhanced and it is 
well-known that RSNA is increased during hypoxia, it is apparent that the mechanism 
driving diuresis and natriuresis during hypoxia overrides the anti-diuretic and anti-
natriuretic effects of RSNA.  
It is not yet determined if the earlier change in renal function is sodium or water 
excretion. Currie et al (68) in this regard suggested that water precedes solute 
excretion. During normal breathing, drinking 500 ml of water in control experiments 
was associated with enhanced diuresis accompanied with natriuresis. Moreover, only 
during the initial phase of the diuretic response, was an increase in sodium excretion 
observed, but subsequently, urine flow continued to rise with no further increase or 
with a decrease in sodium excretion (68). Figure 1.7 summarizes renal functional 
responses to different acute hypoxia experiments in different species. 
 
Figure 1. 7. Variable renal responses to acute hypoxia in different species in 
response to various hypoxic protocols. RPP, renal perfusion pressure; RBF, renal 
blood flow; GFR, glomerular filtration rate; RVR, renal vascular resistance; NO, nitric 




1.7.3. Renal functional changes in chronic hypoxia 
Exposure of rats to short term sustained hypoxia, equivalent to 7,620 m, for one day 
was not associated with changes in kidney function, but with histological damage of 
the renal epithelial cells (58). After 3 and 7 days of exposure, kidney function 
deteriorated gradually with the maximum significant increase in plasma creatinine and 
blood urea nitrogen observed after 7 days, which were associated with more severe 
epithelial tubular damage and tubulointerstitial collagen deposition. However, 
prolonged hypoxia exposure for 3 to 5 weeks (12% O2) elicited increased blood 
pressure and RVC, but no change in RBF or GFR (253), when were measured during 
20 minutes of animals breathing normal air under anaesthesia. Diuresis and natriuresis 
were enhanced during normal air breathing following exposure to chronic hypoxia 
with increased right atrial pressure. It was suggested that pressure diuresis was 
mediated by increased RPP, as aortic occlusion eliminated the enhanced diuresis and 
natriuresis (253). Increased RPP increases interstitial hydrostatic pressure and 
subsequently decreases sodium reabsorption. Chronic hypoxia-exposed rats had 40% 
increase in urinary cGMP, which reflects increased ANP activity. However, it has been 
shown that ANP infusion into the control rats that elevates plasma levels of ANP to 
values similar to chronic hypoxia-exposed rats, did not cause diuresis and natriuresis. 
Chronic hypoxia-exposed rats had normal blood pressure and a normal O2 content in 
response to acute hypoxia (12% O2), compared with decreased blood pressure in 
control rats in response to acute hypoxia. In addition, chronic hypoxia-exposed rats 
had no changes in renal function in response to acute hypoxia, which differed to the 
finding of sodium and water retention in control rats (253). Similarly, renin activity in 
chronic hypoxia-exposed rats was not elevated to the same level as control rats 
breathing 12% O2 (253). Therefore, it is suggested that increased ANP in chronic-
hypoxia exposed rats, which was below the levels required to induce diuresis and 
natriuresis, can inhibit RAAS-mediated anti-diuretic and anti-natriuretic effects during 
acute hypoxia which were observed in control rats.  
Furthermore, in vivo studies have reported increased plasma level of ANP in response 
to hypoxia in different species, as reviewed by Arjamaa et al. (16). Exposure to chronic 
hypoxia was associated with an increase in plasma [ANP] in rats with normal and right 
ventricular hypertrophy. During normoxia, [ANP] decreased to control levels despite 
the hypertrophied myocardium. Similarly, in the Langendorff preparation of the 
66 
 
isolated rodent heart, hypoxia caused a significant increase in [ANP] although 
ventricular pressure was constant (16). Other studies on sleeping seal pups showed 
that plasma [ANP] increases during the apnoea phase and returns to basal levels when 
breathing is restored to normal (16, 405). Therefore, it is hypothesised that blood 
volume and flow changes during the cycle of filling and emptying of the heart 
represent a weak signal to induce natriuretic peptide release. Instead, a large 
physiological stimulus is needed to induce natriuretic peptide secretion such as 
lowered oxygen tension. It is also suggested that hypoxia through HIF activation 
induces the transcription of natriuretic peptides (16). ANP induces a fluid shift from 
the blood to the interstitial space during hypoxia in addition to its diuretic and 
natriuretic effect and this causes a decrease in plasma volume leading to 
haemoconcentration (16, 378). This in turn increases oxygen carrying capacity and 
transport to the peripheral tissues.  
In humans, chronic hypoxia was shown to have variable effects on renal function, 
which are dependent on the balance between RAAS and ANP activity. Some 
individuals subjected to high altitude showed enhanced diuresis with no changes in 
sodium excretion while others showed signs of acute mountain sickness with water 
and sodium retention (140, 253). Short-term exposure to high altitude is associated 
with hyperventilation and respiratory alkalosis (203). Increased plasma [ANP] 
correlated with the early diuretic response in high altitude. In hypobaric chambers of 
4,559 m, ANP levels were unchanged and it was increased in hypobaric chambers of 
6,000 m. However, it was decreased in chambers of 8,848 m (112). Enhanced diuresis 
was also associated with a decrease in ADH levels. Meanwhile, volunteers who 
developed acute mountain sickness has increased ADH levels which correlated with 
the severity of acute mountain sickness (219). In addition, decreased renal sensitivity 
to ADH after two days of high altitude was reported along with an increase in osmotic 
threshold required to induce ADH secretion (112). Moreover, high altitude was 
associated with decreased renin and aldosterone which were restored nearly to basal 
sea levels after 10 days of acclimatisation, reflecting normalisation of the diuretic 
response at a later stage (112). Increased urinary endothelin-1 levels was also observed 
at high-altitude concomitant with enhanced diuresis. The administration of an 
endothelin-1 blocker inhibited the enhanced diuretic response (112). Adrenomedullin 
decreases renin and aldosterone levels in addition to a decrease in RSNA (112). It was 
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shown that the urinary levels of adrenomedullin increases in correlation with low to 
moderate and high altitude (128). Nevertheless, after prolonged exposure to high 
altitude, water and sodium excretion rates were restored. It was also found that high 
altitude residents have low RBF, but preserved GFR and filtration fraction in addition 
to glomerular hypertrophy (112). However, studies at high altitude are confounded by 
the presence of other stressors. Importantly, there is a non-linear relationship between 
hypoxia and diuresis as fraction of inspired oxygen (FiO2) higher than 0.16 was 
associated with no diuresis while FiO2 of 0.12-0.16 resulted in a significant diuretic 





















1.8. Knowledge gaps addressed in this project 
Kidney hypoxia and the modulation of reno-renal reflex induces changes in sodium 
and water excretion which contribute to progression of hypertension and CKD. 
Chronic and acute hypoxia studies have shown major changes in renal 
haemodynamics that led to changes in renal excretory function evidenced by water 
and electrolytes retention or enhanced diuresis and natriuresis. However, studies of 
intermittent hypoxia have focused on the structural changes of the kidney and 
oxidative stress biomarkers with a scarcity of information on sodium and water 
excretion (9, 277, 342, 409). Furthermore, established structural changes of the kidney 
and clinical manifestations of CKD was shown in studies of severe CIH (9, 408, 409). 
Therefore, it is still unknown whether renal pathophysiological changes occur in 
response to hypoxia itself at an early stage of the disease or are developed at a later 
stage due to hypertension and/or hypoxia. Similarly, it is not yet established if kidney 
excretory function is changed early in response to CIH or modulated secondary to 
severe oxidative stress and inflammation, the latter arising subsequent to hypertension 
and sympathetic over-activity.  
Denervation of the kidney during oxidative stress or injury was associated with the 
restoration of the normal baroreflex control (6, 169), providing evidence of the 
presence of afferent signals originating from diseased kidneys causing impaired 
baroreflex. Indeed, impaired baroreflex control of blood pressure contributes to the 
development and exacerbation of hypertension in different models (133, 168, 169, 
363). Renal inflammation and/or oxidative stress is indirectly linked to the impaired 
baroreflex control, in a mechanism that is dependent on the activation of renal afferent 
nerves (2, 6, 170). Moreover, the activity and the expression of receptors involved in 
afferent renal neural activity such as TRPV1 and bradykinin receptors have been 
altered in the presence of hypoxia or inflammation (172, 335). In this regard, previous 
studies have shown early renal changes in CIH presented by the elevation of 
endothelial dysfunction biomarkers (342, 380), changes in oxidative signalling and 
inflammatory cytokines profiles (Appendix I, Table 8.1). Accordingly, blunted 
baroreflex control of heart rate was evident in CIH (62, 74). However, there is little 
information available on high-pressure baroreflex control of RSNA despite many 
reports that showed heightened renal, splanchnic and lumber SNA in CIH (280, 324). 
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Moreover, low-pressure baroreflex control of RSNA, represented by the evaluation of 
the response to fluid overload, was not studied in CIH, although it was impaired in 
other hypertension models (3, 169) that involve renal structural changes similar to the 
ones observed in CIH. Impaired baroreflex control of heart rate was shown in studies 
utilising long durations of CIH exposure (62, 74). Therefore, it remains to be 
determined whether baroreflex dysfunction is one of the mechanisms that contribute 
to the onset of hypertension, or develops at an advanced stage as a consequence of 
hypertension, reflecting the role of the baroreflex mechanism in blood pressure 
elevation in OSA. On the other hand, selective removal of ARNA attenuated 
hypertension in some disease models, indicating an excitatory reno-renal reflex 
contributing to hypertension (24). This is also related to oxidative stress and 
inflammation that can alter the activity and/or the expression of receptors involved in 
afferent neuronal signalling (172, 335). Meanwhile, in other models such as SHR, 
suppression of ARNA in response to the increased renal pelvic pressure (181) and to 
the intra-renal pelvic infusion of bradykinin was shown (190). However, whether CIH 
is associated with suppressed reno-renal reflex, as in SHR (182, 190), or elevated 
excitatory reno-renal reflex, as in kidney-clipped models (18), remains unexplored. 
Furthermore, the direct effect of renal afferent nerve activation on blood pressure and 












1.9. Thesis aims 
The primary aim of this project was to examine whether renal afferent nerves 
contribute to sympathetic over-activity and baroreflex dysregulation in CIH-induced 
hypertension (Figure 1.8). First, since there is considerable evidence that aberrant 
afferent outputs from kidneys interfere with the baroreflex function in hypertension, 
we sought to assess the high- and low-pressure baroreflex control of heart rate and 
RSNA after 14 days of exposure to a relatively moderate CIH protocol. This model is 
associated with modest pathological changes, yet it is sufficient to induce 
hypertension; thus, it mimics mild-to-moderate OSA at an early stage, providing an 
opportunity to determine whether baroreflex dysregulation contributes to the onset or 
progression of CIH-induced hypertension. For this purpose, experiments were 
conducted to study baroreflex control of RSNA and heart rate, and to investigate if 
RSNA sympatho-inhibition and renal functional responses to volume expansion are 
affected by exposure to CIH. Thereafter, we hypothesized that afferent renal nerve 
hyperactivity is responsible for the anticipated dysregulation of the baroreflex control 
of blood pressure. Therefore, studies were designed to interfere with one of the 
receptors involved in afferent renal neural signalling, TRPV1 channels. As such, we 
assessed high- and low-pressure baroreflexes after TRPV1 blockade using intra-renal 
capsaizepine infusion. We also investigated if moderate CIH exposure, reflecting an 
early stage of OSA, is associated with histopathological changes, inflammation and 





Figure 1. 8. A schematic representation of a proposed mechanism of CIH-induced 
hypertension that was investigated in this project. We hypothesized that renal 
afferent nerve hyperactivity, through reflex sympatho-excitation, causes baroreflex 
dysregulation. This results in hypertension, alterations in kidney function and renal 
injury. 
 
Second, we aimed to explore if exposure to CIH is associated with alteration in the 
reno-renal reflex, by studying the direct impact of the activation of reno-renal reflex 
on cardiovascular and renal parameters. We focused on bradykinin receptors and 
TRPV1 channels located in the renal pelvic wall, which are part of the signalling 
pathway of sensory renal nerve endings. For this purpose, three doses of bradykinin 
were infused in random order into the renal pelvis of anaesthetised rats and this was 
repeated following the intra-renal pelvic blockade of bradykinin receptor type 1 and 
2. At the end of the protocol, we infused capsaicin into the renal pelvis to activate 
TRPV1-expressing renal sensory nerve endings. During infusions, blood pressure, 
heart rate, and contralateral RSNA and kidney function were measured. We also 
studied the molecular expression of TRPV1, NK1 and bradykinin receptors in the renal 






























List of Abbreviations 
ANP Atrial natriuretic peptide 
AOPP Advanced oxidation protein products 
CGRP Calcitonin gene-related peptide 
CIH Chronic intermittent hypoxia 
CPZ Capsaizepine 
DBP Diastolic blood pressure 
EGTA Egtazic acid 
ELISA Enzyme-linked immunosorbent assay 
GFR Glomerular filtration rate 
H2O2 Hydrogen peroxide 
HR Heart rate 
HRP Horseradish peroxidase 
IL-1β Interleukin-1 beta 
MAP Mean arterial blood pressure 
NADPH Nicotinamide adenine dinucleotide phosphate 
NK1 Neurokinin 1 receptor 
NOX NADPH oxidase 




RSNA Renal sympathetic nerve activity 
SBP  Systolic blood pressure 
SNP Sodium nitroprusside 
SOD Superoxide dismutase 
TNF-α Tumour necrosis factor- alpha 
TRPV1 Transient receptor potential cation channel subfamily 
V member 1 
UF Urine flow rate 





2.1. Animal model 
Eight-week old male Wistar rats were purchased from Envigo (Bicester, UK) and were 
housed in our institution’s animal facility as age-matched pairs in standard cages. All 
animals were housed under 12-hour light: 12-hour dark cycle receiving ad libitum 
water and standard chow (Teklad, 18% protein rodent diet, Madison, Wisconsin, 
USA). All experimental procedures were conducted under authorization from the 
Health Products Regulatory Authority [AE19130/P073] in accordance with European 
Union directive (2010/63/EU) with prior ethical approval from University College 
Cork (AEEC 2018/002). 
Rats were randomly divided into two groups: CIH and sham (control). Rats of the CIH 
group were placed in commercial environmental chambers attached to a computer-
controlled gas delivery system (Oxycycler™, Biospherix, NY, USA), which delivered 
programmed hypoxia/re-oxygenation cycles, servo-controlled with feedback from an 
oxygen sensor within each chamber. CIH rats were exposed to hypoxia cycles for 14 
days as follows: during the hypoxia phase, O2 concentration was reduced to 6±0.5% 
within 90 sec by infusing N2 into the chamber. This was followed by an immediate 
infusion of pure oxygen into the chamber to elevate the O2 concentration to near 
normal levels (21±2%). The normoxia phase of each cycle was maintained for 210 
sec. This cycle was repeated every 5 minutes (i.e. 12 cycles per hour) for 8 hrs during 
the lights on period, the diurnal sleep period of the animals (Figure 2.1). The sham 
group was housed in the same room and rats were exposed to ambient air (~21% O2) 
for 14 days. Both groups had free access to food and water ad libitum during 
exposures. On day 15, rats were prepared surgically under anaesthesia, for the 
assessment of high- and low-pressure baroreflexes, or the assessment of the reno-renal 
reflex. The experimental protocol was conducted in three successive cohort studies 
that involved 72 rats in total [first cohort (n=10 sham and n=10 CIH); second cohort 
(n=13 sham and n=10 CIH); third cohort (n=15 sham and n=14 CIH)]. One CIH-
exposed rat from the first cohort died during surgery under anaesthesia before baseline 
measurements were recorded. Three sham rats from the second cohort did not produce 
a logistic sigmoidal fit during baroreflex assessment, and so they were excluded, but 
baseline parameters were included in the analysis. In the third cohort, baseline 
readings obtained at the beginning of the surgical protocol were excluded for one CIH 
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rat due to bleeding that had happened during arterial cannulation, and in one sham rat 
because the animal had difficulty in breathing due to mucus secretions before reaching 
an adequate level of anaesthesia to carry out tracheotomy. Moreover, in the third 
cohort, data were excluded from four CIH rats and three sham rats either due to poor 
or no RSNA recording, or due to difficulty in the cannulation of the renal pelvis. In 
addition, results of the reno-renal reflex were excluded from another sham rat due to 
a malfunction that had happened in the heating pad necessary to maintain body 
temperature during anaesthesia, when the rat’s temperature dropped, which 
theoretically can affect the expression of receptors such as TRPV1, which were a focus 









































Figure 2. 1. Oxycycler system and oxygen profiles in two chambers operating 
simultaneously. A pair of rats was placed in each hypoxia chamber while two 
chambers were operating at any time point of the study as shown in the upper panel 
(a). The bottom panel is a snapshot of oxygen profile in one of the hypoxia studies (b). 
During hypoxia, O2 concentration was reduced to 6% within 90 secs followed by a 






2.2. Non-recovery surgical instrumentation  
CIH-exposed (n=34) and sham rats (n=38) were anaesthetized by intra-peritoneal 
injection of a mixture of urethane (416 mg/kg, Sigma-Aldrich, St. Louis, MO, USA), 
α-chloralose (27 mg/kg, Sigma-Aldrich) and sodium pentobarbitone (33 mg/kg, 
Euthatal (200 mg/ml), Merial animal health Ltd, UK). Adequacy of depth of 
anaesthesia was checked by the loss of reflex responses to paw and tail pinch and loss 
of the blinking reflex. Anaesthesia was maintained during the surgery using a 
maintenance dose of a mixture of urethane (62 mg/kg) and α-chloralose (4 mg/kg) 
given as intravenous bolus injection. Animals were placed on a temperature-controlled 
heating pad to maintain body temperature at 37°C (Harvard Apparatus, Cambridge, 
UK). Airway patency was facilitated by tracheotomy (PE240, Portex, Kent, UK). A 
cannula (PE25 attached to PE50) containing heparinized saline (4 U/ml) and 
connected to a fluid-filled pressure transducer (ADInstruments, Hastings, UK), was 
inserted into the right femoral artery to measure arterial blood pressure (MAP) and 
heart rate (HR) throughout the experiment. The pressure transducer was connected to 
a quad-bridge amplifier (ADInstruments, Hastings, UK) that recorded pulsatile blood 
pressure, which was used to generate MAP, systolic blood pressure (SBP), diastolic 
blood pressure (DBP) and HR using LabChart 7 software (ADInstruments, Oxford, 
UK). The right femoral vein was cannulated (PE50) to infuse FITC-inulin (10 
mg/kg/hr, tdB consultancy, Uppsala, Sweden) continuously over the duration of the 
experiment (258). The urinary bladder was cannulated (PE240) to collect urine 
samples in the cohort 1 study (Figure 2.2).  
Before commencing the next step in the surgical procedures and to exclude the effect 
of retroperitoneal access on baseline recordings, blood pressure was recorded for 2 
minutes ~4-5 minutes after femoral artery cannulation and compared between the 
groups, in essence to confirm the hypertensive phenotype in CIH-exposed rats.  
In the first cohort study, CIH-exposed (n=9) and sham animals (n=10) were then 
placed prone on their right side and the left kidney was exposed by a subcostal 
retroperitoneal flank incision. A cannula (PE10) was inserted into the rostral part of 
the left kidney at 3.5-4.5 mm depth, to reach the cortico-medullary region of the kidney 
(3) and was fixed in place using superglue (Ethyl cyanoacrylate and poly(methyl 
methacrylate)). This cannula was connected to a 25 µl micro-syringe (Hamilton, USA) 
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placed on a micro-infusion pump (Figure 2.2, KD Scientific, Linton Instruments, 
Norfolk, UK) to infuse saline or capsaizepine (CPZ, 5 µg/ml, Sigma-Aldrich, St. 
Louis, MO, USA) at 17 µl/min. In the second cohort study, CIH-exposed (n=10) and 
sham rats (n=10) were placed prone on their left side to expose the right kidney, which 
was cannulated using a similar approach to that used in the first cohort. The insertion 
of the intra-renal cannula to target renal pelvic wall was validated as described in 
section 2.2.1.3. 
In the third cohort, CIH-exposed (n=10) and sham rats (n=11) were placed on their 
left side to make a subcostal right retroperitoneal incision to expose the right kidney. 
A custom-made cannula (OD 0.5 mm, ID 0.25 mm, World Precision Instruments, 
Florida, USA) was then placed inside a PE50 cannula (Figure 2.3) and both were 
inserted into the proximal part of the ureter to cannulate the renal pelvis of the right 
kidney. The smaller internal cannula was connected to a 25 µl micro-syringe placed 
on a Hamilton micro-infusion pump to infuse saline over the duration of the 
experiment at 20 µl/min. The outside PE50 cannula facilitated perfusate and urine 
drainage during the experiment. This double luminal cannula was also used to infuse 
different doses of bradykinin, bradykinin receptor antagonists and capsaicin into the 
right renal pelvis. Following renal pelvic cannulation in rats of cohort 3, the right 
retroperitoneal incision was sutured (4-0 Vicryl Rapide, polyglactin 910, Ethicon®, 
Johnson & Johnson Medical Ltd, Scotland, UK) and rats were then placed on their 
opposite flank to make a left retroperitoneal incision to expose the left kidney. Then, 
a PE25 cannula was inserted into the left ureter to collect urine samples from the 
contralateral left kidney during the experiment. 
In all cohorts, using a dissecting microscope, the renal nerve bundle running between 
the renal artery and vein of the left kidney was dissected from surrounding tissues and 
held placed on a bipolar multi-stranded stainless-steel electrode (Medwire, NY, USA). 
The nerve bundle was sealed over the recording electrode using silicone glue (Klasse 
4 dental, Augsburg, Germany). Nerve recording of renal sympathetic nerve activity 
(RSNA) was performed using a high impedance head stage attached to an amplifier 
(NeuroAMP EX®, ADInstruments, UK) connected to a PowerLab data acquisition 
system (Figure 2.2). Signals were amplified (x100,000), filtered (high-pass filter 100 
Hz and low pass filter of 2 kHz) and sampled at 1kHz and recorded on LabChart. Raw 
RSNA signal was rectified and then integrated using a time decay constant of 0.09s 
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Integrated RSNA (µV.s) values were averaged every second and then followed with 

























































































































































































































































































































































































































































































































Figure 2. 3. The design of the intra-renal pelvic cannula. In cohort 3, drugs were 
infused through the renal pelvis without the obstruction of urine drainage. For this 
purpose, a double lumen cannula was custom-made, composed of an inner cannula 
that can easily move through an outer PE50 cannula. Both cannulas were inserted 
through the proximal part of the ureter until both reached the pelvic wall. The end of 
the inner cannula protruded 0.2 mm beyond the outer PE50 cannula, and the length of 
the PE50 cannula was 9 cm. The other end of the inner cannula was connected to a 
Hamilton syringe mounted on a Hamilton syringe pump, which was used to infuse 
saline during the experiment or drugs during experimental protocols. The space 
between the inner cannula and the end of the PE50 cannula inside the renal pelvis 
allows the flow of urine from pelvis to the other end of the PE50 cannula, which is 
opened to the atmospheric pressure. This allowed patent urine flow without increasing 
the pressure inside the renal pelvis during infusion.  
 
2.2.1. First cohort experimental protocol 
2.2.1.1. Baroreflexes assessment  
The experimental protocol of the first cohort study is described in Figure 2.4. After 
surgical instrumentation, a stabilization period of one hour was allowed and baseline 
MAP, HR and RSNA was recorded for two minutes. Intravenous inulin (FITC-inulin 
in saline, 10 mg/kg/hr) infusion started at the beginning of the stabilization period and 
continued throughout the whole surgical protocol. After intra-renal infusion of saline 
(17 µl/min, saline (control) phase) to the left kidney for 30 minutes, phenylephrine 
(PE, 50 µg/ml, 0.2 ml) and sodium nitroprusside (SNP, 50 µg/ml, 0.2 ml) were infused 
intravenously to increase and decrease blood pressure respectively, allowing the 
subsequent generation of high-pressure baroreflex curves. A volume expansion (VE) 
phase (saline phase) was then performed, which was followed by a 90-minute recovery 
period. This phase was called ‘saline phase’ because it was conducted during intra-
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renal infusion of saline into the left kidney. Then, intra-renal infusion was switched 
from saline to CPZ and was sustained (17 µl/min) for 30 minutes. Then, a second VE 
phase (CPZ, drug phase) was performed. Saline and CPZ infusion into the left kidney 
was maintained at 17 µl/min during VE trials.  
Each VE trial involved inulin infusion (FITC-inulin in saline, 10 mg/kg) for 30 
minutes via the femoral vein at 0.25 ml/min/100g body weight using a syringe pump 
(Graseby syringe pump 8100, Dublin, Ireland). Each VE trial period was followed by 
30 minutes of recovery during which saline infusion through the intravenous line was 
stopped, but with continuous intra-renal infusion of saline or CPZ. The animals were 
euthanized at the end of the experiment by an overdose of anaesthetic (mixture of 80 
g/kg urethane and 55 mg/kg α-chloralose) given intravenously. RSNA reaches its 
maximum level during euthanasia due to the sudden precipitous drop of blood 
pressure. This was followed by a complete disappearance of RSNA peaks and this part 
of the recording was used to measure background noise, which was subtracted from 
all recordings.  
 
2.2.1.2. Measurement of Excretory Parameters 
Blood samples (P1, P2 and P3 samples, Figure 2.3) of ~400 µl were collected and 
centrifuged at 10,956 g for 1 minute and the plasma was removed and stored at -20° 
for further analysis of inulin and/or sodium concentration. To minimize any change in 
haematocrit, the blood cells that remained after centrifugation were suspended in an 
equivalent volume of saline and returned to the animal via the arterial line. Further 
blood samples (at P1 and P3) were taken from the femoral artery to measure sodium 
concentration using an I-STAT system (Abbott Laboratories, Abbott Park, IL, USA). 
Two urine samples were collected over 10- and 20-minute periods, respectively (U1 
and U2), during intra-renal infusion of saline or CPZ. In addition, a third urine sample 
was collected over the first 10 minutes of VE (UVE1) and then every 5 minutes until 
the end of the 30-minute VE trial period (UVE2, UVE3, UVE4 and UVE5). An additional 
urine sample was collected during the recovery period i.e. 30 minutes after the end of 
the VE trial (Figure 2.4).  
Urine flow (UF), glomerular filtration rate (GFR), and absolute and fractional Na+ 
excretion were measured at baseline (U1 and U2) and at different time points during 
82 
 
the VE trial (UVE1, UVE2, UVE3, UVE4 and UVE5). Urine volume was measured 
gravimetrically and UF was calculated as: UF = Uv/t; Uv is urine volume, t is time of 
urine collection. GFR was measured as a function of FITC-inulin clearance and 
calculated using the formula: GFR= ([Uin]Uv)/[Pin]; [Uin] is urine concentration of 
FITC-inulin, [Pin] is plasma concentration of FITC-inulin. FITC-fluorescence was 
measured in urine and plasma samples using a fluorometric microplate reader (Wallac 
victor2 1420 multilabel counter, Perkin Elmer, MA, USA). Urinary Na+ concentration 
was measured using flame photometry (M410, Sherwood Scientific, Cambridge, UK). 
Plasma Na+ concentration at P2 was determined using flame photometry. However, 
plasma Na+ concentration (P1 and P3) was measured immediately upon sample 
collection during surgery using the i-STAT system (Abbott Point of Care Inc, IL, 
USA). The latter samples were not drawn for analysis using flame photometry to 
minimize the volume of blood withdrawn and haematocrit change; the amount of 
blood sample required for i-STAT analysis did not exceed 70 µl. Absolute Na+ 
excretion was calculated using the formula: [UNa+].UF; [UNa+] is urinary Na+ 
concentration. Fractional Na+ excretion was calculated using the equation: Na+ 
clearance/GFR.100% where Na+ clearance = ([UNa+]Uv)/[PNa+]; [PNa+] is plasma 
Na+ concentration.  
It is worth mentioning that blood samples were not collected during VE to avoid 
fluctuations in the blood pressure and RSNA during VE challenge and to minimize 
any significant change in haematocrit after multiple blood collections. Therefore, 
inulin concentration in blood samples of P2 was used to calculate GFR values at 
baseline and at 10 minutes of the VE phase (UVE1). Inulin concentration of P3 was 
used to calculate GFR values at 25 and 30 minutes of the VE phase (UVE4 and UVE5). 
Meanwhile, GFR values at 15 and 20 minutes of VE (UVE2 and UVE3) were calculated 
using average inulin concentrations obtained from P2 and P3 blood samples. A similar 
strategy of plasma samples was used in the calculation of absolute and fractional 

























































































































































































































































































































































































































































































































































































































































































































































































































2.2.1.3. Validation of intra-renal infusion 
The purpose of this experiment was to confirm that CPZ infused through the intra-
renal cannula reached renal pelvic wall, where most renal afferent nerves are located 
(180). Therefore, the same surgical experimental protocol was carried out on three 
untreated 10 week old Wistar rats. Following the end of the first VE phase (saline 
phase), Lissamine green stain (George T. Gurr. Limited, London, UK) was infused 
through the intra-renal cannula of the left kidney for 30 minutes instead of CPZ. Then, 
rats were euthanized by an overdose of anaesthesia (mixture of 80 g/kg urethane and 
55 mg/kg α-chloralose) and the left kidney was frozen in optimal cutting compound 
and stored at -80°.  
Kidneys were cross-sectioned (cryostat, Leica Biosystems, Wetzlar, Germany) from 
the middle region (containing the pelvic wall) in 30 µm sections. The middle portion 
of the kidney was approximately divided to top, middle and bottom parts. One of every 
5 sections was placed on polysine glass slides and using a random number generator, 
two sections from each region were imaged using Olympus BX53 upright microscope 
(Tokyo, Japan). A series of multiple images were captured using a 4X magnification 
lens and were digitally-stitched together using the real-time panoramic imaging option 
of CellSense software to create a full image of each kidney section. Areas stained with 
Lissamine green dye were visualized using the bright field filter of the microscope. 
 
2.2.1.4. Atrial natriuretic peptide (ANP) assay 
ANP was quantified in plasma samples at baseline (P2) and at the end of VE (P3) of 
the saline phase in sham (n=7) and CIH-exposed (n=7) groups using a quantitative 
sandwich ELISA kit (My BioSource, San Diego, CA, USA) as per the manufacturer’s 
instructions. The kit is based on an interaction between ANP and horseradish 
peroxidase (HRP) detection antibody. The protocol involves the addition of 
chromogen solution A composed of hydrogen peroxide (H2O2) to each well to assist 
the interaction between HRP and chromogen solution B that is composed of 
tetramethylbenzidine substrate. The latter forms a blue complex which is converted 
into yellow solution after the addition of an acidic stop solution. Samples/standards 
and HRP-conjugated antibody were omitted from blank wells and replaced with buffer 
solution. Optical density was measured at 450 nm using a microplate 
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spectrophotometer (SpectraMax® M3, molecular devices, California, USA). Average 
optical density of blank wells was subtracted from average optical density of standards 
and samples wells. A standard curve was constructed with a cubic fitting between 
standards concentration and corresponding average of duplicate optical density 
readings.  
During VE, the increase in plasma volume dilutes humoral factors within the systemic 
circulation despite their increased levels. Therefore, to account for the dilution factor 
of VE, ANP concentrations obtained from the kit were normalized by estimating 
plasma volume to calculate ANP amounts at baseline and at the end of the VE phase. 
Estimated plasma volume was calculated using the formula: plasma volume estimate= 
GFR (body weight) (100/20), as 20% of the plasma volume passing through the 
glomerulus is filtered. GFR value at baseline was used to estimate plasma volume 
before the initiation of VE. GFR obtained at 30 minutes of VE was used to calculate 
plasma volume at the end of VE phase. The ANP amount at the end of VE (P3) was 
subtracted from the corresponding baseline (P2) amount to calculate delta (∆) change 
in ANP during VE in each group. 
 
2.2.1.5. Statistical analysis 
Data in tables and within text are presented as mean ± SD. Line figures are shown as 
mean ± SE. Baseline MAP and HR were recorded for 2 minutes after arterial 
cannulation i.e. before retroperitoneal incisions were performed to expose the kidneys. 
The parameters in addition to RSNA were also recorded for 2 minutes after the 
stabilization period and were compared between groups using independent sample t-
tests. Baseline RSNA was normalized using the maximum RSNA value recorded at 
the time of euthanasia, and is expressed as RSNA (% of max). Additional baseline 
values were recorded for 2 minutes before intra-renal infusion of saline/CPZ and for 
30 minutes throughout infusion. Baseline values over a 2-minute period were averaged 
and compared between groups before and after the infusion of saline or CPZ using 
repeated-measures two-way ANOVA. To compare the changes in HR and MAP 
during VE, the last two minutes of each VE trial were averaged and compared with 
baseline values before VE. Values were compared between groups and at different 
time points during saline and CPZ phases using repeated-measures two-way ANOVA.  
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Renal sympatho-inhibitory response to VE was expressed as % of baseline 
(baseline=100%) and as RSNA (% of max), and was analysed using repeated-
measures two-way ANOVA followed by a Bonferroni post hoc test to test for 
differences over time. The area under the curve (AUC) of RSNA % decrease vs. time 
was calculated for the VE trial period (without the recovery period) using the 
trapezoidal rule (358). Independent sample t-test and paired t-test were used for 
comparisons of AUC within and between groups during first and second VE trials with 
P˂0.0125 taken as significant taking into consideration correction for multiple 
comparisons.  
Baseline values for UF, GFR, and absolute and fractional Na+ excretion at U1 and U2 
were averaged and compared between CIH and sham groups and across trials, i.e. first 
vs. second VE using repeated-measures two-way ANOVA. During VE, the change in 
functional parameters over time in response to VE was analysed using repeated-
measures two-way ANOVA followed by a Bonferroni post hoc test to indicate 
differences between groups at different time points. Similar to RSNA, the AUC of 
each functional parameter response was calculated and compared between groups and 
between the saline VE phase and CPZ VE phase using independent sample t-test and 
paired t-test, with P˂0.0125 taken as significant, accounting for multiple comparisons. 
High pressure baroreflex function curves were fitted according to a four-parameter 
logistic sigmoidal function equation that shows the relationship between MAP and 
RSNA or HR [y=A1/(1+exp(A2(x-A3)))+A4] where y is the RSNA or HR; A1, 
response range over which baroreceptors operate; A2, gain (curvature) coefficient; A3, 
mid-point blood pressure; A4, minimum response of RSNA or HR (166). During the 
infusion of PE and SNP, integrated RSNA were averaged per second and then divided 
on basal RSNA, which was calculated as an average of 2 minutes, to obtain RSNA (% 
of baseline). This was followed by the calculation of the average of RSNA (% of 
baseline) during a period of 5 mmHg change in MAP. Using the four-parameter 
equation, baroreflex parameters were calculated for each rat. Baroreflex parameters 
obtained from each rat were then used to construct the baroreflex curve for each 
exposure group by the calculation of RSNA (% of baseline) at fixed points of MAP 
using the four-parameter equation. The baroreflex function curve parameters (Figure 
2.5) were compared between groups of the first cohort study using independent sample 
t-test and significance was taken at P<0.05. In addition, the relationship between MAP 
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and RSNA/HR during the assessment of the high pressure baroreflex was fitted using 
a five-parameter logistic sigmoidal equation [y=A1/(1+fx.exp(A2(A3-x))+(1-
fx).exp(A5(A3-x)))+A4]  where fx=[1/(1+exp(-c̅(A3-x)))] and c̅=2(A2.A5)/|A2+A5| 
(214, 302). The meanings of the parameters are identical to the four-parameter 
equation where y is the RSNA or HR; A1, response range over which baroreceptors 
operate; A3, mid-point blood pressure; A4, minimum response of RSNA/HR. This 
equation describes the gain (curvature) coefficient as a function of two parameters, A2 
and A5, estimating the gain of the upper and lower parts of the curvature, when the 
curve is asymmetrical. The four- and the five-parameter models merge when A2 and 
A5 are close to each other, enabling the curve to be symmetrical (302). Therefore, we 
used parameters obtained from the five-parameter model to calculate the index of 
asymmetry of RSNA/HR-MAP baroreflex curves (Appendix, Figure 8.1), [index of 
asymmetry=2(A2-A5)/(A2+A5). The index of asymmetry was analysed in CIH-
exposed and sham rats using one-sample t-test to test if the mean asymmetry index is 
not different from zero. As shown in Figure 8.1 in appendix I, the mean asymmetry 
index of HR and RSNA baroreflex curves was not significantly different from zero in 
CIH-exposed and sham rats. It was shown that if there is no evidence of asymmetry, 
five-parameter equation is substituted by the four-parameter equation (302). 
Therefore, the analysis of the high pressure baroreflex was carried out using the four-
parameter equation during the study.  
Comparisons of baseline and ∆ change in ANP between sham and CIH groups were 
performed using independent sample t-test and Mann-Whitney test. Significance was 





Figure 2.5. Logistic sigmoidal baroreflex function curve. PThr is threshold pressure 
at which the response begins and PSat is saturation pressure at which response start to 
reach its maximum. Maximum gain is the maximum sensitivity calculated at the 
midpoint pressure at which baroreceptors operate (A3). The slope (gain/curvature 
coefficient) is presented as A2. Upper (A4+A1) and lower (A4) plateaus reflect 
minimum and maximum responses. A1 is the RSNA/HR response range. 
 
2.2.2. Second cohort experimental protocol 
The experimental protocol of the second cohort study is shown in Figure 2.6 which is 
similar to the first cohort protocol with some exceptions. First, VE challenges and 
renal function measurements were not carried out. Therefore, saline was infused 
intravenously during the surgical protocol (3 ml/hr) instead of inulin. Second, intra-
renal infusion of saline and CPZ was conducted into the right kidney and RSNA 
recording was from the left kidney. Third, animals were spontaneously breathing 27-
32% O2 through their tracheal cannula instead of room air. 
The protocol involved exclusive assessment of the high-pressure baroreflex response 
in sham (n=13) and CIH-exposed (n=10) rats using PE and SNP during two successive 
phases. The first phase was after 30 minutes of intra-renal infusion of saline (17 
µl/min) and the second phase was after 30 minutes of intra-renal infusion of CPZ (5 




Figure 2.6. A schematic representation of the surgical protocol of the second 
cohort. Following a one-hour stabilization period, baseline cardiovascular parameters 
and RSNA were determined. After intra-renal infusion of saline to the right kidney for 
30 minutes, phenylephrine and sodium nitroprusside were infused intravenously to 
elicit high-pressure baroreflex responses. Following the first assessment of the 
baroreflex (saline phase), one hour was allowed for parameters to recover during 
which intra-renal infusion of saline into the right kidney was maintained. For the 
second phase, intra-renal infusion of CPZ was initiated for 30 minutes into the right 
kidney followed by a second intravenous infusion of phenylephrine and sodium 
nitroprusside to assess high-pressure baroreflex (CPZ phase). Arterial blood was 
sampled before the beginning of each assessment to check blood gases using I-STAT. 
MAP, mean arterial blood pressure; HR, heart rate; RSNA, renal sympathetic nerve 
activity; I.V, intravenous; I.R., intra-renal; CPZ, capsaizepine; PE, phenylephrine; 
SNP, sodium nitroprusside. 
 
2.2.2.1. Statistical analysis 
Data in tables and within text are presented as mean ± SD. Line figures are shown as 
mean ± SE. Baseline analysis was carried out similar to cohort 1 described in section 
2.2.1.5.  
High pressure baroreflex function curves were fitted according to a four-parameter 
logistic sigmoidal function equation that shows the relationship between MAP and 
RSNA or HR [y=A1/(1+exp(A2(x-A3)))+A4] where y is the RSNA or HR; A1, 
response range over which baroreceptors operate; A2, gain coefficient; A3, mid-point 
blood pressure; A4, minimum response of RSNA or HR (166). Baroreflex function 
curve parameters (Figure 2.5) were compared between sham and CIH groups using 
independent sample t-tests. Baroreflex gain curve parameters during the first (saline) 
and second (CPZ) phase were compared using paired t-tests. Significance was taken 




2.2.3. Third cohort experimental protocol 
2.2.3.1. Intra-renal pelvic infusions 
The experimental protocol of the third cohort study is described in Figure 2.7. Rats 
were spontaneously breathing 27-32% O2 through their tracheal cannula instead of 
room air to maintain partial pressure of oxygen in arterial blood ≥ 85 mmHg. After 
surgical instrumentation, a stabilization period of one hour was allowed and baseline 
MAP, HR and RSNA was recorded for two minutes. A blood sample was analysed 
using an I-STAT system (Abbott Laboratories, Abbott Park, IL, USA) at the end of 
the stabilization period to check blood gases and adjust percentage of oxygen supply. 
Intravenous inulin (FITC-inulin in saline, 10 mg/kg/hr) infusion started at the 
beginning of the stabilization period and continued throughout the whole surgical 
protocol. During the last 20 minutes of stabilization, a urine sample was collected from 
the contralateral left kidney to measure basal kidney function.   
Thereafter, protocols of intra-renal pelvic infusion of different drugs were 
commenced. Each intra-renal pelvic infusion protocol involved: a 5-minute baseline 
period, during which saline was infused into the renal pelvis of the right kidney; an 
experimental phase for 5 minutes during which an agonist and/or an antagonist was 
infused; followed by 5 minutes infusion of saline to washout the renal pelvis 
(Recovery). Meanwhile, for 0.4 µg/ml capsaicin and 700 µM bradykinin, the baseline 
period was sustained for 10 minutes and an additional recovery phase of 10 minutes 
was added at the end of the protocol. All intra-renal pelvic infusions of the right kidney 
were carried out at 20 µl/min. Using a random number generator, the order of infusion 
of bradykinin concentrations (150, 400 and 700 µM) through the renal pelvic cannula 
was determined. Following the end of bradykinin infusions, a bradykinin receptor type 
1 (BK1R) blocker, Lys-(des-Arg9, Leu8)-Bradykinin (42 µM, Sigma-Aldrich), was 
infused into the renal pelvis for 5 minutes, followed by an immediate infusion of a 
mixture of Lys-(des-Arg9, Leu8)-Bradykinin with 700 µM bradykinin for another 5 
minutes, followed by a 5-minute recovery phase. The next protocol involved intra-
renal pelvic infusion of Lys-(des-Arg9, Leu8)-Bradykinin (42µg/ml) and BK2R 
antagonist, Bradyzide (46 µM, Sigma-Aldrich), for 5 minutes, followed by an 
immediate infusion of a mixture of Lys-(des-Arg9, Leu8)-Bradykinin, bradyzide and 
700 µM bradykinin for another 5 minutes. The protocol was completed with a 5-
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minute recovery phase. Before proceeding to capsaicin infusion, a blood sample was 
taken from the arterial line for I-STAT system analysis to check blood gases. This was 
followed by an intra-renal pelvic infusion of capsaicin (0.4 µg/ml). During the basal, 
experimental and recovery phases of all aforementioned infusions, MAP, HR and 
RSNA were recorded.  
At the end of the protocol, bradykinin was infused (150 µM, 0.1 ml, at 0.3 ml/min) 
through the intravenous line during which MAP, HR and RSNA responses were 
recorded. This step was performed to confirm that the intra-renal pelvic-induced 
responses were not baroreflex-mediated by blood pressure fluctuations due to spill-
over of intra-pelvic infusion into the systemic circulation.  
Similar to cohorts 1 and 2, animals were euthanized by an intravenous overdose of 
anaesthesia (mixture of 80 g/kg urethane and 55 mg/kg α-chloralose), during which 
RSNA reaches a maximum level due to the sudden drop of blood pressure. This was 
followed by a complete disappearance of RSNA peaks and this part of the recording 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.2.3.2. Measurement of Excretory Parameters 
Urine samples were collected from 6 sham rats and 6 CIH-exposed rats for the analysis 
of kidney function. At the end of stabilization period, a urine sample during a period 
of 20 minutes was collected to measure basal urine flow (UF) and basal absolute Na+ 
excretion. Urine samples were collected over 10-minute periods of baseline (U basal) 
before the intra-renal pelvic infusion of 0.4 µg/ml capsaicin or 700 µM bradykinin. 
Moreover, two urine samples were collected during the 5-minute infusion of capsaicin 
(U Exp) or 700 µM bradykinin, and during a 5-minute period post-infusion of capsaicin 
or 700 µM bradykinin (U Rec).  
Urine volume was measured gravimetrically and UF was calculated as: UF = Uv/t; Uv 
is urine volume, t is time of urine collection. Urinary Na+ concentration was measured 
using flame photometry (M410, Sherwood Scientific, Cambridge, UK). Absolute Na+ 
excretion was calculated using the formula: [UNa+].UF; [UNa+] is urinary Na+ 
concentration. 
 
2.2.3.3. Validation of concentrations of bradykinin and capsaicin 
The concentrations of bradykinin used were based on previous reno-renal reflex 
studies (101, 187). Moreover, we conducted a pilot study on 6 control male Wistar rats 
of similar age to rats used in the main study. We infused 150, 400 and 700 µM 
bradykinin through the renal pelvic route of 4 rats, while 700, 1000 and 1500 µM 
bradykinin were infused into the renal pelvis of two other rats. The RSNA (% of 
baseline) responses during the last minute of the infusion were plotted against 
corresponding concentrations of bradykinin to draw a dose-response curve. As a 
result, concentrations of bradykinin of 150, 400 and 700 µM were selected for 
subsequent use in the main experiment. Additionally, we tested three concentrations 
of capsaicin that were used in a previous reno-renal reflex study (192): 0.4, 10 and 100 
µg/ml. The first concentration i.e. 0.4 µg/ml was infused into the renal pelvic wall of 
8 rats and the other two concentrations were tested in 3-4 rats. The maximum change 
in RSNA during infusion was compared and 0.4 µg/ml of capsaicin was chosen for 




2.2.3.4. Possible desensitization of bradykinin receptors 
In six control male Wistar rats of similar age to rats used in the main study, bradykinin 
of 700 µM was infused repeatedly three times through the intra-renal pelvic route. The 
protocol used was similar to the one used in the main study: a 5-minute baseline 
period, during which saline was infused into the renal pelvis of the right kidney; an 
experimental phase for 5 minutes during which 700 µM bradykinin was infused; 
followed by 5 minutes and further 10 minutes infusion of saline to washout the renal 
pelvis (Recovery). This protocol was repeated for another two successive times. 
During infusions, MAP, HR and RSNA were recorded.  
 
2.2.3.5. Statistical analysis 
Data in tables and within text are shown as mean ± SD and line figures are displayed 
as mean ± SE. Baseline MAP and HR were averaged for 2 minutes before arterial 
cannulation i.e. before retroperitoneal incisions to expose the kidneys. Additional 
baseline values of MAP and HR, in addition to RSNA, were recorded for two minutes 
at the end of the stabilization period. All baseline parameters were compared between 
sham and CIH-exposed rats using independent sample t-test. Baseline RSNA values 
were expressed as absolute values (µV.s) or as a percentage of maximum value (% of 
max). The latter is calculated by the normalization of RSNA values to the maximum 
RSNA obtained during euthanasia by an overdose of anaesthesia.  
During the intra-renal pelvic infusion of bradykinin, capsaicin and bradykinin receptor 
antagonists, MAP, HR and RSNA were recorded and averaged for 5 minutes prior to 
the start of the infusion, which represents a baseline reading. Thereafter, during the 
infusion of each drug, MAP, HR and RSNA were recorded and averaged for every 30 
seconds until the end of the 5-minute infusion period. This was followed by averaging 
parameters for every minute during the 5-minute period of recovery phase (during the 
intra-renal pelvic infusion of saline). Averaged values of MAP, HR and RSNA were 
plotted against time, taking into consideration the baseline averaged value at zero time. 
HR was expressed either as an absolute value or in terms of change in HR from 
baseline value (∆HR). Similarly, RSNA responses during infusions were expressed in 
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two fashions; in terms of percentage change from baseline recording (% of baseline, 
baseline = 100%) and as absolute values normalized to maximum RSNA obtained 
during euthanasia (% of max). 
Responses of MAP, HR, ∆HR, RSNA (% of baseline) and RSNA (% of max) to the 
intra-renal pelvic infusion of drugs were analysed using repeated measures two-way 
ANOVA followed by a Bonferroni post hoc analysis to test responses over time 
(Exposure x Time). The same analysis was carried out to test cardiovascular and 
RSNA responses during the intra-renal pelvic infusion of bradykinin receptor 
antagonists before the infusion of bradykinin, with p<0.05 taken as significant.  
The AUC of RSNA and HR responses vs. time was calculated using the trapezoidal 
rule, without considering the recovery phase. The AUC values were analysed using 
repeated measures two-way ANOVA followed by a Bonferroni post hoc test 
(Exposure x Bradykinin concentration). Similarly, the AUC of responses to the intra-
renal pelvic infusion of 700 µM bradykinin, 700 µM bradykinin with an antagonist of 
BK1R, and 700 µM bradykinin with BK1R and BK2R antagonists, were analysed 
using repeated measures two-way ANOVA followed by a Bonferroni post hoc test 
(Exposure x Drug). Significance was taken at p<0.05.  
To compare intra-renal pelvic with intravenous infusion of 150 µM bradykinin, the 
minimum of MAP, an average of 30 seconds, that was attained during infusions were 
subtracted from basal MAP (∆MAP) to compare between the two routes of infusion 
and exposure groups by repeated measures two-way ANOVA. Similarly, HR and 
RSNA were averaged every 30 seconds. The maximum change in HR (∆HR) and 
RSNA (% of baseline) were analysed using repeated measures two-way ANOVA 
followed by Bonferroni post hoc analysis. Significance was taken at p<0.05. 
Basal UF and absolute Na+ excretion were calculated from a urine sample that was 
collected over a period of 20 minutes, and were compared between groups using 
independent sample t-test. During the infusion protocol of capsaicin and the 700 µM 
bradykinin, baseline urine sample was collected for 5 minutes prior to infusion, for 5 
minutes during the infusion and 5 minutes post infusion. The three urine samples were 
used to compare between CIH-exposed and sham rats in terms of responses of UF and 
absolute Na+ excretion using repeated measures two-way ANOVA (Exposure x time). 
Significance was taken as p<0.05. 
96 
 
2.3. Tissue preparation 
In separate studies, male Wistar rats were either exposed to 14 days of CIH or to 
normoxia as described previously (section 2.1). On day 15, rats were euthanized by an 
overdose of intra-peritoneal sodium pentobarbital (Dolethal (200 mg/ml), Vetoquinol, 
France, 60 mg/kg). The left kidney was collected and halved along its sagittal plane. 
Each half was cut transversely into three sections: top, middle (containing the pelvic 
wall) and bottom. Sections were preserved at -80⁰C for later use. Immediately after 
harvesting the left kidney, the left renal artery and vein were closed by a bulldog 
clamp. Intra-cardiac puncture via the left ventricle was performed and warmed 
heparinized saline (~ 63 U/ml) was infused. The rate of infusion was 35 ml/min, which 
was raised gradually to 60 ml/min until 250-300 ml of heparinized saline was infused 
into each animal. This was followed by infusion of 4% paraformaldehyde at an 
infusion rate of 60 ml/min (Formalin solution, neutral buffered, 10%, Sigma-Aldrich, 
St. Louis, MO, USA) to fix organs including the right kidney for staining purposes. 
The upper and lower poles of the right kidney were removed, and the remnant kidney 
was either post-fixed for 24 hours for immunofluorescence, or wax-embedded in 
paraffin. Some kidneys that were harvested from sham and CIH-exposed rats that 
underwent surgical procedures were also perfusion-fixed and wax-embedded in 
paraffin. Paraffin blocks were stored at 4⁰C until sectioning for histological 
assessment. In separate sham (n=6) and CIH-exposed rats (n=6) that were not 
perfusion-fixed, the right kidneys were removed and after removal of the upper and 
lower poles, were directly post-fixed in formalin solution for 24 hours. Then, fixed 
tissues were incubated in 20% sucrose until the tissue sank in solution. Next, kidneys 
were frozen in optimal cutting temperature compound and stored at -80°C for 
subsequent use in immunofluorescence studies.   
The middle part of the left kidney was homogenized (Omni tissue homogeniser, 
Kennesaw, Georgia, USA) in a buffer made of: 10X RIPA lysis buffer, deionized H2O, 
sodium fluoride (200mM), phenylmethylsulfonyl fluoride (100 mM) and protease 
cocktail inhibitor [(5 mM EDTA, 1 mM EGTA, 5 µg/ml leupeptin, 5 µg/ml aprotinin, 
2 µg/ml pepstatin, 120 µg/ml Pefabloc, 2 mM 1,10-phenanthroline and sodium 
orthovanadate (200 mM) (Sigma-Aldrich)]. Samples were homogenized on ice using 
10 Χ 10 sec bursts separated by 10 sec periods. Homogenates were kept on ice for 20 
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minutes with intermittent vortex. Samples were then centrifuged at 15,339 g at 4⁰C for 
15 minutes. The supernatant was aliquot into ice-cold Eppendorf tubes and stored at -
80⁰C for use in an Advanced Oxidation Protein Products (AOPP) assay (Cell Biolabs, 
San Diego, CA), superoxide dismutase (SOD) and catalase activity assays (sham, 
n=12; CIH, n=8) (Cayman Chemical, Ann Arbor, MI, USA). Supernatant was also 
used for TRPV1, bradykinin 1 and bradykinin 2 receptors (Mybiosource, Tokyo, 
Japan) ELISA assays to determine protein abundance. The same homogenization 
protocol was used to prepare samples for the assessment of NADPH oxidase (NOX) 
activity and to determine the concentrations of inflammatory cytokines in renal tissue 
(sham, n=11; CIH, n=10) except for the use of a lysis buffer made of Tris-HCL (20 
mM, pH 7.5, Sigma-Aldrich), sodium chloride (150 mM) and 1% Triton-X-100 
(Molekula, Dorset, UK) instead of RIPA during homogenization. In a separate cohort, 
pelvic walls of left kidneys were isolated and harvested from 4 CIH and 4 sham rats 
and were preserved at -80º.  In addition, pelvic walls of left kidneys were isolated from 
2 CIH and 2 sham rats post-surgery and were also preserved at -80°. The same 
homogenization protocol described above was carried out to homogenize pelvic wall 
samples for subsequent use in CGRP, bradykinin receptors 1 and 2 ELISA assays. A 
bicinchoninic protein assay (Pierce Biotechnology, Fisher scientific, Ireland) using 
bovine serum albumin standards was conducted prior to the performance of each 













2.4. Biochemical assays 
All assays were conducted in duplicate and readings were carried out using a 
microplate spectrophotometer (SpectraMax® M3, molecular devices, California, 
USA) and SoftMax Pro 6.2.2 software. 
 
2.4.1. TRPV1 ELISA 
TRPV1 cation channel expression in kidney tissues of sham (n=12) and CIH (n=8) 
rats was quantified using a competitive enzyme immunoassay ELISA kit as per the 
manufacturer’s instruction. The plate was pre-coated with an anti-TRPV1 antibody. 
Samples and TRPV1-HRP conjugate were incubated in the plate together for one hour 
at 37° to compete for the antibody binding site. Then, a substrate for HRP enzyme is 
added to each well. The substrate and TRPV1-HRB conjugate forms a blue coloured 
complex and a stop solution will convert the blue coloured solution into yellow. The 
absorbance was measured at 450 nm using a microplate reader. The binding sites of 
TRPV1 antibody are limited and if TRPV1 from sample binds to the antibody, there 
will be less available binding sites to TRPV1-HRB conjugate. Therefore, colour 
intensity produced was inversely proportional to the amount of TRPV1 in samples. In 
blank wells, TRPV1-HRB conjugate was omitted and sample was replaced with an 
equivalent volume of phosphate-buffered saline. Absorbance obtained from kit 
standards were plotted against their concentration using a four-parametric logistic fit. 
Concentration of TRPV1 in each sample was calculated based on corresponding mean 
absorbance value from the standard curve and was multiplied by the appropriate 
dilution factor. 
 
2.4.2. Bradykinin receptor 1 ELISA assay 
Bradykinin receptor 1 expression in kidney tissues of sham (n=11) and CIH-exposed 
(n=8) rats and in pelvic wall of 6 sham and 6 CIH-exposed rats was quantified using 
a competitive enzyme immunoassay similar in principle to the TRPV1 ELISA. The 
kit involved a microplate pre-coated with a polyclonal bradykinin 1 receptor antibody. 
Wells were filled with samples or standards and incubated with bradykinin receptor 
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1-HRP conjugate for one hour at 37°. Then, a substrate for HRP enzyme is added to 
each well that resulted in a blue coloured complex formation. Stop solution turned 
solution colour into yellow and absorbance was measured at 450 nm using a 
spectrophotometer. Colour intensity was inversely proportional to the abundance of 
bradykinin receptor 1 in samples.  Bradykinin receptor 1- HRP conjugate was omitted 
from blank wells and samples/standards were replaced with an equivalent volume of 
phosphate-buffered saline. Analysis of results was similar to that described for the 
TRPV1 ELISA. 
 
2.4.3. Bradykinin receptor 2 ELISA assay 
Bradykinin receptor 2 expression in kidney tissues of sham (n=12) and CIH-exposed 
(n=8) rats and in pelvic wall of 4 sham and 4 CIH-exposed rats was quantified using 
sandwich enzyme immunoassay kit as per manufacturer’s instructions. The assay 
principle is similar to the CGRP assay and is based on the use of a microplate that is 
pre-coated with bradykinin receptor 2 specific antibody. Samples and standards were 
incubated for one hour at 37° which was followed by an hour incubation with biotin-
conjugated antibody. Then, avidin attached to HRP was added to each well for 30 
minutes at 37°. Then, tetramethylbenzidine substrate was added to each well to 
develop a blue colour. Blank wells were included containing an equivalent volume of 
phosphate-buffered saline instead of sample. The optical density was measured at 450 
nm using a spectrophotometer and optical density values (Log x-axis) were plotted 
against standards concentrations (Log y-axis) and a fit-line was drawn. Protein 
concentration of bradykinin receptor type 2 in each sample was calculated based on 
corresponding mean optical density logarithmic values of the curve with subsequent 
multiplication of the appropriate dilution factor. 
 
2.4.4. AOPP assay 
AOPP OxiSelect assay kit is used as a measurement of total oxidative stress. These 
products are oxidative toxins such as chloramines and hypochlorous acid that are 
produced from the reaction of proteins with chlorinated oxidants. Kidney tissue 
homogenates from sham (n=12) and CIH-exposed (n=8) rats were de-frosted on ice 
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and the protocol was followed as per the manufacturer’s instruction. In each well, a 
chloramine reaction initiator and sample were incubated together for 5 minutes at 
room temperature. AOPP in the biological sample will cause the formation of 
chloramines. Absorbance was measured at 340 nm which correspond to chloramine 
concentration as chloramine equivalents (µM). Sample diluent was added to blank 
wells instead of sample/standard. Absorbance obtained from kit standards were plotted 
against chloramine concentration (µM) and a linear best-fit line was drawn. 
Concentration of chloramine in sample was calculated corresponding to the mean 
optical density value of the standard curve and was multiplied by the appropriate 
dilution factor. 
 
2.4.5. NOX activity assay 
NOX activity in sham (n=11) and CIH-exposed (n=10) groups was assessed using a 
protocol that depends on formazan blue formation from the reaction of nitroblue 
tetrazolium (NTB) with superoxide radicals generated by NOX enzymes present in 
biological samples as previously detailed (301) (Figure 2.8). A cocktail was prepared 
that contained: NTB, sodium cyanide and diethylene-triamine-penta-acetic acid, all in 
Tris-HCl pH 8 buffer. A fresh solution of NADPH (1mM) was also prepared and 
kidney tissue homogenates were diluted using Tris-HCl pH 8. Each well was filled 
with 20 µl of sample, 250 µl of cocktail and 30µl of NADPH solution. In blank wells, 
samples were replaced with an equivalent volume of diethylene-triamine-penta-acetic 
acid in pH 8 buffer. Absorbance was then measured at 560 nm at room temperature 
every 20 sec for 40 minutes. NOX activity was expressed as the slope of formazan 
blue formation, taking into consideration the linear part of the reaction curve (between 




Figure 2.8. Formation and dismutation of superoxide radicals. The black scheme 
shows NADPH oxidation conjugated with the generation of superoxide radicals. 
NADPH oxidase assay is based on the conversion rate of tetrazolium salt to formazan 
blue through redox reaction mediated by superoxide radicals. The orange scheme 
shows the principle of the superoxide dismutase assay which depends on the 
dismutation of superoxide radicals to hydrogen peroxide (H2O2). Each two molecules 
of H2O2 are subsequently detoxified to water and oxygen molecules through the 
reductive activity of catalase enzyme (purple scheme). 
 
2.4.6. SOD activity assay 
SOD catalyses the conversion of oxygen radicals to oxygen and H2O2 (an antioxidant 
mechanism, Figure 2.8). SOD activity in sham (n=12) and CIH-exposed (n=8) groups 
was assessed as per the manufacturer’s instructions. The assay protocol reflects SOD 
total activity and does not differentiate the activity of Cu/Zn, Mn and FeSOD. The 
assay utilizes tetrazolium salt which is converted to formazan blue by superoxide 
radicals. Superoxide radicals were generated in each well by the addition of xanthine 
oxidase enzyme and hypoxanthine. Higher activity of SOD in wells is associated with 
greater dismutation of superoxide radicals; thus less formation of formazan blue and 
less colour intensity. SOD standard/tissue sample were incubated with assay reagents 
for 30 minutes at room temperature. A blank was carried out for each sample while 
wells of zero standard concentration were considered as a blank for all standards wells. 
All reagents were added to blank wells except that xanthine oxidase was replaced by 
sample buffer. Absorbance was measured at 450 nm and SOD activity was expressed 
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as unit/ml using a linear standard curve. The background absorbance of each blank 
well was subtracted from corresponding average sample absorbance. One unit of SOD 
reveals the amount of enzyme needed to exhibit 50% dismutation of superoxide 
radicals.  
 
2.4.7. Catalase activity assay 
This protocol was performed for kidneys harvested from sham (n=12) and CIH-
exposed (n=8) groups. Catalase is an oxidoreductase enzyme that retains reduction 
and peroxidation activities. The reductive activity of catalase enzyme involves the 
conversion of H2O2 to two molecules of water and one molecule of oxygen (Figure 
2.8, purple scheme). The peroxidative activity principle is used in the assay protocol 
to convert H2O2 in presence of methanol to formaldehyde and two molecules of water 
(Figure 2.9). The reaction was carried out for 20 minutes at room temperature. As a 
final step, purpald (4-Amino-3-hydrazino-5-mercapto-1,2,4-triazole) was added to 
each well which was oxidized by the formaldehyde generated to a purple product. 
Blank wells were composed of all reagents except for the sample/standard. 
Absorbance was measured at 540 nm and absorbance values were plotted against 
formaldehyde standards concentrations. One unit is equivalent to the amount of 
enzyme required to generate 1 nmol of formaldehyde per minute.  
 
Figure 2.9. The peroxidase activity of catalase enzyme. 
 
2.4.8. Renal inflammatory cytokines 
Pro-inflammatory and anti-inflammatory cytokines (IFN-γ, IL-1β, IL-4, IL-5, IL-6, 
keratinocyte chemoattractant/growth related oncogene, IL-10, IL-13, and TNF-α) 
were analysed by sandwich immunoassay method using V-plex proinflammatory 
panel 2 rat kit (Meso Scale Discovery, Rockville, MD, USA), as per the 
manufacturer’s instructions. One-hundred micrograms of protein from tissue 
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homogenate was added to sample wells of a multi-spot plate. The bottom of each well 
was made of a high binding carbon electrode attached to 9 different capture antibodies 
at 9 different specific locations of each well to detect different cytokines. 
Standards/samples were incubated in wells for two hours at room temperature. After 
multiple washings, a detection antibody conjugated with sulfo-tag labels was added to 
each well for one hour at room temperature. Plate was analysed using QuickPlex SQ 
120 plate reader (Meso Scale Discovery) that applies electricity to plate electrodes 
which generates electrochemiluminescence from attached sulfo-tag labels. The 
intensity of each emitted light is directly proportional to the amount of each different 
cytokine in samples. A linear standard curve was constructed and the amount of 
cytokines in samples was calculated, taking into consideration dilution factor 
thereafter. IL-1β, TNF-α and keratinocyte chemoattractant/growth related oncogene 


















Frozen, formalin-fixed kidneys were sectioned to 20 µm sagittal sections using a 
cryostat (Leica Biosystems, Wetzlar, Germany). Every two subsequent sections were 
mounted onto polysine-coated glass slides (VWR, Belgium) and stored at -80°C. 
Three sections that contained the renal pelvic wall were randomly selected from each 
kidney by systematic random sampling. Generally, slides were washed in phosphate-
buffered saline three times each of 15 minutes duration. Following each incubation in 
blocking solution, with primary and secondary antibodies, slides were washed in 
phosphate- buffered saline three times each of 15 minutes duration. At the end of each 
protocol, sections were covered with anti-fade mounting medium (Vectashield, Vector 
laboratories, Burlingame, CA, USA) and coverslip (Thickness No 1.5, VWR, 
Belgium). 
 
2.5.1. TRPV1 receptors 
Immunofluorescence for TRPV1 protein expression in the renal pelvic wall was 
carried out on 3 CIH-exposed and 3 sham kidneys that were perfusion-fixed and post-
fixed, in addition to 6 CIH-exposed and 5 sham kidneys that were only post-fixed. 
Non-specific binding was blocked by incubating sections in 5% goat serum and 1% 
bovine serum albumin (with 0.5% triton-X) for one hour. Then, sections were 
incubated with rabbit polyclonal anti-TRPV1 antibody (1:200, ACC-030, Alomone 
labs) diluted with 5% goat serum, 1% bovine serum albumin and 0.5% triton-X for 
two hours at 37°C. Sections were incubated with goat anti-rabbit FITC secondary 
antibody (1:100, Sigma-Aldrich, St. Louis, MO, USA) diluted in phosphate-buffered 
saline (mixed with 2µg/ml DAPI, Sigma-Aldrich, Saint Louis, MO, USA) for two 
hours at room temperature.  
 
2.5.2. CGRP and NK1 receptor 
Indirect immunofluorescence was carried out to examine the protein expression and 
the co-localization of CGRP and NK1 receptor in renal pelvic wall. Kidneys were 
harvested from 3 CIH-exposed and 2 sham rats that were perfusion-fixed and post-
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fixed, in addition to, kidneys harvested from 6 CIH-exposed and 7 sham rats that were 
post-fixed only. Sections were blocked for one hour in 5% goat serum and 1% bovine 
serum albumin (mixed with 0.3% Triton-X). Sections were incubated with rabbit 
polyclonal anti-CGRP IgG antibody (1:500, Sigma-Aldrich, Saint Louis, MO, USA) 
or mouse monoclonal anti-NK1 IgG1 antibody (1:200, Invitrogen, Illinois, USA) 
diluted with 5% goat serum and 1% bovine serum albumin (mixed with 0.3% Triton-
X) for two hours at 37º. For co-localization purpose, both primary antibodies were 
mixed in one solution of the same diluent and composition.  
For CGRP detection, sections were then incubated with goat anti-rabbit FITC IgG 
secondary antibody (1:100, Sigma-Aldrich, St. Louis, MO, USA) diluted with 1% 
bovine serum albumin for two hours at room temperature. For NK1 receptor analysis, 
sections were incubated with goat anti-mouse IgG Fcγ subclass 1 Alexafluor 594 
antibody (Jackson ImmunoResearch, West grove, Pennsylvania, USA) diluted with 
5% goat serum, 1% bovine serum albumin and 0.3% Triton-X in phosphate-buffered 
saline. All secondary antibody solutions contained 4 µg/ml DAPI. For co-localization, 
both secondary antibodies were prepared in one solution and using same 
concentrations in 5% goat serum, 1% bovine serum albumin and 0.3% Triton-X. 
 
2.5.3. Image analysis 
Images were captured using a laser scanning confocal microscope (Olympus FV1000-
IX71, Tokyo, Japan) provided with excitation lasers of 488 nm (for CGRP and TRPV1 
detection), 543 nm (for NK1 receptor detection) and 408 nm (DAPI). Before imaging, 
slides labels were covered with a sticker and marked with a random number to blind 
from the treatment group during imaging. 
For TRPV1 analysis, sections were initially visualized using 20X magnification under 
the DAPI filter and three regions of the pelvic wall were randomly selected from each 
section. After selection, the 488 nm laser was switched on to capture images. Positive 
staining was detected in the uroepithelial layer and submucosa/ muscularis propria 
layers of the pelvic wall. A similar imaging procedure was used for CGRP and NK1 
detection except that one region of the pelvic wall was randomly selected from each 
section and the 543 nm laser was switched on to capture NK1 images of selected 
106 
 
regions. Positive staining of CGRP and NK1 was mainly detected within the 
muscularis propria of renal pelvic wall. 
Images were transferred to greyscale and the threshold was adjusted to highlight the 
area occupied by positive fluorescent labelling using Image J software. Threshold area 
was calculated and normalized to the total area of the uroepithelium within the image 
to quantify the expression of TPRV1 in that region. Similarly, threshold TRPV1 area 
in the submucosa and muscularis propria layers were calculated and normalized to the 
total layer area identified in the image. For CGRP and NK1, threshold area was 
normalized to the total area of the pelvic wall in each image. Data are expressed as a 
percentage of area occupied by positive labelling.  
For CGRP analysis, results were collected from 9 CIH-exposed and 9 sham kidneys. 
For NK1 receptor analysis, a kidney from each group was excluded due to poor signal 
to noise ratio; thus, thresholding difficulty. Therefore, for the latter, data were obtained 
from 8 CIH-exposed and 8 sham kidneys. Meanwhile, data from 9 CIH-exposed and 















2.6. Renal histopathological staining 
Paraffin blocks were cross-sectioned to 10 µm tissue sections using a rotary microtome 
(Leica RM2135, Germany). Kidneys were taken from sham (n=3) and CIH-exposed 
(n=5) rats that underwent surgical procedures as well as from rats euthanized 
following exposure to gasses without undergoing surgery (sham, n=5; CIH, n=3). Four 
of 10 kidney sections were held on polysine-coated glass (VWR, Belgium). Two 
sections were randomly selected by random number generator each from the upper, 
middle and bottom parts of the paraffin block (a total of 6 sections from each kidney 
block). 
 
2.6.1. Haematoxylin and eosin stain  
The protocol for staining was carried out as follows: 
 Sections were de-waxed using Neo-Clear® xylene substitute (Merck, 
Darmstadt, Germany) three times each of 3 minutes.  
 Sections were washed with down-graded levels of ethanol (100% for two 
minutes, 95% for one minute and 70% for one minute). This was followed by 
immersing sections in distilled water for one minute. 
  Tissue sections were then stained in haematoxylin (Haematoxylin Solution, 
Harris Modified, Sigma-Aldrich, St. Louis, MO, USA) for 6 minutes followed 
by washing in distilled water for one minute.  
 Haematoxylin stain was differentiated by immersing sections in 0.3% 
hydrochloric acid prepared in 70% ethanol.  
 Sections were washed in distilled water for one minute followed by another 
washing in Scott tap water (Sigma-Aldrich, St. Louis, MO, USA) for another 
minute.  
 Sections were then stained with eosin (Surgipath Europe LTD, 
Cambridgeshire, UK) for two minutes.  
 Sections were dehydrated in 95% ethanol (one minute) and 100% ethanol 
(three times, each of one minute duration).  
 As a final step, sections were cleared in Neo-Clear® xylene substitute (three 
times, each of one minute duration) 
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 Sections were mounted with DPX mounting medium (Sigma-Aldrich, St. 
Louis, MO, USA) and cover-slipped (Thickness No 1, VWR, Belgium).  
 
2.6.2. Sirius red stain 
The protocol for staining was carried out as follows: 
 Sections were cleared using Neo-Clear® xylene substitute and washed in 
graded levels of ethanol in a similar fashion as for the haematoxylin and eosin 
staining protocol.  
 Slides were dipped in 0.1% Direct red 80 (Sigma-Aldrich, India) for an hour.  
 Sections were then washed in 0.5% acetic acid prepared in distilled water twice 
each of two minutes’ duration.  
 Similar to haematoxylin and eosin, sections were dehydrated with ethanol and 
cleared in Neo-Clear® xylene substitute, mounted with DPX mounting 
medium and cover-slipped.  
 
2.6.3. Histological analysis 
Haematoxylin and Eosin staining was used for the assessment of total glomerular tuft 
area. A virtual grid comprised of 91 squares was created to enable random sampling 
of cortical areas of each kidney section. The grid was drawn over the kidney under 4X 
magnification. Selected squares were magnified using 40X magnification lens to 
image selected glomeruli (only when the juxtaglomerular apparatus was evident). As 
some squares did not include any glomeruli and/or the juxtaglomerular apparatus was 
not visible in some glomeruli, other squares were randomly chosen so that overall total 
of 3 glomeruli per kidney section were analysed. As 6 sections were randomly selected 
from each animal, a total of 18 glomeruli per animal were chosen to measure 
glomerular tuft area. Images were taken using 40X magnification (Olympus inverted 
BX53F microscope, Tokyo, Japan) and tuft area was measured using ImageJ software. 
Sirius red stain was used to semi-quantify collagen areas in the cortex and outer 
medulla. We used another virtual grid with 25 squares to enable random selection of 
cortical and medullary areas. The grid was drawn over the kidney using 4X 
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magnification lens and selected squares were magnified using 20X magnification to 
capture images. Three cortical areas and two outer medullary areas per kidney section 
were randomly chosen. As 6 sections were stained from each animal, a total of 18 
cortical areas and 12 areas from the outer medulla were selected for analysis. 
Glomeruli and perivascular fibres were blanked from images to analyse 
tubulointerstitial fibrosis. Images were transformed to grey scale and the black area 
was marked with red colour which presented the collagen area (Figure 2.10). The 
fibrotic area of each image was normalized to the total area of the captured image to 
generate the % fibrotic area.  
Figure 2.10. Assessment of renal fibrosis. A virtual grid was used for the random 
selection of kidney regions. Sirius red stained images were converted to grey scale and 




2.6.4. Statistical analysis 
Comparisons of TRPV1 and bradykinin receptor 1 and 2 protein abundance, cytokine 
concentrations, enzymatic activities, histology and immunofluorescence between 
sham and CIH-exposed rats were performed using independent sample t-tests or 
Mann-Whitney tests, and significance was taken at P<0.05. All statistical analyses 
were performed using SPSS software (SPSS Statistics for Windows, v25.0. IBM corp., 
NY, USA). All graphs were plotted using GraphPad® Prism (v6, GraphPad software, 






















Chapter 3: Effect of chronic intermittent hypoxia on the 
high-pressure baroreflex control of heart rate and renal 










List of Abbreviations 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ARNA Afferent renal nerve activity 
AT-1  Angiotensin II type 1 
BP  Blood pressure 
CIH Chronic intermittent hypoxia 
CNS Central nervous system 
CPZ Capsaizepine 
DBP Diastolic blood pressure 
HIF-1α Hypoxia-inducible factor-1alpha 
HR Heart rate 
IH Intermittent hypoxia 
IL-10 Interleukin-10 
MAP Mean arterial pressure 
MSNA Muscle sympathetic nerve activity 
NF-κB Nuclear factor kappa B 
NMDA N-methyl-D-aspartate 
NTS Nucleus tractus solitarius 
OSA Obstructive sleep apnoea 
PO2 Partial pressure of oxygen 
PVN Paraventricular nucleus 
ROS Reactive oxygen species 
RSNA Renal sympathetic nerve activity 
RVLM Rostral ventrolateral medulla 
SBP  Systolic blood pressure 
SFO Subfornical organ 
sLTF Sensory long-term facilitation 
SNP Sodium nitroprusside 
SOD Superoxide dismutase 
TNF-α Tumour necrosis factor-alpha 





A rapid surge of sympathetic nerve activity (SNA) and blood pressure occurs in the 
last phase of each apnoea cycle during sleep in people with obstructive sleep apnoea 
(OSA) (250). This is necessary to maintain adequate oxygen supply to peripheral 
tissues. Lowering of arterial PO2 (partial pressure of oxygen) during recurrent apnoeas 
stimulates the carotid bodies, which in turn triggers sympathetic outflow and nocturnal 
hypertension (251, 281). However, clinical studies have shown that people with OSA, 
during normal breathing while awake, exhibit normal resting blood pressure with 
heightened sensitivity of carotid bodies (250) or diurnal hypertension and sympathetic 
over-activity (35, 64). Enhanced neural firing of the carotid bodies modulates second-
level neurons of the central nervous system (CNS) that receive inputs from 
baroreceptors. Subsequently, heightened chemoreflex drive disrupts the balance 
between sympathetic and parasympathetic outflow (250). Baroreflex control of heart 
rate (HR) is impaired in normotensive and hypertensive people with OSA (35, 64), 
while it was unaltered in another study of normotensive OSA (250). These differences 
are likely related to variable severity of hypoxaemia and apnoea duration between 
individuals. Therefore, whether impaired cardiac baroreflex contributes to the onset of 
hypertension or exacerbates blood pressure elevation at later stages of the disease, 
remains unclear.  
Exposure to chronic intermittent hypoxia (CIH) in animals mimics the episodic arterial 
hypoxaemia of OSA, which is the primary stimulus for autonomic dysfunction and 
sympatho-excitation (318, 324, 417). Of note, repetitive apnoeas during room air 
breathing was not associated with an increase in muscle sympathetic nerve activity 
(MSNA) or blood pressure elevation in humans (207). Meanwhile, voluntary 
intermittent hypoxic apnoea for 20 minutes resulted in an increase in MSNA shortly 
after 5 minutes of the beginning of the protocol which lasted for three hours following 
the last apnoea cycle during normoxia (69). Furthermore, the increase in blood 
pressure and MSNA was comparable during intermittent isocapnic and hypercapnic 
hypoxic apnoeas (69). This illustrates that the neurogenic manifestation of 
hypertension in OSA is predominantly related, yet not confined to arterial 
hypoxaemia. Thus, other pathological features of OSA, not modelled in CIH, such as 
hypercapnia and inputs from lung stretch receptors in response to intra-thoracic 
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pressure swings, are not crucial for autonomic dysfunction and excessive sympathetic 
outflow observed in OSA.  
The impact of CIH on baroreflex control of HR has been widely explored. Exposure 
to a relatively moderate protocol of CIH showed either no change (202, 392) or 
increased sensitivity of HR baroreflex (416). Conversely, baroreflex control of HR 
was blunted in response to CIH of long duration and/or of high frequency of episodes 
(74, 217). However, it is not established if impaired baroreflex is a direct consequence 
of CIH exposure or secondary to hypertension, or both together. Moreover, there is 
insufficient knowledge about high-pressure baroreflex control of renal sympathetic 
nerve activity (RSNA). This is of significance as previous studies have shown that the 
response of RSNA to the activation of high-pressure baroreceptors might be modified 
differently from the HR response in the same physiological model (243) and in 
pathophysiological models (133, 363). Accordingly, we hypothesized that exposure to 
CIH, sufficient to cause hypertension, disrupts the high-pressure baroreflex control of 
RSNA.  
Afferent renal nerves are densely located in the renal pelvic wall, ureter and to a lesser 
extent in the renal cortex (237). Selective renal deafferentation was associated with 
attenuation of hypertension, similar to the extent of blood pressure decrease obtained 
following total renal denervation (46, 101). Moreover, renal denervation resulted in 
restoration of blunted high-pressure baroreflex in hypertensive models that involve 
kidney injury (168). As discussed in chapter 1, transient receptor potential vanilloid 1 
(TRPV1) channels in the renal pelvic wall are co-localised with SP and CGRP 
neurotransmitters that mediate the activity of afferent renal nerves (15, 385). TRPV1 
channels modulate afferent renal nerve activity (ARNA) by increasing intracellular 
Ca2+ and by stimulating the release of SP and CGRP (15, 414). Using whole-cell patch 
clamp, the membrane conductance of HEK293T cells, transfected with rat TRPV1 
channels, was increased during exposure to 3%O2. This was revealed by an increase 
in the amplitude of rectified TRPV1 currents which was associated with an increase 
in the concentration of intracellular calcium. The addition of tiron, an intracellular 
oxygen radical scavenger, attenuated the basal conductance of TRPV1 channels 
during hypoxia, suggesting that the activity of TRPV1 was enhanced by reactive 
oxygen species (ROS) (172). Furthermore, intra-renal pelvic infusion of an agonist 
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dose of capsaicin increases RSNA and blood pressure, indicating an excitatory afferent 
renal reflex mediated by TRPV1 channels. This is associated with increased c-fos 
labelling and superoxide radicals in the paraventricular nucleus (PVN) (287, 397). 
Afferent renal inputs are transmitted to nucleus tractus solitarius (NTS), rostral 
ventrolateral medulla (RVLM) and PVN, which are the integration centers of the 
baroreflex loop (151). Therefore, we propose that the activity of TRPV1 channels 
located in the renal pelvic wall is enhanced following exposure to CIH due to altered 
oxidative signalling in the kidney, which elicits an excitatory afferent renal reflex. We 
hypothesized that TRPV1 blockade restores the anticipated CIH-induced blunting of 
the high-pressure baroreflex control of RSNA. 
We tested our hypothesis using vasoconstrictor and vasodilator agents to induce blood 
pressure changes and assess high-pressure baroreflex activity. RSNA (% change from 
baseline) and HR were recorded during blood pressure fluctuations. This protocol was 
conducted in two phases: a first phase when saline was infused into the kidney in 
cohort 1 and 2, and a second phase when intra-renal capsaizepine (CPZ, TRPV1 
blocker) was infused in cohort 2.  
 
3.2. Results 
3.2.1. General  
Body weight gain in rats exposed to CIH was lower than the corresponding shams 
during 14 days of exposure in all cohorts (Appendix I, Figure 8.2 and Table 8.3). Body 
weights on the day of the surgical experiments (one day after day 14) were not 
significantly different between CIH-exposed and sham rats of both cohorts. In cohort 
1, rats were not provided with supplementary oxygen during surgery and there was no 
significant difference in arterial PO2 or partial pressure of carbon dioxide (PCO2) 
between CIH-exposed and sham rats (Table 8.4). Blood gases remained relatively 
stable before the first VE vs. the second VE, as shown in Table 8.4. However, under 
anaesthesia, CIH-exposed and sham rats had low arterial PO2, which can activate 
peripheral chemoreceptors and causes an increase in the sympathetic outflow. 
Therefore, rats of the second cohort were provided with supplementary oxygen during 
the surgical protocol. PO2 and PCO2 were not significantly different between CIH-
exposed and sham rats of the second cohort. However, CIH-exposed rats required less 
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percentage of supplementary oxygen compared with shams to maintain PO2 levels 
above 80 mmHg during surgery (Table 8.4). Moreover, rats of cohort 2 were acidotic, 
which was comparable between CIH-exposed and sham rats. Haematocrit levels were 
comparable between CIH-exposed and sham rats of both cohorts (Table 8.4). 
 
3.2.2. Effect of CIH on baseline values of MAP, HR and RSNA 
A representative recording of baseline parameters is shown in Figure 3.1. In the first 
cohort study, CIH-exposed rats had higher mean arterial pressure (MAP) values before 
and immediately after the stabilization period (97±11 vs. 84±9 mmHg, ↑15.5%, 
p=0.028, Table 3.1) compared with sham rats. Baseline RSNA was greater in CIH-
exposed rats compared with sham rats (RSNA (% of max), 36±15% vs. 17±7%, 
p=0.006), when normalized to maximum RSNA values obtained during euthanasia. 
Before retroperitoneal incisions and before the stabilisation period, MAP was greater 
in CIH-exposed rats (by ~10.4%) of the second cohort compared with sham rats, but 
to a lesser extent compared with rats of the first cohort study (by ~15.3%).  
 
Figure 3. 1. Original recordings of cardiovascular parameters and RSNA in an 
anaesthetised rat. Representative original recordings of baseline arterial pressure 
(AP), heart rate (HR) which was derived from the AP recording, and raw and 





Table 8.6 (Appendix I) illustrates baseline parameters in CIH-exposed and sham rats 
between cohorts 1 and 2. Rats of cohort 2 showed modest MAP and HR compared 
with rats of cohort 1. This was revealed by lower MAP (Cohort, p <0.001) and HR 
(Cohort, p=0.010) values, measured before retroperitoneal incisions, in sham and CIH-
exposed rats of the second cohort compared with sham and CIH-exposed rats of the 
first cohort. MAP was significantly higher in CIH-exposed rats compared with sham 
rats of both cohorts (Exposure, p<0.001). Meanwhile, following retroperitoneal 
incisions and after the stabilization period, rats of cohort 2 had higher MAP compared 
with rats of cohort 1 (Cohort, p=0.002). Moreover, basal MAP, measured after the 
stabilization period, was comparable between CIH-exposed rats and sham rats of both 
cohorts. We suggest that the use of anesthesia caused the variability observed in 
baseline parameters after the stabilization period compared with baseline parameters 
before retroperitoneal incisions. Stabilization period was attained following 3-4 hours 
of surgical instrumentation under adequate anaesthesia. Nonetheless, RSNA and HR 
were significantly elevated in CIH-exposed rats compared with sham rats in both 
















Table 3. 1. Baseline cardiovascular and RSNA parameters in sham and CIH-
exposed rats. 
Data are presented as mean±SD and were collected from the first (sham, n=10; CIH-
exposed, n=9) and second cohorts of animals (sham, n=13; CIH-exposed, n=10). 
Baseline cardiovascular parameters were recorded for 2 minutes after ~4-5 minutes of 
arterial cannulation i.e. before retroperitoneal incisions were performed to expose the 
kidneys. Cardiovascular parameters and RSNA were also recorded for 2 minutes after 
the stabilization period, 1 hour following renal surgical instrumentation. Parameters 
were analysed using independent samples t-test or Mann-Whitney test. * p<0.05 
between exposure groups. CIH, chronic intermittent hypoxia; MAP, mean arterial 
blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart 
rate; RSNA (% of max), renal sympathetic nerve activity normalized to maximum 
activity recorded during baroreflex activation during euthanasia. 
 
 
3.2.3. Effect of CIH on the high-pressure baroreflex 
Representative recordings from high-pressure baroreflex trials are shown in Figure 
3.2. The slope of the RSNA baroreflex function curve of CIH-exposed rats was less 
than that of sham rats (A2 parameter: 0.09±0.05 vs. 0.29±0.27 mmHg-1, p=0.016, 
Figure 3.3a). This was related to a significant elevation in the response range (A1 
parameter: 73±26 vs. 104±32%, p=0.043) and operating range in CIH-exposed rats 
Parameter Sham CIH p-value Sham      CIH p-value 
After arterial cannulation (before renal surgical instrumentation) 
First cohort Second cohort 
MAP (mmHg) 124±13 143±7* 0.001 115±11 127±9* 0.014 
SBP (mmHg) 143±17 163±11* 0.008 137±13 144±12 0.154 
DBP (mmHg) 114±12 133±5* <0.0001 104±11 118±10* 0.005 
HR (beats min-1) 432±28 461±39 0.083 411±29 425±41 0.355 
After stabilization (after renal surgical instrumentation) 
MAP (mmHg) 84±9 97±11* 0.028    103±12 107±18 0.565 
SBP (mmHg) 116±14 125±15 0.262 134±15 132±22 0.871 
DBP (mmHg) 69±8 82±11* 0.043 88±13 94±19 0.365 
HR (beats min-1) 400±52 445±47 0.084 436±19 450±34 0.204 
RSNA (% of max) 17±7 36±15* 0.006 24±10 32±18 0.387 
RSNA (µV.s) 0.66±0.30 1.34±0.73 0.231 1.39±0.84 1.67±0.65 0.878 
Maximum 
RSNA (µV.s) 
4.70±2.03 4.03±2.18 0.349 7.04±5.29 6.60±3.54 1.000 
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compared with sham rats (Table 3.2). A rightward shift in the pressure at which the 
baroreceptors operate (A3 parameter), by ~20 mmHg (p=0.005), in CIH-exposed rats 
was observed (Figure 3.3a). This is consistent with the elevated MAP in CIH-exposed 
rats (by 13 mmHg) compared with sham rats, measured after the stabilisation period 
(Table 3.1) and immediately before the assessment of the high-pressure baroreflex. 
Conversely, data from the second cohort study (with a more modest increase in MAP 
in CIH-exposed rats) revealed no difference in any of the parameters between CIH-
exposed and sham rats (Figure 3.3b, Table 3.2). Parameters of the baroreflex control 
of HR were not significantly different between CIH-exposed and sham rats in either 
of the two cohort studies (Table 3.2). Baroreflex curves of raw data obtained from a 
sham rat and a CIH-exposed rat in each cohort are shown in Figure 8.3 in Appendix I. 
 
Figure 3. 2. Original recordings illustrating high-pressure baroreflex control of 
RSNA in anaesthetised rats.  Representative original recordings of arterial blood 
pressure, raw and integrated RSNA responsiveness to blood pressure manipulations 
evoking the high-pressure baroreflex. Recordings are shown for representative sham 
and CIH-exposed rats showing responses during intra-renal infusion of saline and 
intra-renal infusion of CPZ, (TRPV1 blocker). AP, arterial blood pressure; RSNA, 




Figure 3. 3. High-pressure baroreflex control of RSNA. Data (meanSE) are shown 
for RSNA (% of baseline) as a function of arterial blood pressure in sham and CIH-
exposed rats of the first (a; sham, n=10; CIH, n=8) and second cohort (b; sham, n=10; 
CIH, n=10). In each animal, the mean arterial blood pressure (MAP) was binned by 5 
mmHg and corresponding values of RSNA (% of baseline) within each bin were 
averaged. A sigmoidal curve of RSNA-MAP relationship was drawn for each rat using 
the four-parameter equation. Then, the baroreflex curve for each exposure group was 
constructed by using the four parameters obtained from each rat in each exposure 
group to calculate the RSNA (% of baseline) at fixed points of MAP using the four-
parameter equation. In graphs (c) and (d), data (meanSE) are shown for RSNA (% of 
baseline) as a function of arterial blood pressure during intra-renal infusion of saline 
and CPZ (TRPV1 blocker) of sham (c) and CIH-exposed rats (d) of the second cohort. 
Data for baroreflex parameters are shown in table 3.2 and table 3.3. RSNA, renal 
sympathetic nerve activity; BP, blood pressure. 
 
These apparently conflicting results obtained from the two cohorts are likely explained 
by the moderate correlation (Figure 3.4) that we found between baseline blood 
pressure recorded after the stabilization period and the slope (A2, R2=0.386, p=0.017) 
and mid-point pressure (A3, R2= 0.639, p<0.0001) of baroreflex gain curves of all rats 








Table 3. 2. High-pressure baroreflex parameters during intra-renal infusion of 
saline in sham and CIH-exposed rats (cohort 1 and cohort 2). 
Parameter Sham CIH p-value Sham      CIH p-value 
RSNA baroreflex  
First cohort Second cohort 
A1 (%) 73±26 104±32* 0.043 114±30 100±22 0.280 
A2 
(mmHg-1) 
0.29±0.27 0.09±0.05* 0.016 0.10±0.03 0.15±0.14 0.912 
A3 (mmHg) 109±6 129±14* 0.005 123±8 121±17 0.757 
A4 (%) 35±20 22±13 0.131 14±13 24±10 0.062 






0.237 2.8±0.9 3.4±2.5 0.739 
HR baroreflex 
First cohort Second cohort 
A1 (beats min-1) 59±25 65±44 0.732 88±31 92±40 0.843 
A2  
(mmHg-1) 
0.16±0.18 0.19±0.19 0.673 0.12±0.08 0.11±0.04 0.674 
A3 (mmHg) 116±9 122±15 0.341 125±17 125±15 0.999 
A4 (beats min-1) 370±46 410±59 0.139 387±38 397±76 0.707 
Max. gain  
(beats min-1. 
mmHg-1) 
1.8±1.5 2.1±1.5 0.423 2.2±0.8 2.2±0.9 0.821 
Data are expressed as mean±SD and represent baroreflex parameters of cohort 1 
(sham, n=10; CIH, n=9) and cohort 2 (sham, n=10; CIH, n=10). Data were analysed 
using independent sample t-tests. * p<0.05 vs. sham group. CIH, chronic intermittent 
hypoxia; RSNA, renal sympathetic nerve activity; HR, heart rate; A1, response range 
of RSNA/HR; A2, the gain coefficient; A3, midpoint pressure of input; A4, the 






Figure 3. 4. Correlations between baseline MAP and baroreflex parameters. The 
relationship between mean arterial blood pressure and the baroreflex parameters, A3 
and A2, are shown for all sham (n=20) and CIH-exposed rats (n=18). Linear regression 
analysis was performed. Significance was taken at P<0.05. MAP, mean arterial blood 
pressure; A3, midpoint pressure of the response; A2, gain coefficient.  
 
3.2.4. Effects of intra-renal TRPV1 blockade  
Baseline MAP was decreased during intra-renal infusion of CPZ in CIH-exposed and 
sham rats compared with before infusion of CPZ. However, HR and RSNA were not 
changed during intra-renal infusion of CPZ (Table 3.3). Intra-renal CPZ did not 
significantly affect high-pressure baroreflex of RSNA or HR in CIH-exposed and 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3. 4. High-pressure baroreflex parameters during intra-renal infusion of 
capsaizepine in sham and CIH-exposed rats (cohort 2). 
Parameter Sham CIH p-value Sham     CIH p-value 
RSNA baroreflex HR baroreflex 
A1 (% or beats 
min-1) 
95±46 90±17 0.780 67±36 82±40 0.370 
A2 (mmHg-1) 0.15±0.08 0.13±0.04 1.000 0.23±0.21 0.11±0.04 0.180 
A3 (mmHg) 113±8 116±15 0.588 112±11 116±15 0.586 
A4 (% or beats 
min-1) 
29±26 24±12 0.533 390±43 386±51 0.650 




3.1±1.4 2.9±1.1 0.692 3.5±4.7 2.1±1.0 0.880 
Data are expressed as mean±SD from sham (n=10) and CIH-exposed (n=10) groups 
and were analysed using independent sample t-tests. CIH, chronic intermittent 
hypoxia; RSNA, renal sympathetic nerve activity; HR, heart rate; A1, response range 
of RSNA/HR; A2, the gain coefficient; A3, midpoint pressure of input; A4, the 
minimum response. 
 
3.2.5. Validation of intra-renal (cortico-medullary) cannulation  
Lissamine green stain was infused into the kidney of three control rats for 30 minutes 
through the cortico-medullary cannula used to infuse CPZ. Tissue sections (30 µm) 
were imaged using a 4X magnification lens. All image shots were stitched together to 
generate a full image of each kidney section. In two out of three kidneys, the renal 
pelvic wall area was clearly stained by the green dye (Figure 3.5a and 3.5b). In the 
third kidney, the intra-renal cannula was correctly positioned to reach the renal pelvic 
area (Figure 3.5c), so we conclude that the lack of staining relates to a technical fault 
during sectioning using the cryostat. Accordingly, we conclude that intra-renal 
infusion for 30 minutes was sufficient to deliver CPZ to TRPV1 channels located in 




Figure 3. 5. Validation of intra-renal (cortico-medullary) infusion of TRPV1 
blocker, capsaizepine. Lissamine dye was infused for 30 minutes into the right kidney 
of three control rats using a cortico-medullary cannula similar to the one used to infuse 
capsaizepine into the kidney of experimental rats. Each image in the figure represents 
multiple shots captured and stitched together from a single kidney section of each 
control rat. Cortico-medullary infusion of lissamine green shows successful staining 
of the renal pelvic wall after 30 minutes of infusion in two (a and b) out of three rats. 




Exposure to CIH resulted in ̴ 16 mmHg increase in MAP recorded under anaesthesia 
and was associated with greater RSNA compared with sham rats (Table 3.1, Table 8.6 
in Appendix I). The high-pressure baroreflex was modestly affected in CIH-exposed 
rats, an outcome that was related to the magnitude of blood pressure increase after 
exposure to CIH, as high-pressure baroreflex control of RSNA was intact in CIH-
exposed rats with modest hypertension (+12 mmHg basal MAP, second cohort) but 
was altered in rats with more severe hypertension (+19 mmHg basal MAP, first 
cohort). 
 
3.3.1. Chronic intermittent hypoxia causes hypertension 
The CIH paradigm used in the present study was relatively modest, yet sufficient to 
induce hypertension, which was associated with increased RSNA. The current CIH 
model caused ̴ 15.3% increase of MAP in CIH-exposed rats vs. control of first cohort 
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and ̴ 10.4% increase of MAP in CIH-exposed rats of second cohort. Similar increases 
in MAP were reported after 4, 7 and 14 days of CIH exposure (74, 97, 392). Using the 
same CIH protocol to that of our study, increases in basal MAP (+9.2% and +18.5%) 
were reported in separate studies from our laboratory (226, 257). However, Del Rio et 
al. (75), using similar CIH paradigm, showed an increase in blood pressure after 21 
days, but not after 7 or 14 days of exposure. The same model elicited augmented 
chemosensory drive and enhanced ventilatory response to acute hypoxia after 7 and 
14 days of CIH exposure, despite no change in MAP before day 21 (75). The 
variability in blood pressure elevation reported by different studies using similar CIH 
protocols is likely to be related to the anaesthetic agent used and depth of anaesthesia 
that was attained during blood pressure recording. Del Rio et al. (75) used sodium 
pentobarbital of 40 mg/kg to induce and maintain an adequate level of anaesthesia, a 
dose that can cause a 20% decrease in MAP during two hours of recording (377). In 
our study, sodium pentobarbital was used at a lower dose (33 mg/kg) to induce 
anaesthesia and was omitted from maintenance doses where urethane and α-chloralose 
were used. In other aforementioned studies conducted in our lab, urethane alone was 
used to maintain anaesthesia. Subsequently, studies are needed to compare the effect 
of different anaesthetic agents on cardiovascular modulation mediated by CIH.  
Nevertheless, the method used to record blood pressure has a profound effect on the 
magnitude of MAP increase reported in different CIH studies. In addition to arterial 
catheterization used in our experiment, other studies have used radiotelemetry and 
cuff-tail methods to monitor blood pressure changes during CIH exposure (81). For 
example, Fletcher et al. (99) implemented a CIH paradigm of 35 days (120 cycles/hr, 
6-8 hr/day, 3-5% O2) and reported an increase in MAP by 13.5 mmHg in CIH-exposed 
rats recorded by catheterization of the abdominal aorta, compared with 21 mmHg 
increase when blood pressure was measured by tail-cuff method. Interestingly, 
telemetry recording in conscious rats revealed that exposure to CIH for 3 to 5 days is 
associated with a prompt increase in MAP without progressive elevation of blood 
pressure after longer durations of CIH exposure (75, 138, 201, 236). Exposure to CIH 
for 30 days (48 cycles/hr, 6 hr/day, 2-6% O2) resulted in a maximum increase in MAP 
by ~12.2%, reached after 7 days and was maintained during 30 days of continuous 
CIH exposure (201), which is similar to the magnitude of increase in MAP shown in 
our study. Moreover, MAP was elevated by ~10 mmHg after 3 days of CIH exposure 
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(15 cycles/hr, 12 hr/day, 10% O2), with no further elevation of blood pressure during 
the exposure period of 28 days (236).  
Our findings illustrated that basal HR in CIH-exposed rats was similar to shams. CIH 
exposure (12 cycles/hr, 8 hr/day, 10% O2) in rats was associated with a significant 
increase in HR during the light (sleep) cycle, which was restored to levels that are 
equivalent to shams the following day, after the end of CIH protocol, during normoxic 
breathing (138). Indeed, no change or an increase in resting HR has been described in 
rats exposed to CIH (56, 226).  
The magnitude of blood pressure increase depends on the parameters of the CIH model 
used, including duration of CIH exposure, frequency of hypoxia cycles and intensity 
of hypoxia (minimum FiO2 attained in the hypoxia cycle) (15). Peng et al. (272) have 
shown that 10 days of CIH exposure of multiple hypoxic episodes per day (9 cycles/hr, 
8 hr/day, 5% O2) was associated with 32% increase in MAP, while there was no blood 
pressure elevation in rats exposed to a CIH paradigm of less frequent cycles (4 hours 
of 5% O2, once per day for 10 days) (272). Basal discharge of carotid bodies and 
sensory long term facilitation (sLTF, persistent elevation of basal chemoafferent 
activity in normoxia), was heightened in rats exposed to the former CIH paradigm of 
frequent episodes, but were not altered following exposure to the latter CIH protocol 
(272). Moreover, adrenaline and noradrenaline efflux of the adrenal medulla was 
greatly induced in response to acute hypoxia in rats pre-treated with CIH paradigm of 
frequent episodes compared with rats pre-treated with less frequent episodes of CIH 
(199). In support of this, it was previously shown that the severity of systemic 
inflammation is heightened in response to a CIH protocol composed of more frequent 
hypoxia cycles (406). Serum levels of tumour necrosis factor alpha (TNF-α), nuclear 
factor kappa B (NF-κB) and hypoxia-inducible factor-1 alpha (HIF-1α) were elevated 
after exposure to 6 weeks of 10, 20, 30 and 40 cycles/hr of intermittent hypoxia (IH), 
with more significant elevation of inflammatory cytokines in rats exposed to more 
frequent IH cycles. In addition, the decrease of interleukin-10 (IL-10, an anti-
inflammatory cytokine) level was greater when rats were exposed to more frequent 
cycles of IH (406). Administration of a superoxide dismutase (SOD) mimetic 
eliminated the increase in blood pressure and prevented the enhanced chemoreflex 
drive induced by acute hypoxia in CIH-exposed rats (272). Furthermore, tempol, an 
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SOD mimetic, attenuated the CIH-induced modulation of pro-inflammatory / anti-
inflammatory cytokine profile (406). Therefore, it is strongly suggested that the 
cyclical pattern of hypoxia and re-oxygenation plays a major role in the autonomic 
and cardiorespiratory alterations induced by CIH, due to the generation of superoxide 
radicals during the re-oxygenation phase of each cycle. Hence, available evidence 
focuses on the role of frequency of hypoxia cycles in CIH-induced cardiorespiratory 
modulation. However, the parameter of CIH model that induces the predominant 
effect at the level of tissue injury, autonomic disruption and cardiorespiratory changes 
is not fully understood.  
Consistent with other models of hypertension (198, 227), a neurogenic mechanism 
leading to increased renal sympathetic tone is activated early in CIH models (123, 
224). We analyzed the integrated RSNA and presented our results in terms of absolute 
RSNA (µV.s) and values normalized to the maximum RSNA obtained during 
euthanasia. Our comparisons showed that absolute basal RSNA in CIH-exposed rats 
was not significantly different from sham group (Table 3.1). Normalisation of RSNA 
reduces the variability obtained from different recording conditions on different days 
from multiple groups. To minimize the variability in RSNA recordings, a dramatic 
increase in RSNA is induced and data are expressed in terms of percentage of 
maximum activity. Previous studies have shown that nasopharyngeal reflex in 
response to cigarette smoking induces a substantial increase in RSNA and complete 
attenuation of renal blood flow. This protocol was commonly used to normalize RSNA 
recordings to a maximum value in conscious rabbits and was reported in some pre-
clinical studies of conscious rats (32, 42, 213, 241, 242). Another method of 
normalization involves the recording of maximum RSNA obtained during injection of 
sodium nitroprusside (SNP) (208). However, in our study, we observed that maximum 
RSNA obtained in response to blood pressure decrease during SNP injection (Cohort 
1: Sham, 1.05±0.92 V.s; CIH, 1.46±0.97 V.s; Cohort 2: Sham, 1.96±1.28 V.s; 
CIH, 2.35±1.45 V.s) was less than the maximum RSNA observed during euthanasia 
in response to the profound drop in blood pressure caused by an overdose of 
anaesthesia (Cohort 1: Sham, 4.70±2.03 V.s; CIH, 4.03±2.18 V.s; Cohort 2: Sham, 
7.04±5.29 V.s; CIH, 6.60±3.54 V.s). Therefore, our basal values were expressed in 
terms of percentage of maximum obtained (average of 5 s) during euthanasia. Our 
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results showed a significant increase in basal RSNA (% of max) in CIH-exposed rats 
compared with sham rats of cohort 1. 
Previous studies have reported an increase in splanchnic, muscle, lumbar, thoracic and 
renal nerve activity in different models of CIH (224, 235, 280, 324, 417). Prior 
evidence has shown that exposure to 5 or 10 cycles of acute IH caused a ramp increase 
in RSNA and splanchnic sympathetic nerve activity, which was gradually progressing 
one hour after the end of the last hypoxia cycle (323). Acute optogenetic intermittent 
stimulation of neurons in the caudal NTS generated a similar ramp increase of RSNA 
and phrenic nerve activity, but of a lesser magnitude (393). This suggests that 
disrupted RSNA in IH might be induced by central plasticity of NTS neurons, 
independent of afferent signals coming from peripheral chemoreceptors (393). 
Overall, heightened RSNA might be related to down regulation of potassium/ATP 
channels in NTS neurons, activation of angiotensin II type 1 (AT1) receptors in the 
subfornical organ (SFO) and activation of neurons within the NTS in response to 
afferent inputs from the carotid bodies (323, 393) and possibly other sites such as the 
kidney (15). 
 
3.3.2. High-pressure baroreflex control of HR 
Disrupted autonomic control of blood pressure is associated with the pathogenesis of 
CIH-induced hypertension (320, 416). In relation to that, impaired cardiac baroreflex 
function was previously reported in people with OSA (64, 300) and conflicting results 
were reported regarding baroreflex control of HR in rats exposed to CIH (202, 392, 
416). Our data showing no change in the baroreflex control of HR in CIH-exposed 
rats, is in agreement with previous studies utilizing 5, 7 and 10 days of CIH exposure 
(202, 392). Indeed, long-term exposure to CIH was associated with decreased cardiac 
baroreflex gain (74, 122, 217). In contrast, Zoccal et al. (416) showed enhanced 
cardiac baroreflex sensitivity after exposing juvenile rats to CIH for 10 days. Indeed, 
their finding were supported by subsequent studies by Moraes et al. (246) who 
revealed enhanced inhibitory baroreflex inputs in juvenile rats exposed to CIH. 
Enhanced inhibitory inputs was associated with an increase in the inhibition of RVLM 
pre-sympathetic neurons during the expiratory phase (246). Lai et al. (202) analysed 
day-to-day arterial blood pressure and baroreflex sensitivity of the heart in conscious 
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rats. They found that MAP was higher by 15 mmHg after 5 days of exposure to CIH, 
but with no measurable alteration in baroreflex function. This was followed by a 
decline in baroreflex sensitivity starting 10 days after the onset of exposure to CIH 
(202). Of note, parameters other than duration of exposure must be taken into account 
in the comparison of severity of exposure between different studies and in the 
determination of the stage of the disease. Altogether, previous studies proposed that 
cardiac baroreflex sensitivity increases during the early phase of CIH exposure 
decreasing the sympatho-excitatory response to carotid body hypersensitivity and acts 
to bring blood pressure back to normal (246). However, with the disease progression, 
the augmented chemoreflex drive overwhelms the activity of the baroreceptors to 
control blood pressure (246). Other studies indicated that resetting of the cardiac 
baroreflex after 28 days of CIH exposure was restored to sham levels after bilateral 
carotid body ablation (62, 74).  
Impaired baroreflex control of HR following CIH exposure could be related to a 
dysfunction of multiple components of the baroreflex circuit, which results in an 
imbalance between sympathetic and parasympathetic activities. A previous study has 
shown that the electrical stimulation of cardiac vagal efferent neurons produced 
bradycardia, which was enhanced in CIH-exposed rats (217). Moreover, using 
anterograde tracing, the density of synapse-like endings of efferent vagal neurons was 
increased in CIH-exposed rats, suggesting that efferent postganglionic vagal neurons 
do not contribute to blunted baroreflex control of HR in CIH (217). On the other hand, 
immunofluorescence labelling revealed downregulation in glutamate, N-methyl-D-
aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors in the nucleus ambiguus region in the brain. Therefore, injection 
of glutamate, NMDA or AMPA into nucleus ambiguus produced a decrease in HR 
that was attenuated in CIH-exposed rats (217, 394). In support of this notion, exposure 
to CIH mixed with hypercapnia blunted the spontaneous excitatory glutamatergic 
transmission into the preganglionic vagal neurons of nucleus ambiguus in rats (89). 
Therefore, current evidence shows that blunted cardiac baroreflex is mediated by 
dysfunction in the central baroreflex component controlling the parasympathetic 
outflow. In addition, a heart rate variability study showed an increase in the low 
frequency to high frequency ratio after 14 days of CIH exposure indicating a shift 
towards sympathetic over parasympathetic control of HR (75).  In normotensive 
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individuals with OSA, Cortelli et al. (65) showed enhanced bradycardia response to 
cold pressor test despite attenuated baroreflex sensitivity. This agrees with enhanced 
vagal efferent neurotransmission reported in CIH-exposed rats (217).  
In the first cohort, RSNA- and HR-MAP relationship curves had no evidence of 
asymmetry around the mid-pressure point, as shown in Figure 8.1 in appendix I. A 
previous study showed a comparison between the four- and the five-parameter models 
in the analysis of the high-pressure baroreflex control of RSNA and HR (302). It was 
shown in that study that the five-parameter equation composed of two curvature (gain) 
coefficients can be reduced to four parameters accounting one curvature (gain, A2) 
coefficient, if there is no asymmetry. Therefore, the four-parameter model was used 
to analyse the high-pressure baroreflex control of RSNA and HR. 
 
3.3.3. High-pressure baroreflex control of RSNA 
CIH-exposed rats of the first cohort showed a significant shift in mid-point blood 
pressure by almost 20 mmHg, which was associated with an increase in the operating 
range of the RSNA baroreflex. Moreover, a marked increase in response range (A1 
parameter) of the RSNA baroreflex was evident in CIH-exposed rats. Elevation in the 
operating and response range of RSNA resulted in decreased slope of the baroreflex 
gain curve (A2 parameter). These changes were concomitant with a substantial 
hypertensive phenotype (Table 3.1). Conversely, CIH-exposed rats of the second 
cohort which showed modest hypertension displayed baroreflex responsiveness that 
was equivalent to the respective sham group. Interestingly, a significant correlation 
between basal MAP and the slope of the baroreflex curve (A2) and between MAP and 
mid-point pressure (A3) was evident (Figure 3.4). This indicates that resetting of the 
RSNA baroreflex and the decreased slope of the curve are associated with elevated 
blood pressure. It is likely that baroreflex adjustments following exposure to CIH in 
this study and marked attenuation of baroreflex function of HR observed in severe 
CIH protocols, are secondary to the development of hypertension following exposure 
to CIH. This is supported by the notion that the second cohort of rats were hypertensive 
(modest compared with cohort 1), but displayed no changes in baroreflex parameters 
indicating that the latter was not obligatory for the manifestation of CIH-induced 
hypertension. Hypertension overrides the baroreceptors’ capacity to control blood 
132 
 
pressure, causing resetting of the baroreflex and decreasing the baroreflex sensitivity. 
Additionally, hypertension is associated with vasoconstriction, which in turn 
exacerbates the tonic activity of chemoreceptors and aggravates sLTF. Subsequently, 
excessive chemoreflex drive mediates central plasticity in brain regions involved in 
baroreflex regulation (75).  In support of this argument, exposure to CIH in neonatal 
rats (20 cycles/hr, 12 hr/day, 8% O2) for 30 days did not blunt baroreflex control of 
RSNA. However, following exposure to acute IH (6 cycles of 10% O2 for 90s), 
neonatal rats pre-exposed to CIH had augmented sLTF of carotid bodies and showed 
decreased baroreflex control of RSNA (332). Nonetheless, in humans with OSA, a 
normal baroreflex control of HR was reported with no changes in MSNA response to 
phenylephrine, but with selective attenuation of MSNA increase in response to SNP 
injection (250).  
The high-pressure baroreflex loop of RSNA is composed of afferent inputs from 
baroreceptors, central integration, efferent sympathetic preganglionic neurons and 
post ganglionic neurons with their synapse-like terminals (395). Different models of 
CIH showed elevated pro-inflammatory cytokines and c-fos labelling in NTS and 
RVLM, brainstem regions of preganglionic sympathetic neurons (263, 332). Exposure 
to CIH depletes ATP levels required for potassium efflux to cause hyperpolarization 
in neuronal cells, which results in enhanced neuronal excitability in NTS and 
augmented sympathetic outflow (407). Furthermore, blunted cardiac baroreflex in 
chronic kidney disease-induced hypertension was found to be associated with 
increased glutamate and decreased GABA levels, and downregulation of GABA 
receptors in the NTS (54). In the latter study, elevated blood pressure and the blunted 
baroreflex were normalized following renal denervation. Therefore, based on the 
available evidence, it is suggested that modulation of the sympathetic baroreflex is 
mediated by dysfunction in the central nervous system component, and whether other 
components of the baroreflex loop are impaired warrants investigation.   
In our study, baroreflex control of RSNA was altered in CIH-exposed rats of cohort 1 
that had more severe hypertension, while baroreflex control of HR was maintained in 
all CIH-exposed rats of both cohorts. The difference between baroreflex control of 
RSNA and HR in the present study may be explained by the fact that the heart is 
regulated by the sympathetic and parasympathetic systems such that both systems 
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work together to sustain normal baroreflex control of HR (243). Moreover, we can 
speculate that distinctive sites within the NTS and RVLM control sympathetic outflow 
to the kidney and the heart. These sites might be modulated differently in response to 
CIH and hypertension, in addition to the presence of different ganglionic connections 
which requires investigation. Divergence has also been previously observed in other 
hypertensive disease models where baroreflex control of HR was decreased, while the 
baroreflex control of RSNA was unaltered (133, 363).  
 
3.3.4. Blockade of TRPV1 channels 
In our study, we aimed to test if blockade of renal TRPV1 channels restores the blunted 
baroreflex control of RSNA. The basis of this hypothesis was that PVN and RVLM 
are the main integration centres of baroreceptors inputs. The stimulation of renal 
afferent nerves induces an excitatory afferent reflex, activating neurons located in the 
supraoptic nucleus and PVN, which regulate the activity of preganglionic sympathetic 
neurons of RVLM (50, 325). This reflex increases blood pressure, which is clearly 
observed in cats, rats and mice (50, 261, 325). Of note, electrical stimulation of carotid 
sinus nerves activated 70-80% of hypothalamic regions that are activated during the 
electrical stimulation of renal afferent nerves (43). Inputs from carotid sinus nerve 
inhibit ~60% of hypothalamic units that are inhibited by renal afferent nerves, 
including PVN, lateral hypothalamus and preoptic region (43). Electrical stimulation 
of sensory renal nerves in mice results in an increase in splanchnic, lumbar and renal 
SNA (261). A subset of sensory renal nerves express TRPV1 channels that induce the 
entry of Ca+2 ions when activated, which stimulates SP and CGRP release, resulting 
in the activation of afferent renal nerves (160, 414). In our study, we used CPZ at a 
similar dose to that used in previous studies to block TRPV1 with marked changes in 
RSNA (209). Our intention was to deliver CPZ into the renal pelvic wall, to target 
TRPV1 channels which are part of renal afferent nerves (Figure 3.5). However, we 
cannot exclude the possibility of spill-over of CPZ to the surrounding renal cortical 
areas, where TRPV1 mediates vasodilation of renal arterioles (210). Furthermore, a 
previous study has shown that activation of TRPV1 located in the renal interstitium 
increases ARNA (82). Therefore, based on lissamine green images (Figure 3.5), we 
expect that we did not inhibit all renal afferent nerves that contain TRPV1. In addition, 
during the first cohort, we cannulated the left kidney and measured the ipsilateral 
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RSNA. However, a previous study has shown that the contralateral reno-renal reflex 
is more apparent that the ipsilateral arm of the reflex. Therefore, in the second cohort, 
we aimed to infuse saline/CPZ to the contralateral right kidney. Nevertheless, we don’t 
expect this difference between cohort 1 and 2 to affect our results because we did not 
study the effect of TRPV1 blockade in the first cohort rather than CPZ was infused 
during the second cohort only.  
Following 30 minutes of intra-renal infusion of CPZ, MAP was decreased in CIH-
exposed and sham rats with no change in RSNA and HR. This finding disagrees with 
prior studies that showed no change in basal MAP in sham rats following CPZ infusion 
into the kidney (209). In animal models of CIH, increases in systemic and renal 
inflammatory biomarkers and ROS have been reported together with impaired 
baroreflex control of HR (74, 202, 392). Pharmacological inhibition of inflammation 
and renal denervation restored the blunted high-pressure baroreflex control of RSNA 
in obese rats (170). Moreover, ROS modulate the downstream signalling pathway of 
TRPV1 channels (172) and cortico-medullary TRPV1 blockade normalised the 
blunted high-pressure baroreflex control of RSNA in a cisplatin model of renal failure 
(1). For logistical reasons, the high-pressure baroreflex function was not assessed after 
intra-renal CPZ in rats of cohort 1, where baroreflex changes were subsequently 
revealed. The effect of intra-renal CPZ was assessed in rats of cohort 2, but high-
pressure baroreflex control of RSNA was not altered in these rats with modest 
hypertension. Therefore, a possible role for TRPV1 signalling in modulating high-
pressure baroreflex control of RSNA in CIH-exposed rats cannot be excluded and this 
warrants further attention.  
In cohort 2, CIH-exposed and sham rats had respiratory acidosis, which is related to 
the use of anaesthesia (404). It was previously shown that hypercapnic acidosis 
increases baroreflex sensitivity (371). However, in our cohort and before the intra-
renal infusion of saline, the magnitude of respiratory acidosis was comparable between 
CIH-exposed and sham rats. In addition, baroreflex parameters were not different 
between CIH-exposed and sham rats during the saline phase of cohort 2 (Table 8.4, 
Appendix I). Meanwhile, after the end of the intra-renal saline phase and before the 
intra-renal infusion of CPZ, blood gases of CIH-exposed rats were different from sham 
rats of the second cohort. CIH-exposed rats displayed metabolic acidosis and 
normalised levels of PCO2 compared with sham rats (Table 8.4, Appendix I). This 
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might be due to increased hyperventilation in CIH-exposed rats compared with sham 
rats in response to phenylephrine and sodium nitroprusside during the preceding intra-
renal saline phase. Nevertheless, baroreflex parameters were not changed during the 




In conclusion, our findings show that rats exposed to CIH with established 
hypertension have moderate alterations in the high-pressure baroreflex control of 
RSNA with no changes in the baroreflex control of HR. We suggest that modulation 
of high-pressure baroreflex control of RSNA in this model is a consequence of 
hypertension and is less likely related to hypoxia per se, but might proceed to a 
pathological level and contribute to the maintenance of hypertension. Similarly, high-















Chapter 4: Effect of chronic intermittent hypoxia on renal 
sympatho-inhibition and renal functional responses to 










List of abbreviations 
ADH  Antidiuretic hormone 
AHI  Apnoea hypopnoea index 
Ang II  Angiotensin II 
ANP  Atrial natriuretic peptide 
AT-1  Angiotensin II type 1 
AUC Area under the curve 
CGRP Calcitonin gene-related peptide 
CIH Chronic intermittent hypoxia 
CKD Chronic kidney disease 
CPAP Continuous positive airway pressure 
CPZ Capsaizepine 
CSNA Cardiac sympathetic nerve activity 
eGFR Estimated glomerular filtration rate 
eNOS Endothelial nitric oxide 
ESRD  End-stage renal disease 
GFR Glomerular filtration rate 
H2O2 Hydrogen peroxide  
HR Heart rate 
MAP Mean arterial blood pressure 
NOX4  NADPH oxidase 4 
OSA Obstructive sleep apnoea 
PO2 Partial pressure of oxygen 
PVN Paraventricular nucleus 
RAAS Renin-angiotensin-aldosterone system 
ROS Reactive oxygen species 
RSNA Renal sympathetic nerve activity 
RVLM Rostral ventrolateral medulla 
SHR Spontaneously hypertensive rat 
SNA Sympathetic nerve activity 
SON Supraoptic nucleus 
SP Substance P 
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TRPV1 Transient receptor potential vanilloid 1 
UF Urine flow  
































Obstructive sleep apnoea (OSA) is prevalent in 50% of individuals with chronic 
kidney disease (CKD) (228). A clinical trial of 200 participants has shown that the 
diagnosis of OSA becomes more frequent as kidney function deteriorates: 25% of 
participants with estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m2 and 
35% of participants with eGFR >30 ml/min/1.73 m2 had OSA compared with 45% of 
participants with eGFR <30 ml/min/1.73 m2 diagnosed with OSA (13). Hypertension, 
OSA and CKD were described as a “triad” wherein each contributes to the onset and 
progression of the other complication (21). OSA worsens renal function through a 
direct effect of hypoxia and indirectly through sympathetic over-activity, endothelial 
dysfunction, activation of renin-angiotensin-aldosterone system (RAAS), and 
hypertension (21). All of these pathophysiological features are similarly presented in 
different models of chronic intermittent hypoxia (CIH) (15, 196).  
OSA severity, as determined by apnoea hypopnoea index (AHI), and deterioration of 
kidney function are linked through the volume status and body water content, as OSA 
is characterised by fluid accumulation and rostral fluid shift from legs into the neck 
and upper airway region during sleep. Individuals with CKD have 12% decreased 
pharyngeal area and increased neck circumference (21). Moreover, individuals with 
end-stage renal disease (ESRD) and OSA have markedly increased extracellular 
volume in the legs, neck and thoracic area. They have also greater reduction in 
nocturnal fluid volume in their legs compared with individuals with ESRD without 
OSA. In addition, AHI correlates with serum urea and creatinine clearance in 
individuals with CKD (11). Thus, dialysis using nocturnal ultrafiltration decreased 
AHI and fluid volume in ESRD (228). There was also a significant correlation between 
improvements in AHI and neck circumference (21). Subsequently, administration of 
diuretics caused improvements in AHI. In addition, treatment with continuous positive 
airway pressure (CPAP) resulted in decreased proteinuria and glomerular filtration 
fraction, and increased renal blood flow (11, 21). On the other hand, OSA worsens 
kidney function due to enhanced sympathetic outflow which causes RAAS activation, 
hyperaldosteronism, increased endothelin release, and subsequently endothelial 
dysfunction and blood pressure elevation. Indeed, treatment with CPAP was 
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associated with an increase in nitric oxide and a decrease in blood pressure in 
hypertensive individuals (21, 410).   
Volume status of the body is mainly maintained by the diuretic and natriuretic 
functions of the kidney. Under physiological conditions, blood pressure increase 
causes pressure diuresis and natriuresis to protect against blood pressure elevation 
(130). Fluid overload, defined as an increase in blood volume, activates low-pressure 
baroreceptors located in the cardiopulmonary region of the heart (260). These volume 
receptors are located in the atria, ventricles and lungs (245). Afferent inputs from low-
pressure baroreceptors induce reflex sympatho-inhibition, which causes a fall in renal 
sympathetic nerve activity (RSNA) followed by diuresis and natriuresis (291). A 
previous study has shown that cardiac receptors are the primary source for vagal 
afferent inputs in response to fluid overload, while receptors located in the lungs have 
a minor impact on the reflex (245).  
Low-pressure baroreflex is not widely examined in hypertension disease models. 
Clinical trials of essential hypertension have revealed that high-pressure baroreflex 
sensitivity is blunted in individuals with borderline hypertension and with moderate 
and severe hypertension (233). Meanwhile, low-pressure baroreflex control of 
splanchnic nerve activity is heightened in response to lower body negative pressure in 
individuals with borderline hypertension (233). The increased sensitivity of 
cardiopulmonary receptors in borderline hypertension is compensatory to decreased 
high-pressure baroreflex control of sympathetic nerve activity (SNA) and vascular 
tone. Meanwhile, the function of low-pressure baroreflex deteriorates with the 
progressive elevation of blood pressure in individuals with moderate-to-severe 
hypertension (233). In addition, the low-pressure baroreflex is blunted at advanced 
stages of hypertension when changes in cardiac structure begin. Cardiopulmonary 
reflex sensitivity was higher in normotensive individuals that have relatives with 
essential hypertension than in normotensive individuals with no evidence of familial 
hypertension (356). In contrast, Grassi et al. (121) reported a decrease in the sensitivity 
of the low-pressure baroreflex control of renin release and vascular tone in individuals 
with mild hypertension. The sensitivity was progressively deteriorated in individuals 
that have severe hypertension and left ventricular hypertrophy (121). In relation to 
that, a significant correlation was shown between decreased sensitivity of the 
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cardiopulmonary baroreflex with heart thickness and with renal vascular tone in 
humans (356).  Interestingly, normotensive individuals with OSA have increased left 
ventricular mass similar to hypertensive individuals with no OSA (21). It was 
suggested that repetitive hypoxaemia during apnoeic episodes causes continuous 
activation of intra-thoracic pressure, and subsequently results in blood pressure 
increase and left ventricular hypertrophy (21). AHI was correlated with left ventricular 
mass (72), indicating that low-pressure baroreflex control could be altered in the early 
stages of OSA and CIH models.  
Previous studies have revealed blunted low-pressure baroreflex control of RSNA in 
response to fluid overload in disease models that involve kidney injury (3, 168, 169). 
In this regard, similar renal pathophysiological changes to that observed due to 
exposure to CIH were reported in renal injury disease models (80, 224, 380, 381, 409). 
However, the influence of exposure to CIH on the low-pressure baroreflex control of 
RSNA and kidney function has not yet been examined. 
Kidneys are innervated by afferent and efferent sympathetic nerves that interact to 
maintain normal water and electrolyte balance, through reno-renal reflex mechanisms 
(6). Studies have shown that activation of afferent renal nerves induces sympatho-
excitation and a decrease in renal blood flow (24, 135, 180, 256, 267, 383). Electrical 
stimulation of afferent renal nerves in cats and rats enhanced the activity of neurons 
in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) and subsequently, 
this increased plasma levels of antidiuretic hormone (ADH) in the absence of any 
change in plasma osmolality (50, 325). Studies utilizing selective renal deafferentation 
techniques reported attenuation of hypertension (46, 101). Ditting et al. (83) have 
shown that dendritic cells and macrophages are in close proximity to renal afferent 
nerve endings. Accordingly, pharmacological inhibition of renal inflammation and/or 
oxidative stress was associated with normalization of low-pressure baroreflex control 
of RSNA in many hypertensive disease models (3, 170). TRPV1 channels are involved 
in the activation pathway of renal afferent nerves (172), and their activity is enhanced 
following exposure to hypoxia (15). Moreover, the PVN is the main control site for 
efferent RSNA, and it receives inputs from low-pressure baroreceptors and from renal 
afferent nerves. Indeed, renal afferent nerves were found to be activated by TRPV1 
agonists (151, 287, 397).  
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We aimed to explore the impact of CIH exposure on low-pressure baroreflex control 
of RSNA with possible changes in renal excretory responses to fluid overload. We 
hypothesised that renal TRPV1 blockade improves the baroreflex regulation of RSNA 
and alters kidney diuretic and natriuretic responses. Therefore, we induced volume 
expansion (VE) using IV saline infusion for 30 minutes and we recorded RSNA and 
sodium and water excretion before, during and after VE. This was performed in two 
phases in study cohort 1. The first phase was performed in the presence of a 
background of intra-renal infusion of saline (vehicle) while the second phase was done 
in the presence of a background intra-renal infusion of capsaizepine (CPZ, TRPV1 
blocker). We also examined TRPV1 expression in the renal pelvic wall and kidney 
tissue. The plasma levels of atrial natriuretic peptide (ANP) in response to VE was 
also analysed in CIH-exposed and sham rats. 
 
4.2. Results 
4.2.1. Basal haemodynamic and renal excretory parameters before VE 
Exposure to CIH had no significant effect on any of the basal renal excretory 
parameters (Table 4.1). During intra-renal infusion of CPZ, there was a significant 
increase in urine flow (UF) and sodium excretion, both in CIH-exposed and sham rats 
compared with respective values measured during saline infusion (Table 4.1). 
 
Prior to VE challenge, intra-renal infusion of saline had no significant effect on blood 
pressure, heart rate (HR) and RSNA. In contrast, mean arterial pressure (MAP) was 
lower during intra-renal infusion of CPZ, both in CIH-exposed and sham rats, 
compared with respective baseline values measured prior to CPZ infusion, whereas 









Table 4. 1. Baseline renal excretory parameters in sham and CIH-exposed rats. 
 GFR  
(ml min-1 kg-1) 
UF  
(µl min-1 kg-1) 
Absolute Na+ 
excretion  




After intra-renal infusion of saline/before VE 
Sham 11.19±8.43 32.87±15.53 4.08±3.07 0.25±0.20 
CIH 8.94±3.42 46.18±23.60 7.05±4.73 0.57±0.45 
After intra-renal infusion of CPZ/before VE 
Sham 11.78±4.48 81.71±35.59* 17.02±6.95* 1.22±0.87* 
CIH 10.53±3.02 101.26±43.85* 23.64±11.19* 1.53±0.64* 
2X2 
ANOVA 
    
Exposure P=0.169 P=0.155 P=0.090 P=0.166 
Drug P=0.242 P<0.001 P<0.001 P<0.001 
Exposure X 
drug 
P=0.585 P=0.760 P=0.394 P=0.976 
Data are expressed as mean±SD in sham (n=9) and CIH-exposed rats (n=9). Two basal 
urine samples were averaged and data were compared between CIH-exposed and sham 
rats during saline and CPZ phases by repeated-measures two-way ANOVA. * p<0.05 
vs. corresponding value during intra-renal infusion of saline. GFR, glomerular 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.2. Effect of CIH on the low-pressure baroreflex control of RSNA 
RSNA recordings during VE challenge are shown in Figure 4.1. The low-pressure 
baroreflex was examined in terms of RSNA response to VE challenge. VE caused a 
progressive significant decrease in RSNA, which reached its maximum after 28-30 
minutes. The drop in RSNA during VE in the presence of intra-renal infusion of saline 
was not significantly different between CIH-exposed and sham rats (Figure 4.2). 
 
4.2.3. RSNA response to VE during intra-renal TRPV1 blockade 
During intra-renal infusion of CPZ, the decrease in RSNA (% of max) in response to 
VE was equivalent in CIH-exposed and sham rats (Figure 4.2). However, an apparent 
potentiation of the RSNA sympatho-inhibitory response to VE was observed in both 
groups when RSNA (% of baseline) was considered. 
 
 
Figure 4. 1. Representative recordings of RSNA response to VE in anaesthetised 
rats. Raw and integrated RSNA responsiveness to VE evoking the low-pressure 
baroreflex. Recordings are shown for representative sham and CIH-exposed rats 
showing responses during intra-renal infusion of saline and intra-renal infusion of 
CPZ, (TRPV1 blocker). RSNA, renal sympathetic nerve activity; Int. RSNA, 




Figure 4. 2. RSNA responses to VE. In sham (n=8) and CIH-exposed rats (n=9), 
RSNA responses to VE challenges were determined. In the left-hand panels, the time 
course of responses to and recovery from VE during intra-renal infusion of saline or 
CPZ (TRPV1 blocker) are shown. Integrated RSNA values were averaged every two 
minutes during both VE challenges and every 5 minutes during the recovery after VE 
(mean±SE). Each averaged RSNA value was either normalized to baseline RSNA, 
which was taken as 100% (upper left panel), or normalized to the maximum RSNA 
(lower left panel). Maximum RSNA was obtained during euthanasia and was 
calculated as an average of 5s. Two-way ANOVA (time x exposure) was used to 
statistically compare the data. # p<0.05 for time;  p<0.05 for time points significantly 
different from respective baseline (post-hoc analysis). In the right-hand panels, area 
under the curve (AUC) analysis for the respective responses were calculated using the 
trapezoidal rule by the summation of the VE period. AUC data are expressed in 
arbitrary units (AU) and represent the sum of small areas (trapezoids) that are 
calculated for every two minutes of the VE challenge. Data are shown as individual 
data points for each rat, with box and whiskers plots representing the interquartile 
range and maximum and minimum values. AUC data were compared using 
independent t-tests. Significance was taken at p<0.0125, accounting for multiple 
comparisons. RSNA, renal sympathetic nerve activity; CPZ, capsaizepine; VE, 






Figure 4. 3. Cardiovascular and renal excretory responses to VE. In sham (n=8) 
and CIH-exposed rats (n=9), MAP, HR, UF, GFR, absolute and fractional Na+ 
excretion responses to VE challenges were determined. In the left-hand panels, the 
time course of responses to and recovery from VE during intra-renal infusion of saline 
or CPZ (TRPV1 blocker) are shown. Data (meanSE) were averaged over each 2-
minute period during VE trials. Two-way ANOVA (time x exposure) was used to 
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statistically compare the data. # p<0.05 for time;  p<0.05 for time points significantly 
different from respective baseline (post-hoc analysis);  p<0.05 for exposure; * 
p<0.05 compared with corresponding time point in sham rats. In the right-hand panels, 
area under the curve (AUC) analysis for the respective responses is shown (expressed 
in arbitrary units, AU), calculated using the trapezoidal rule, by the summation of the 
VE period. Data are shown as individual data points for each rat, with box and 
whiskers plots representing the interquartile range and maximum and minimum 
values. Data were compared with independent t-tests. Significance was taken at 
p<0.0125, accounting for multiple comparisons. MAP, mean arterial pressure; UF, 
Urine flow; GFR, glomerular filtration rate; MAP, mean arterial blood pressure; HR, 
heart rate; CPZ, capsaizepine. 
 
4.2.4. Effect of CIH on renal excretory responses to VE 
VE in CIH-exposed and sham rats resulted in significant increases in GFR, UF and 
Na+ excretion (Figure 4.3c-f). The response pattern and magnitude of GFR and 
fractional Na+ excretion during VE were similar in sham and CIH-exposed rats. 
Diuresis in response to VE was of significantly lesser magnitude in CIH-exposed rats 
compared with sham rats after 25 and 30 minutes (Figure 4.3c). Similarly, absolute 
Na+ excretion was significantly less in CIH-exposed rats after 30 minutes of VE 
(Figure 4.3e). Analysis of area under the curve (AUC), reflecting the temporal 
cumulative response to VE, revealed that UF was significantly less in CIH-exposed 
rats compared with sham rats (Figure 4.3c). 
 
4.2.5. Renal excretory responses to VE during intra-renal TRPV1 blockade 
During intra-renal infusion of CPZ, significant increases in UF and absolute Na+ 
excretion in response to VE were observed in CIH-exposed and sham rats, with no 
significant difference between the experimental groups (Figure 4.3).  
 
4.2.6. Cardiovascular responses to VE  
Baseline ANP concentration in plasma prior to VE challenge was not significantly 
different between CIH-exposed and sham rats (CIH vs. sham; 157±17 vs. 167±36 
pg/ml). In response to VE, the estimated ANP amount in plasma was increased in both 
groups. However, there was a lesser increase of ANP in CIH-exposed compared with 
sham group (∆ ANP: CIH vs. sham; 1.54±0.28 vs. 4.36±1.55 ng, p=0.026). MAP and 
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HR data during each VE trial are shown in Figure 4.3a and 4.3b. During the last 2 
minutes of each VE trial, MAP was not significantly different from respective baseline 
values recorded prior to VE (Table 4.2). HR was significantly elevated during the last 
2 minutes of each of the VE trials, both in CIH-exposed and sham rats (Table 4.2). 
 
4.2.7. Content of TRPV1 in renal tissue  
TRPV1 channels are mainly expressed in the nerve fibres located between the 
muscular layer and the uroepithelium of the renal pelvic wall (Figure 4.4). Positive 
staining was also expressed in the uroepithelium (Figure 4.4). TRPV1 fluorescence 
occupied 5.1±1.0% of the area of the muscularis propria of the pelvic wall of CIH-
exposed rats, which was equivalent to sham rats (6.4±1.9%, Figure 4.4f). Similarly, 
TRPV1 expression in the uroepithelium was equivalent between CIH-exposed and 
sham rats (3.7±0.9% vs. 3.9±1.1%). TRPV1 protein concentration in whole kidney 
tissue measured by ELISA (Figure 4.4f, bottom) was not significantly different 




Figure 4. 4. TRPV1 immunofluorescence in the renal pelvic wall. 
Immunofluorescence labelling of renal pelvic wall showing TRPV1-positive labelling 
within the muscularis propria (white arrows) and uroepithelium layer (red arrows). (a) 
is a representative image from a sham kidney and (b) is a representative image from a 
CIH-exposed kidney. Negative controls demonstrate specificity of the antibodies used 
in the study (c, primary antibody omitted; e, secondary antibody omitted); Blue 
labelling of nuclei by DAPI. (d) Immunofluorescence labelling of TRPV1 channels in 
neuronal cell bodies of lumbar dorsal root ganglia as a positive control. Scale bar 50 
µm. Data for TRPV1-positive staining (% of total area) in sham (n=8) and CIH-
exposed rats (n=9) are shown as individual data points for each rat, and box and 
whiskers plots representing the interquartile range and maximum and minimum values 
(f, top). Data for TRPV1 protein concentration of kidney tissue homogenate in sham 
(n=12) and CIH-exposed rats (n=8) are shown as individual data points for each rat, 
with box and whiskers plots representing the interquartile range and maximum and 
minimum values (f, bottom). Data were compared with independent t-tests. 




4.3. Discussion  
The key new findings of the present chapter are as follows: 1) In CIH-exposed rats, 
diuretic and natriuretic responses to VE were impaired, notwithstanding that the 
sympatho-inhibitory response of RSNA to fluid overload was preserved. 2) 
Preliminary observations suggest that intra-renal TRPV1 blockade with CPZ restored 
the renal excretory responses to VE in CIH-exposed rats, but this requires further 
testing.  
 
4.3.1. Low-pressure baroreflex control of RSNA 
VE has been previously used to study the integrity of the low-pressure baroreflex and 
associated RSNA and kidney functional changes (168, 169). During VE, a marked 
decline (~30%) in RSNA was observed in sham rats of the current study, which is 
similar to previous studies (41, 168). HR was significantly elevated during VE which 
might be related to the Bainbridge reflex and increased cardiac sympathetic nerve 
activity (CSNA) in response to fluid overload (129). An increase in blood volume 
induces distinct SNA responses such as an increase in CSNA, a decrease in splanchnic 
and renal SNA, but was not shown to change lumbar SNA (19, 129, 260, 292). There 
was no significant change in MAP during VE in this study, which was also observed 
in previous studies (3, 41). 
Exposure to CIH did not affect the sympatho-inhibitory response of RSNA to VE. 
This suggests that altered low-pressure baroreflex control of RSNA does not 
contribute to CIH-induced hypertension. However, impaired low-pressure baroreflex 
was indeed evident in cisplatin-induced renal failure and other models of severe 
hypertension such as spontaneously hypertensive rats (SHR) (120, 168, 374). 
Moreover, central activation of angiotensin II type 1 (AT-1) receptor, which are 
upregulated in the SON of CIH-exposed rats (319), blunts the sympatho-inhibitory 
response of RSNA to VE (7). Therefore, we predict that altered low-pressure 
baroreflex control of RSNA in our model might manifest later, suggesting it is a 
consequence of hypertension during disease progression. Further studies to explore 
the low-pressure baroreflex in severe models of CIH are therefore warranted. 
152 
 
Low-pressure baroreflex is composed of afferent inputs from volume receptors in the 
cardiopulmonary region, inter-neurons in the brainstem and hypothalamus, and 
efferent pre- and post-ganglionic sympathetic and parasympathetic neurons. In 
hypertensive disease models such as SHR (107, 357), cardiac remodelling was 
associated with impaired RSNA sympatho-inhibitory response to VE and reduced fall 
in forearm vascular resistance (232, 357). Treatment of individuals with anti-
hypertensive agents resulted in greater decrease in forearm vascular resistance and 
reduced left ventricular weight (232). Moreover, in essential hypertension in humans, 
the decrease in forearm vascular tone and renin release in response to an increase in 
central venous pressure by leg elevation was markedly blunted. The responses were 
further attenuated in hypertensive participants with cardiac hypertrophy (121). A 
coherent correlation between the degree of cardiac remodelling and impaired RSNA 
response to VE was evident, indicating a change in the sensitivity of cardiopulmonary 
receptors at peripheral level. In relation to this, severe models of CIH revealed cardiac 
hypertrophy (396, 398). At the same time, aggravated chemoreflex drive occurs at an 
early stage of CIH exposure which induces central modulation and dysregulation of 
sympathetic outflow (75), suggesting that altered low-pressure baroreflex might occur 
at later stages of the disease. This alteration in the baroreflex is suggested to be a 
consequence of the dysfunction in the central circuit or in the peripheral vagal 
receptors in association with cardiac structural changes during persistent hypertension.  
In our study, we examined the overall change in RSNA in response to VE. Our analysis 
did not measure the frequency of neural bursts distinctively from the amplitude of 
RSNA signal. Indeed, an increase in the amplitude indicates recruitment of nerve 
fibres. In sheep, VE induced a decrease in the frequency of bursts and amplitude of 
RSNA (293). In contrast, a decrease in the amplitude with no change in the frequency 
of bursts in response to VE was revealed in rabbits (204). 
Of note, VE challenges were performed following the assessment of the high-pressure 
baroreflex, discussed in chapter 3. The effects of phenylephrine and sodium 
nitroprusside on the RSNA and cardiovascular parameters are short-lived, as shown 
in Figure 3.2. Sufficient time (~30 minutes) was allowed before the beginning of the 
first VE phase to ensure the return of parameters to baseline levels. Therefore, it is less 
likely that the assessment of the high-pressure baroreflex using vasoactive agents had 
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an effect on the low-pressure baroreflex. Moreover, previous studies in our laboratory 
utilized this approach (2, 141).  
 
4.3.2. Renal excretory responses to VE       
Basal renal function was not significantly different between sham and CIH-exposed 
rats despite increased basal RSNA in the CIH group (Table 3.1). Nevertheless, the 
renal excretory response to VE in CIH-exposed rats was blunted with a resultant 
sodium and water retention (Figure 4.3c and 4.3e). These findings suggest that 
compensatory mechanisms in the kidney ensure maintenance of normal basal kidney 
function in the face of CIH-related stress and sympathetic over-activity. Dysfunction 
was revealed however, during VE challenge, with evidence of blunted diuretic and 
natriuretic responses, which appear independent of neural control of the kidney. 
Similarly, in streptozotocin-induced diabetic rats, basal diuresis and natriuresis was 
equivalent to non-diabetic rats, but excretory responses were impaired during VE 
(379). The underlying mechanisms that contribute to impaired excretory responses 
during VE are multifactorial and do not depend solely on changes in RSNA. Such 
mechanisms include alterations in RAAS activity, renal perfusion pressure, and 
glomerular filtration rate (GFR). Thus, our findings of blunted sodium and fluid 
excretion during VE in CIH-exposed rats, despite preserved reflex reduction in RSNA, 
highlighted that other mechanisms might contribute to diuretic and natriuretic 
responses to VE and revealed that one or more of these mechanisms are perturbed by 
exposure to CIH.  
In conscious and anaesthetized rats, diuresis and natriuresis responses were eliminated 
following bilateral removal of atrial appendages which were comparable to responses 
obtained after selective right atrial appendectomy, indicating that vagal receptors, 
located in the right atrium, are linked to the VE-mediated renal excretory responses 
(308). However, vagotomy in another study in rats decreased the diuretic but it did not 
have any effect on the natriuretic response to VE (361). Vagotomy was also associated 
with 75% attenuation in RSNA sympatho-inhibitory response in dogs (19). It is worth 
mentioning that balloon inflation in the left atrium and negative pressure breathing 
were associated with diuresis, but not natriuresis (19). Moreover, an increase in 
extracellular volume with no alteration in plasma volume was associated with 
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natriuresis (315). This provides evidence for differential mechanisms involved in the 
regulation of diuretic and natriuretic responses to VE. In response to VE in dogs, the 
increase in sodium excretion preceded the increase in diuresis (19). Based on these 
observations, it was hypothesized that there are extrathoracic receptors that detect 
increased blood volume, in addition to other receptors in the interstitial compartment 
of the body (19). In support of this notion, infusion of hyperoncotic saline, a colloidal 
fluid of 5% albumin, during haemorrhage restored the blunted water excretion to 
baseline, while sodium retention persisted along with excessive aldosterone levels 
(19), suggesting a distinct mechanism controlling sodium excretion in response to 
changes in blood volume.  
Diuresis occurred without any consistent and uniform change in GFR between groups. 
Sodium and fluid excretion reached its maximum at the end of VE (after 25 to 30 
minutes), while GFR showed a transient increase at the beginning of the challenge, 
followed by a decline until the end of the 30-minute period. Previous VE studies 
reported either no change, or small inconsistent changes in GFR, concomitant with 
increased sodium and fluid excretion (19, 134). Hegde et al. (134) using 60 minutes 
of VE in normal rats, showed a transient increase in GFR after 30 minutes of VE 
initiation followed by a decline until the end of the 60 minute period. Furthermore, in 
humans, a decrease in venous return was associated with a decline in GFR and sodium 
excretion. When venous return was restored to normal, GFR was normalized but with 
sustained decrease in sodium excretion, which was later restored to normal (315). 
Therefore, variable GFR responses in our study were in line with previous studies 
using similar VE challenges. Possible alterations in GFR during VE result from 
changes in renal haemodynamics (an increase in renal blood flow and a decrease in 
renal vascular resistance). Franchini et al. (102) showed that changes in renal 
haemodynamics are not strictly dependent on neural control of the kidney. VE using 
isotonic saline results in haemodilution and decreased blood viscosity, which was 
associated with a decrease in renal vascular resistance and an increase in renal blood 
flow. However, VE using whole blood infusion was associated with no changes in 
renal haemodynamics, suggesting that rheological changes of blood induce renal 
haemodynamic changes during VE. In the current study, the change of haematocrit 
during VE in saline and CPZ phases was not significantly different between exposure 
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groups (Appendix I, Figure 8.4), indicating that haemodilution is less likely to 
contribute to the differences in excretion between CIH-exposed and sham rats. 
A decrease in oncotic pressure in response to VE inhibits water and sodium 
reabsorption from proximal tubules (39). It was shown that the addition of albumin to 
the volume-expanded fluid restored water and sodium reabsorption in proximal 
tubules. We performed volume expansion using saline which resulted in a decrease in 
blood oncotic pressure, reducing the oncotic gradient between peritubular capillaries 
and the lumen of proximal tubules. Accordingly, oncotic pressure changes during VE 
contribute to diuresis and natriuresis by decreasing sodium and water fractional 
reabsorption through the proximal tubule (331). Proteinuria was evident after exposure 
to a CIH paradigm similar to the one used in this study (258), suggesting higher 
luminal oncotic pressure in CIH-exposed rats compared with shams. Therefore, it is 
less likely that differences in the oncotic pressure gradient between CIH and sham 
groups contribute to differences in diuresis and natriuresis observed in this study. 
Although we did not observe differences in the GFR response to VE between CIH-
exposed and sham rats, indicating less likelihood of differences in glomerular 
hydrostatic pressure, the possibility of changes in  peritubular capillary hydrostatic 
pressure exerting an effect on tubular water and sodium reabsorption cannot be ruled 
out (145).  
On the other hand, it has been shown that acute VE is associated with suppressed levels 
of renal and plasma angiotensin II (Ang II) with no change in the intraluminal content 
of Ang II in the proximal tubule (34). A dissociation between extraluminal and 
intraluminal renal tubular levels of Ang II was reported during VE. It was suggested 
that Ang II production and degradation are differentially altered inside proximal 
tubules compared with renal interstitium (34). Remarkably, chronic hypoxia was 
associated with reduced protein and gene expression of neutral endopeptidase 24.11, 
responsible for Ang II degradation in the proximal tubule (362). Moreover, decreased 
cortical PO2 (partial pressure of oxygen) with unaltered oxygen tension in the medulla 
was shown in  a model of CIH, similar to the one used in this study (258). The latter 
suggests altered sodium transport at superficial segments of the nephron. Further 
studies are required to examine whether the regulation of Ang II in proximal tubules 
is altered and if it contributes to the blunted diuresis during VE. Together, these 
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observations suggest the presence of a tubular-related mechanism controlling diuresis 
and natriuresis (30, 52, 306), which is adversely affected in CIH.  
Of note, our results showed a concomitant increase in natriuresis and diuresis during 
30-minute VE. We measured total urine volume which does not indicate free water 
excretion. VE studies provided evidence that the natriuretic response to VE is 
independent of increased diuresis. A previous study showed that fractional sodium 
excretion is increased while free water excretion is decreased during isotonic saline 
VE (238). Nonetheless, blunted natriuresis in CIH-exposed rats of this study was 
linked to decreased absolute sodium excretion, while fractional sodium excretion was 
comparable between CIH-exposed and sham rats. This might indicate that sodium load 
into the kidney was less in CIH-exposed rats. In support of this notion, there was a 
linear correlation between increased fractional sodium excretion and decreased 
filtration fraction (i.e. decreased sodium load on tubules) in a previous study (288).  
Sodium load is affected by renal haemodynamics (renal blood flow and vascular 
resistance) and by Starling forces (hydrostatic and oncotic pressures). However, these 
measurements were beyond the scope of this study and this requires further 
investigation.   
Martinez-maldonado et al. (238) have shown that medullary and papillary solute 
concentration is increased in response to isotonic saline VE although fractional sodium 
excretion is increased. This strongly indicates that sodium reabsorption increases 
during VE across the early segment of the nephron. Subsequently, impaired sodium 
reabsorption occurs beyond the ascending  limb of the loop of Henle (238), through a 
mechanism that is not fully understood. Similarly, Sonnenberg et al. (331) showed that 
absolute proximal transport did not change during VE and suggested that excretory 
responses are due to changes at the distal parts of the nephron.  
Natriuretic peptides are stored in cardiomyocytes and are released in response to 
stretch of the cardiac wall. ANP is the most abundant natriuretic peptide, which binds 
to natriuretic peptide receptor A located in the kidney to boost diuresis and natriuresis 
(378). During VE, it was suggested that ANP mediates natriuresis by acting on the 
distal segment of the nephron (23). In the current study, the magnitude of ANP 
increase during VE was less in CIH-exposed rats compared with sham rats. In a 
previous study, VE in anaesthetized rats resulted in diuresis and natriuresis in the 
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presence of increased plasma ANP (308), similar to our observation. In another group 
of rats, synthetic ANP bound to bovine thyroglobulin was injected to produce 
antibodies and autoimmunity to ANP. These rats had no increases in water and sodium 
excretion during VE (308). Interestingly, bilateral removal of atrial appendages 
resulted in no change in plasma ANP and eliminated the diuretic and natriuretic 
responses (308), indicating that renal excretory responses to VE in anaesthetized rats 
is dependent upon ANP. A previous study from our laboratory has shown that 
exposure to the same CIH protocol was associated with hypertrophy of the right and 
left interventricular septum, and increased cardiac output (226). Thickening of the 
right side of the heart is usually caused by pulmonary hypertension, which was 
observed following exposure to a different protocol of CIH (255). VE studies indicated 
that volume receptors are located in the left and the right atria of the heart. Therefore, 
the presence of hypertrophy and apoptosis of cardiomyocytes, which was observed 
previously in a CIH model (388), suggests that the attenuated release of ANP in CIH-
exposed rats during VE might be related to decreased elasticity of the heart. 
Meanwhile, the main stimulus for the myocardial stretch and the release of ANP is the 
increase in atrial pressure during fluid overload, which could be different between 
CIH-exposed and sham rats. The measurement of atrial pressure during VE challenges 
was beyond the scope of this study, which requires investigation.  
Of note, however, VE in conscious rats caused diuresis and natriuresis with no change 
in plasma ANP. On another hand, in conscious ANP autoimmune rats, there was a 
similar diuresis and natriuresis response during VE compared with control rats (308). 
Moreover, it has been shown that ANP rises within 5 minutes of VE initiation, whereas 
natriuresis peaked between 15-20 minutes after challenge (25). The latter study 
suggested that ANP is responsible for the initial natriuretic response, whereas the 
subsequent sodium excretion is due to prolonged suppression of RAAS by an ANP-
independent mechanism (378). Based on these studies, blunted diuresis and natriuresis 
responses to VE in CIH-exposed rats are also related to additional factors beyond the 
demonstrated suppressed release of ANP. Changes in other humoral factors such as 
inhibition of ADH secretion and decreased aldosterone levels may also explain the 
diuretic and natriuretic responses (19). Indeed, a more modest CIH paradigm than that 
used in the current study, resulted in up-regulation of ADH receptors in the rostral 
ventrolateral medulla (RVLM) and rostral ventral respiratory column (278). In 
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addition, exposure to CIH for 7 days was sufficient to increase the activity of the 
adrenal gland with marked elevation in aldosterone (289). In relation to that, elevated 
levels of aldosterone was also reported in OSA patients (284). Both ADH and 
aldosterone exert a direct tubular effect on the reabsorption of sodium and water (19).  
In contrast, Brattleboro rats (a strain of rats which lacks the ability to produce ADH) 
showed similar diuretic and natriuretic responses to VE compared with ADH-supplied 
rats under both anaesthetic and conscious conditions (308). In another study, blunted 
natriuresis during VE was attributed to reduced dopamine in healthy rats and elevated 
nitric oxide in diabetic rats (134, 379). However, this is a weak argument regarding 
the CIH model, as elevated dopamine levels and reduced nitric oxide bioavailability 
were reported after CIH exposure (22, 171). Nonetheless, further studies are required 
to explore further mediators that account for impaired diuresis and natriuresis in the 
CIH model. 
In summary, we exposed rats to 14 days of CIH which was not associated with 
significant changes in basal kidney function but resulted in blunted diuresis and 
natriuresis in response to fluid overload. Exposure to CIH for longer durations was 
associated with marked deterioration of kidney function at basal levels including 
increased serum creatinine level, proteinuria and decreased GFR (9, 303). It is likely 
that impairment in kidney function in CIH models develops gradually and originates 
from a combination of factors that are directly related to hypoxia and as a major player, 
a vicious cycle of sympatho-excitation and hypertension.  
 
4.3.3. Blockade of TRPV1 channels 
A subgroup of afferent renal nerves are positively labeled with TRPV1 channels, 
which are co-localized with substance P (SP) sensory neurotransmitter in the renal 
pelvic wall (160, 385). In rats, cortico-medullary infusion of the TRPV1 agonist, 
capsaicin, induces an increase in contralateral RSNA (287, 397). Capsaicin also 
increases c-fos labelling in the PVN, where magnocellular neurons responsible for 
ADH release are located (325). Reactive oxygen species (ROS) increase the activity 
of TRPV1 receptors. Acute hypoxia increases the tonic activity of TRPV1, which was 
suppressed using CPZ and Tiron, a membrane permeable ROS scavenger (172). On 
another hand, overnight exposure to chronic hypoxia was associated with reduced de-
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sensitization of TRPV1 channels normally observed during their continuous 
stimulation (304). It was shown that TRPV1 activation decreases cell viability and 
induces apoptosis (343). P38 MAPK-mediated apoptosis is one of the pathways 
activated by TRPV1 receptors, which was also found to be activated in kidney tissue 
of CIH-exposed rats (382). Moreover, endogenous hydrogen peroxide (H2O2) released 
by the activation of renal pelvic NADPH oxidase 4 (NOX4) stimulates TRPV1 
containing afferent renal nerves (216). Therefore, in the CIH model, we investigated 
the role of renal TRPV1 receptors in baroreflex regulation of RSNA during VE, in 
addition to their putative effect on diuretic and natriuretic responses to VE. We aimed 
to target TRPV1 receptors that are involved in the activation of afferent renal nerves. 
Intra-renal infusion of CPZ caused a significant reduction in MAP, but without an 
attendant decrease in RSNA (Table 4.2). CPZ was also associated with increased 
diuretic and natriuretic responses to VE in CIH-exposed and sham rats. However, the 
renal sympatho-inhibitory response (RSNA % of max) to VE after CPZ administration 
was unaffected, both in CIH-exposed and sham rats. The effect of CPZ on the renal 
excretory function in CIH group suggests a potential role of renal TRPV1 receptors in 
CIH-induced impairment of renal excretory function. In the two-kidney, one-clip 
model, unilateral selective denervation of afferent renal nerves containing TRPV1 
channels by high dose of periaxonal application of capsaicin decreased blood pressure 
and attenuated renal cytokines in the clipped kidney (261). In addition, in vitro studies 
showed that TRPV1 activation increases ROS and intra-cellular calcium influx, which 
was associated with enhanced apoptosis. Treatment of H9C2 cardiomyocytes with 
CPZ improved cell viability after hypoxia-reperfusion injury (343). The increased 
basal activity of TRPV1 in response to hypoxia was associated with increased 
amplitudes of TRPV1 currents. This was associated with no alteration in protein 
expression (172), similar to our observation in this study.  
Conversely, other studies have revealed cardiac and renal protective effects of TRPV1 
in an ischaemia-reperfusion injury model because TRPV1 channels are distributed in 
tubules and expressed in the endothelial cells of renal arterioles (57, 160, 210, 401). 
TRPV1 activation by subcutaneous injection of capsaicin after ischaemia-reperfusion 
injury reduced tubular damage and elevated urine to water intake ratio compared with 
healthy rats after high-salt diet (401). This was mediated by arteriolar vasodilatation 
and increased GFR and was completely inhibited when SP and calcitonin gene-related 
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peptide (CGRP) were blocked (210). These conflicting reports suggest that TRPV1 
activation elicits protective effects due to SP and CGRP release, while calcium influx 
provokes pathological consequences (343).  
On the other hand, TRPV1 channels are involved in the sensory mechanism of 
different peripheral organs. They are located in the carotid sinus and the walls of aortic 
arch as part of the mechanosensing mechanism of baroreceptors (341). Vascular 
TRPV1 channels mediate vasorelaxation when activated (418). Accordingly, systemic 
inhibition of TRPV1 and/or gene knockout eliminates the protective activity of 
TRPV1 channels at some peripheral sites. Meanwhile, activation of TRPV1 located at 
other regions, such as kidney and adipose tissue, mediates an excitatory reflex, 
resulting in an increase in SNA (71, 135, 397). Therefore, we surmise that TRPV1 
receptors have dual neural and peripheral (vascular) effects, and the pathological 
deterioration that was observed in TRPV1 knockout mice in cardiovascular disease 
models (57, 368) might be related to the blockade of TRPV1 at sites other than renal 
or adipose tissues. It was found that selective blockade of TRPV1 at the latter induces 
a decrease in SNA with protective consequences. In support of this notion, 
incorporating capsaicin as an agonist into the diet of two-kidney, one-clip rats resulted 
in attenuation of high blood pressure and was associated with enhanced 
phosphorylation of endothelial nitric oxide synthase (eNOS). The co-administration 
of a NOS inhibitor with capsaicin eliminated the protective effects of capsaicin with 
blood pressure values that remained similar to untreated kidney clipped rats (313).  
In the current study, RSNA and renal excretory responses to VE were measured during 
two subsequent challenges. A previous study that was performed in our laboratory has 
shown that the RSNA sympatho-inhibitory response to two successive VE challenges 
were comparable (7). However, the enhanced renal excretory response during the 
second VE might be affected by the preceded first VE. Moreover, we cannot exclude 
the possibility that intra-renal CPZ induced diuresis and natriuresis per se, which was 
independent of RSNA. This effect of CPZ may have contributed to the recovery of 
renal excretory responses to VE in CIH-exposed rats and masked the original 
mechanism contributing to impaired renal excretory function. Therefore, our results 
should be viewed as preliminary and the molecular mechanisms contributing to CIH-





Our study confirmed that the low-pressure baroreflex control of RSNA during VE was 
unaltered in CIH-exposed rats with established hypertension. Notwithstanding, 
sodium and water excretion was blunted following exposure to CIH. Our results 
suggest that exposure to CIH is associated with impaired excretory function, which 
may be relevant to OSA. Blockade of TRPV1 channels increased sodium and water 
excretion during VE in CIH-exposed rats to levels equivalent to shams. Impaired renal 
excretory response to VE in CIH was associated with blunted increase in ANP. Further 
studies are required to examine other humoral factors potentially involved in impaired 
kidney function and to determine conclusively if TRPV1 channels contribute to the 



















Chapter 5: Molecular changes in kidney tissue exposed to 
chronic intermittent hypoxia 
 
 








List of abbreviations 
Ang II  Angiotensin II 
ANP Atrial natriuretic peptide 
CGRP Calcitonin gene-related peptide 
CIH Chronic intermittent hypoxia 
CKD Chronic kidney disease 
CTGF Connective tissue growth factor 
ECM Extracellular matrix 
H2O2 Hydrogen peroxide  
HIF-1α Hypoxia inducible factor-1 alpha 
HO-1 Heme oxygenase-1 
HR Heart rate 
ICAM Intercellular adhesion molecule 1 
IL-6 Interleukin-6 
MAPK Mitogen-activated protein kinase 
NF-κB Nuclear factor kappa B 
NK1 Neurokinin-1 
NO Nitric oxide 
NOX  NADPH oxidase 
NQO1 NADPH quinone dehydrogenase 1 
Nrf2 Nuclear factor erythroid 2-related factor 2 
NTS Nucleus tractus solitarius 
OSA Obstructive sleep apnoea 
PAI-1 Plasminogen activator inhibitor-1 
RAAS Renin-angiotensin-aldosterone system 
ROS Reactive oxygen species 
RSNA Renal sympathetic nerve activity 
RVLM Rostral ventrolateral medulla 
SHR Spontaneously hypertensive rat 
sLTF Sensory long-term facilitation 
SNA Sympathetic nerve activity 
SOD Superoxide dismutase 
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SP Substance P 
TGF-β Transforming growth factor-beta 
TNF-α Tumour necrosis factor-alpha 
TRPV1 Transient receptor potential vanilloid 1 





























Clinical studies have shown that obstructive sleep apnoea (OSA) induces a decline in 
kidney function and accumulating evidence has indicated that OSA alleviation 
improves kidney performance in individuals with chronic kidney disease (CKD) (11, 
21, 410). Repetitive re-oxygenation during hypoxia (i.e. intermittent phenomenon) 
provokes reactive oxygen species (ROS) production and inflammatory cytokine 
release, causing multisystem injury and pathological consequences in different organs 
(146, 273, 342). Previous studies of chronic intermittent hypoxia (CIH) have shown 
oxidative stress and increased inflammatory cytokines in renal tissues (9, 224, 342). 
NADPH oxidase 2 (NOX2) in carotid bodies and NOX4 in kidney tissue are 
upregulated in CIH, promoting the production of ROS (200, 223). NOX activation 
induces hypoxia-inducible factor-1 alpha (HIF-1α) upregulation in kidney, rostral 
ventrolateral medulla (RVLM), nucleus tractus solitarius (NTS) and carotid bodies, 
which regulates the transcription of genes responsible for the release of tumour 
necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and IL-1β (200, 224, 273, 330, 
382, 409). However, it is unclear if renal inflammation results from episodic hypoxia 
per se or if it is secondary to sympatho-excitation and hypertension. Decreased oxygen 
concentration in the kidney enhances ROS production and causes fibrinogenesis, 
which leads to a vicious cycle of hypoxia, causing glomerularsclerosis and proteinuria, 
the primary clinical manifestations of CKD (11). The inhibition of mitochondrial 
release of ROS attenuated kidney damage in diabetic rats (264). Meanwhile, 
sympathetic over-activity increases vascular tone, depletes nitric oxide (NO) and 
causes endothelial dysfunction (345), thus, decreasing kidney oxygen supply. This 
causes renin-angiotensin-aldosterone system (RAAS) activation and increased sodium 
reabsorption. The renal medulla is vulnerable to hypoxia due to high demand of O2 
required for sodium reabsorption in the thick ascending limb of the loop of Henle 
(264). Of note, reduced oxygen tension in renal cortex was observed in a CIH model 
similar to the model used in our study (258).  
Renal denervation in a CIH animal model was associated with attenuation of 
hypertension, and inflammation and oxidative stress in kidney and brainstem regions 
(RVLM, NTS) that are responsible for sympathetic outflow (164). In obese rats, 
impaired baroreflex control of renal sympathetic nerve activity (RSNA) was 
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associated with renal inflammation (170). Treatment with tacrolimus, an anti-
inflammatory agent, eliminated kidney inflammation and restored high- and low-
pressure baroreflex function (170), suggesting that inflammation contributes to 
baroreflex dysfunction and disruption in the autonomic control of blood pressure, 
through a renal nerve-dependent mechanism. 
Immunofluorescence studies have shown co-localisation between TRPV1, NOX4 and 
hydrogen peroxide (H2O2) in the renal pelvic wall (216). H2O2 sensitises TRPV1 
channels and is produced in response to NOX activation and/or decreased expression 
and activity of catalase (216). Moreover, it was shown that the activation of 
neurokinin-1 (NK1) receptor ex vivo stimulates superoxide production with 
subsequent augmentation of capsaicin-induced activation of peripheral neurons (218). 
Of note, sensory long term facilitation (sLTF) of carotid bodies in CIH-exposed 
animals was associated with increased levels of superoxide and H2O2, which was 
abolished by catalase (270).  
Overall, the interaction between sympathetic over-activity and 
inflammation/oxidative stress is evident at peripheral and central sites in CIH models. 
However, each CIH protocol mimics a certain stage of the OSA disorder. Whereas 
many CIH studies have examined kidney pathology, they did not include concomitant 
measurement of sympathetic nerve activity (SNA) and/or blood pressure. The 
mechanism by which kidney injury occurs, i.e. either due to intermittent hypoxia itself 
or secondary to hypertension and sympatho-excitation, or combinations of these 
stressors, remains unclear.  
 
5.2. Results 
5.2.1. Renal histopathological assessment 
Hematoxylin and eosin staining was used to examine glomerular tuft area of ~18 
glomeruli per kidney. The average glomerular tuft area of the CIH-exposed group was 
not different from sham rats (CIH vs. sham; 7364±902 vs. 7831±486 µm2, p=0.219, 
Figure 5.1). A slightly greater degree of fibrosis was observed in the cortex of CIH-
exposed kidneys compared with sham kidneys (CIH vs. sham; 7.47±0.60 vs. 
6.73±0.70%, p=0.04, Figure 5.1b and d). In contrast, there was no significant 
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difference in collagen expression in the outer medulla between CIH-exposed and sham 
kidneys (Figure 5.1c and d).   
 
Figure 5. 1. Renal histology. Representative images from a sham and CIH-exposed 
rat are shown. (a) shows hematoxylin and eosin staining; (b) shows Sirius red staining 
of renal cortex; (c) shows Sirius red staining of renal outer medulla. Scale bar 50 µm. 
Data for glomerular tuft area and percentage fibrotic area are presented in (d) and (e) 
as individual data points for each rat, with box and whiskers plots representing the 
interquartile range and maximum and minimum values. Data from sham (n=8) and 
CIH-exposed rats (n=8) were compared using independent t-tests. Significance was 
taken at p<0.05. 
 
5.2.2. Renal oxidative stress, inflammation and protein oxidation 
The activity of NOX, superoxide dismutase (SOD) and catalase enzymes was 
measured in whole kidney tissue and there was no significant change in the activity of 
these enzymes after exposure to CIH (Table 5.1). Furthermore, there was no evidence 
of greater protein oxidation in the kidneys of CIH-exposed rats (Table 5.1). Cytokine 
concentrations (IL-1β, keratinocyte chemoattractant/growth related oncogene and 




Table 5. 1. Biomarker concentrations in kidney tissue homogenates of sham and 
CIH-exposed rats. 
Parameter Sham CIH p-value 





































Data are expressed as mean±SD. AOPP, advanced oxidation protein products; SOD, 
superoxide dismutase. SOD activity, keratinocyte chemoattractant/growth related 
oncogene and IL-1β concentrations were analysed using independent samples t-test. 
Other biomarkers were analysed using Mann-Whitney test.  
 
5.2.3. Adjunct molecular analysis on renal tissue  
Expression of CGRP and NK1 receptor 
Immunofluorescence labelling showed positive staining of calcitonin gene-related 
peptide (CGRP) in uroepithelium, lamina propria and the muscular layer of renal 
pelvic wall. The percentage of renal pelvic area occupied by positive staining of CGRP 
was equivalent in CIH-exposed and sham kidneys (CIH, 6.8±1.8%; Sham, 5.5±2.5%, 
Figure 5.2a and Figure 5.4i). NK1 was abundant in the outer muscular layer and 
occupied 2.9±0.7% of the total renal pelvic wall area of CIH-exposed kidneys, which 
was equivalent to the percentage of renal pelvic wall area positively labelled with NK1 
in sham kidneys (3.1±0.8%, Figure 5.3a and Figure 5.4j). No labelling was detected 
in negative control images of renal pelvic wall (Figure 5.2b and c; Figure 5.3b and c). 
169 
 
Most of the NK1 fluorescence was co-localised with sensory neurotransmitter CGRP 
in the muscular layer of renal pelvic wall (Figure 5.4c and g). Representative images 
of immunofluorescence of CGRP and NK1 co-labelling in the ureter are provided in 
Figure 8.5 of Appendix I. 
 
Figure 5. 2. Immunofluorescence labelling of CGRP in the renal pelvic wall. 
Immunofluorescence staining of the renal pelvic wall showing CGRP-positive 
labelling of renal afferent nerves. CGRP labelling is distributed from the outermost 
adventitia to the innermost layer of uroepithelium. (a, top) is a representative image 
from a sham kidney and (a, bottom) is a representative image from a CIH-exposed 
kidney. Negative controls demonstrate specificity of the antibodies used in the study 
(b, primary antibody omitted; c, secondary antibody omitted); Blue labelling of nuclei 





Figure 5. 3. Immunofluorescence of NK1 in the renal pelvic wall. 
Immunofluorescence staining of the renal pelvic wall showing NK1 receptor-positive 
labelling. NK1 labelling is mainly located in the outermost muscular layer of the renal 
pelvic wall. (a, top) is a representative image from a sham kidney and (a, bottom) is a 
representative image from a CIH-exposed kidney. Negative controls demonstrate 
specificity of the antibodies used in the study (b, primary antibody omitted; c, 
secondary antibody omitted); Blue labelling of nuclei by DAPI (4, 6-diamidino-2-

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.1 No evidence of kidney injury 
Previous studies of CIH have suggested that protective compensatory mechanisms are 
activated in response to acute oxidative stress in the early phase and/or after short 
duration of CIH exposure (342, 380). Meanwhile, after long-term exposure to CIH, 
anti-oxidative mechanisms become overwhelmed and incapable of maintaining 
efficient oxygen balance, leading to renal fibrosis, tissue peroxidation and 
inflammation (380, 409).  
A relatively moderate paradigm of CIH was utilized in the present study, sufficient to 
elaborate sustained hypertension, yet with only subtle pathological consequences at 
the tissue level (226). Histological assessment in the CIH-exposed rats showed modest 
cortical tubulointerstitial fibrosis, which may relate to decreased cortical oxygen 
tension, reduced renal blood flow and decreased cortical NO previously reported by 
our group using a similar CIH protocol (258). Exposure to more severe protocols of 
CIH (more frequent cycles and/or longer duration) resulted in significant fibrosis 
along with an increase in the expression of transforming growth factor-β (TGF-β), 
collagen type 1 and type IV and connective tissue growth factor (CTGF) (9, 224, 380, 
409). Hypoxia accelerates fibrosis and kidney function deterioration. Genes of 
extracellular matrix (ECM) proteins are activated by ROS, which in turn exacerbates 
hypoxia, causing a vicious cycle (224). Zhang et al. (409) showed that fibroblasts in 
the kidneys of CIH-exposed rats were co-localised with increased expression of CD68 
macrophages. Of note, the susceptibility of tissues to changes induced by CIH varies 
among different animal species. For example, exposure to 30 cycles of CIH per hour 
(5% O2) for 3 weeks was not associated with renal histopathological changes in mice 
(380); meanwhile, a similar protocol induced renal fibrosis and an increase in the 
expression of growth factors after 2 weeks in rats (224).  
In chronic hypertension and when autoregulatory mechanisms are saturated, 
intraglomerular pressure increases (359). The activation of RAAS causes efferent 
arteriolar vasoconstriction through Ang II (359). This eventually causes mesangial 
expansion, which increases glomerular tuft area and develops to glomerulosclerosis 
(143, 399). The increase in glomerular pressure causes an increase in the capillary wall 
strain and promotes the release of ROS and endothelin-1 (100). These factors induces 
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mesangial proliferation and causes an imbalance between glomerular matrix 
generation and degradation (9). Intermittent hypoxia per se, through the generation of 
ROS, increases the levels of growth factors. Chronic hypertension accompanying 
intermittent hypoxia induces structural changes in the glomerulus, as was described in 
severe models of IH (9, 382). However, in our study, no glomerular hypertrophy was 
observed in rats exposed to CIH and had developed hypertension. Nevertheless, 
structural changes might occur at an advanced stage of CIH and hypertension. 
Previous studies have shown that exposure to CIH of more frequent episodes (40 
cycles/hr) or of long duration (>4 weeks) was associated with glomerular hypertrophy, 
mesangial expansion, tubular atrophy and necrosis along with increased blood urea 
nitrogen and serum creatinine (9, 277, 382).  
Although previous CIH studies reported attenuated protein expression of SOD and 
catalase enzymes (224, 277, 381), their enzymatic activities were not altered in the 
CIH model of this study. Moreover, there was no sign of protein oxidation in renal 
tissue of CIH-exposed rats. The differences between results from the current study and 
prior studies, which reported a decrease in anti-oxidant protein expression and an 
increase in pro-fibrotic factors (224, 277, 330, 380), is likely related to differences in 
the CIH paradigm used. In this regard, Wu et al. (380) showed that the protein 
expression of Nrf2, the main defence antioxidant controlling redox signalling, and 
metallothionein, and the mRNA expression of downstream antioxidant genes (HO-1, 
NQO1) were increased following 3-7 days of exposure to CIH (30 cycles/hr, 8% O2, 
12 hr/day) (342). Potentiation of anti-oxidative mechanisms persisted but of lesser 
magnitude after exposure to 1 week and up to 3 weeks of CIH. However, these anti-
oxidative markers were depressed after 3 weeks of CIH exposure to levels lower than 
the sham group. Malonaldehyde, a marker for lipid peroxidation, was significantly 
elevated in renal tissue after 3 and 7 days (342, 380), indicating that kidneys sense 
decreased partial pressure of oxygen at an early stage of exposure to CIH. 
Furthermore, an increase in the levels of the inflammatory markers including ICAM, 
VCAM and PAI-1 was evident after 3 days of CIH (342, 380). However, the lack of 
cardiovascular measurements in these latter studies makes it difficult to propose the 
temporal sequence of renal hypoxia and inflammation, kidney function deterioration 
and hypertension.  
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Inflammatory cytokine concentrations were unchanged or below the level of detection 
in this study. A previous study has indicated that oxidative stress precedes 
inflammation in a model of CIH (146). Treatment with an anti-oxidant eliminated 
oxidative stress and the increase in inflammatory cytokines in carotid bodies. 
However, administration of an anti-inflammatory agent did not abolish the oxidative 
stress (146). In support of this notion, ROS release activates NLRP3 inflammasome, 
which was found in renal tissue of CIH-exposed rats (381). Elevated levels of 
inflammatory cytokines such as nuclear factor-κB (NFκB), TNF-α and IL-1β were 
only reported in studies of prolonged CIH protocols (≥ 21 days) and/or relatively 
severe hypoxia cycles (≥ 30 cycles/hr) (224, 382, 409). Moreover, we did not observe 
changes in NOX activity in renal tissue of CIH-exposed rats. However, NOX4 
upregulation in kidney was described following exposure to another protocol of CIH 
(223). The antioxidant, N-acetyl cysteine, increased renal SOD, decreased blood 
pressure and RSNA in CIH-exposed rats (223). Therefore, it appears that variable 
renal outcomes occur at the molecular level related to the pattern, duration and 
intensity of CIH as summarized in Appendix I, Table 8.1 (15). Nevertheless, we 
acknowledge that many other oxidative signalling pathways/mediators were not 
explored in this model and these could be altered in our model. This includes the 
measurement of the activity of xanthine oxidase enzyme, which is altered in different 
tissues following exposure to severe protocols of CIH (85, 147). Moreover, xanthine 
oxidase and aconitase enzymes activities are altered in other tissues when exposed to 
CIH protocol similar to the one used in this study (249, 271, 375). Anti-oxidative 
biomarkers, other than catalase and SOD, were shown to be altered in different tissues 
following exposure to CIH (152, 342, 375, 380). This includes glutathione peroxidase, 
glutathione reductase and the expression of nuclear factor erythroid 2 (Nrf2), the main 
transcription factor that regulates the expression of antioxidative enzymes. 
Importantly, however, our study revealed that kidney oxidative stress and 
inflammation are not obligatory for the development of CIH-induced hypertension. 
 
5.3.2. Expression of other receptors in the renal pelvic wall 
In the present study, we focused on the role of renal TRPV1 channels in the baroreflex 
control of RSNA. Meanwhile, other receptors located in the renal pelvic wall regulate 
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the release of substance P (SP) and CGRP from afferent renal nerve endings. 
Activation of TRPV1 and bradykinin receptors stimulates the release of SP, which is 
the primary neurotransmitter that binds to NK1 receptors to activate afferent renal 
nerves (15). Down-regulation of NK1 receptor in small dendrites of caudal NTS 
neurons was shown following 10 days of CIH (206). Moreover, in DOCA 
hypertension, NK1 antagonism attenuated proteinuria and tubulointerstitial damage 
(370).  However, we revealed no change in NK1 receptor or CGRP expression in the 
renal pelvic wall of CIH-exposed rats.  
 
5.4. Conclusion 
Overall, a relatively modest CIH paradigm used in this study was sufficient to induce 
hypertension, without evidence of renal inflammation and/or oxidative stress. This 
suggests that pathophysiological changes at the tissue level, when they occur, are more 
likely to be secondary to hypertension rather than a direct effect of exposure to CIH, 
although they may present due to the direct effect of exposure to severe CIH. These 
changes may also arise due to synergistic effects of hypertension and hypoxia at an 
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ANP  Atrial natriuretic peptide 
ADH Antidiuretic hormone 
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In response to low partial pressure of oxygen (PO2), protective mechanisms are 
activated to increase sympathetic nerve activity (SNA) and blood pressure to defend 
against tissue hypoxia. Persistent activation of these protective mechanisms results in 
pathophysiological changes and the development of pathological conditions such as 
hypertension, arrhythmias and stroke. It is suggested that the carotid bodies and the 
kidneys are involved in the adaptive mechanisms in response to low PO2 levels (268). 
Hypoxia (PO2 ~60 mmHg) induces increased activation of glomus cells of the carotid 
bodies which persists in chronic intermittent hypoxia (CIH)-exposed rats even during 
normoxic breathing (270). Type I glomus cells have high oxygen consumption (87), 
such that despite high blood supply to carotid bodies, they are highly sensitive to 
decreased blood oxygen levels. Therefore, enhanced tonic activity of carotid bodies 
and increased responsiveness to acute challenges following hypoxic exposure is a 
well-established mechanism in the development of hypertension in CIH models (74, 
320). In addition, Ashton et al. (18) have shown that perfusion of the kidney with 
hypoxic blood (PO2 ~ 36 mmHg) caused ~ 34 mmHg increase in the femoral perfusion 
pressure. This was eliminated following denervation of the perfused kidney. Indeed, 
in models that involve chronic hypoxia, such as renovascular hypertension, dorsal 
rhizotomy resulted in the attenuation of hypertension (383). Therefore, Patinha et al. 
(268) have proposed that the carotid bodies and kidneys cooperate to induce reflex 
sympatho-excitation and elevated blood pressure in response to hypoxia. In CIH 
models, the decrease in PO2 in kidney tissue is mostly related to endothelial 
dysfunction with subsequent decrease in renal blood flow and oxygen supply, resulting 
in acute hypoxia (125, 215, 345). This was reported in a previous study from our 
laboratory using a CIH model similar to the one used in this study (258), where a 
decrease in cortical PO2 and nitric oxide (NO) bioavailability were observed. 
However, the threshold of PO2 needed for the activation of renal afferent nerves 
remains unknown. Interestingly, it was found that the threshold for the increase of 
femoral perfusion pressure in response to kidney perfusion with hypoxic blood was at 
PO2 of ~ 73 mmHg in rabbits (18), showing an activation threshold higher than that 
needed to activate the carotid bodies. Despite the decrease in renal blood flow and 
GFR reported earlier in CIH, our findings have shown that basal sodium and water 
excretion tend to be higher in CIH-exposed rats, where diuresis was significantly 
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elevated in CIH-exposed rats of cohort 3. These changes in the excretory function 
were against a backdrop of heightened basal RSNA in CIH-exposed rats of all cohorts. 
This suggests the presence of humoral mechanisms that supersede sympathetic over-
activity at rest and encourages kidney excretory function in CIH-exposed rats, 
independent of neural control and renal haemodynamic changes. Our findings have 
shown that the decrease in PO2 in CIH (258) might also be related to increased oxygen 
demand, as the kidney of CIH-exposed rats of this study displayed sodium and water 
retention in response to fluid overload. In support of this notion, it was shown that 
renal denervation in CIH-exposed rats (164) and in individuals with obstructive sleep 
apnoea (OSA) (376) attenuates hypertension for up to 6 months. 
Chemosensory inputs from the kidney and carotid bodies are transmitted to brain 
regions involved in the integration of baroreflex inputs such as nucleus tractus 
solitarius (NTS), paraventricular nucleus (PVN) and rostral ventrolateral medulla 
(RVLM). Many studies have shown that exposure to CIH is associated with 
hypertension, enhanced sensory drive of the carotid bodies and blunted cardiac 
baroreflex gain (74, 75, 122). Whereas it was shown that enhanced carotid body 
activity precedes hypertension development in CIH (75), the temporal sequence of the 
disrupted baroreflex function and the onset of blood pressure elevation remains 
uncertain. Moreover, the contribution of baroreflex control of renal sympathetic nerve 
activity (RSNA) in CIH-induced hypertension remains unclear. Therefore, we 
hypothesised that high- and low-pressure baroreflex control of RSNA and heart rate 
contributes to hypertension development at an early stage of the disease. We used a 
CIH protocol of 12 cycles/hr mimicking mild-to-moderate OSA, causing hypertension 
in rats. We found that high-pressure baroreflex control of RSNA was maintained in 
rats exposed to CIH despite their hypertensive phenotype. Meanwhile, rats displaying 
a higher magnitude of blood pressure elevation (rats of cohort 1), had decreased 
baroreflex control of RSNA, and a clear correlation was found between decreased 
slope of the baroreflex curve and resting levels of blood pressure in CIH-exposed and 
sham rats. Baroreflex control of heart rate was less sensitive to CIH exposure and was 
not modulated in CIH-exposed rats of both cohorts displaying modest or severe 
hypertension. This indicates that cardiac baroreflex control is preserved for a longer 
time during CIH exposure, which could be due to a compensatory mechanism 
mediated by an increase in the parasympathetic activity that has been shown in 
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previous CIH studies (217). In a further study described in this thesis, RSNA response 
to the hypotensive effect of intravenous bradykinin was blunted in CIH-exposed rats 
of cohort 3 and the increase in heart rate was similar in both exposure groups. Our 
findings indicate that blunted baroreflex control of RSNA and heart rate do not 
contribute to the onset of CIH-induced hypertension. However, at severe stages of the 
disease, the protective autonomic baroreflexes become overloaded by the sustained 
hypertension and the persistent sympatho-excitation, leading to dysfunction. This is 
consistent with CIH studies that showed blunted baroreflex control of heart rate after 
long durations of exposure to CIH (122, 217). However, this is in contrast with a 
previous clinical study that showed blunted baroreflex sensitivity in normotensive 
individuals with OSA; however, participants in this study had severe OSA of 50 
apnoeas/hr (65).  
Low-pressure baroreflex control of RSNA, which is blunted in many hypertensive 
disease models (3, 169), was unchanged in our CIH model of mild-to-moderate OSA. 
This indicates that impaired low-pressure baroreflex does not contribute to the 
initiation of hypertension. The assessment of low-pressure baroreflex control of 
RSNA is worth investigating using prolonged CIH exposure or a CIH protocol of more 
frequent cycles of hypoxia. This is relevant to left ventricular hypertrophy observed in 
severe CIH (396, 398) and humans with OSA (21). Although previous studies have 
shown blunted low-pressure baroreflex control of RSNA was associated with 
increased weight of the heart (121), it is not necessary that blunted low-pressure 
baroreflex is related to the resetting in the peripheral cardiac receptors. In this regard, 
the impaired baroreflex is possibly caused by oxidative stress and inflammation in 
brain regions involved in the baroreflex loop (263, 332). However, during the 
assessment of low-pressure baroreflex which showed no change in the renal 
sympatho-inhibitory response to volume expansion (VE), kidney excretory responses 
to VE were impaired in CIH-exposed rats. Meanwhile, basal sodium and water 
excretion in CIH-exposed rats showed an increase compared with sham rats despite 
heightened basal RSNA in the CIH rats. Therefore, we conclude that the diuretic and 
natriuretic response to VE was independent of the neural control of the kidney. The 
impaired diuresis and natriuresis was associated with an impaired increase in the 
plasma level of the atrial natriuretic peptide (ANP) during VE, suggesting a possible 
contribution of decreased ANP to the sodium and water retention in CIH-exposed rats. 
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This notion agrees with a previous study that showed diuretic and natriuretic response 
to VE to be dependent on ANP (308). Nevertheless, impaired diuresis and natriuresis 
could be related to other humoral factors that normally regulate body fluid homeostasis 
including aldosterone and antidiuretic hormone (ADH). Altered humoral control of 
kidney function observed during VE may also be relevant to basal renal function in 
the light of increased diuresis and natriuresis in CIH-exposed rats, which reached 
statistical significance in cohort 3 for water excretion. Moreover, it was shown 
previously that exposure to high altitude decreased ADH and aldosterone levels (112, 
128). This indicates that changes in humoral factors such as decreased ADH and 
aldosterone could be responsible for the augmented excretory function at baseline, 
which counters the effect of heightened basal RSNA. During fluid overload, it is 
known that the physiological response includes an increase in ANP and a decrease in 
ADH and aldosterone (19, 308), and blunted increase in ANP was found in CIH-
exposed rats. This suggests that the humoral system is activated in CIH perhaps near 
to saturation levels compared with shams, and a further decrease in ADH and 
aldosterone could not be attained during fluid overload resulting in impaired diuresis 
and natriuresis.  
Interestingly, denervation of the carotid bodies in CIH-exposed rats resulted in the 
restoration of normal blood pressure and the resetting of the mid-pressure of the 
cardiac baroreflex curve to near normal levels (74). However, the blunted cardiac 
baroreflex gain in response to phenylephrine and sodium nitroprusside was maintained 
following the ablation of the carotid bodies. Moreover, in guinea pigs, which are 
known to be hypoxia insensitive, a blunted bradycardic response to phenylephrine was 
observed after exposure to a mild protocol of CIH (6 cycles/hr, 6.5% O2, 12 days) 
(225). This suggests the presence of other peripheral sensory mechanisms and/or 
central disruption causing alteration in the baroreflex autonomic control.  
Since the kidney is highly sensitive to decreased oxygen levels and a decrease in 
cortical PO2 was shown in this CIH protocol (258), we hypothesized that heightened 
afferent renal nerve activity is responsible for the impaired baroreflex and that the 
interruption of renal afferent nerves restores the impaired baroreflex control of RSNA 
and modulates kidney function. The transient receptor potential cation channel 
subfamily V member 1 (TRPV1) plays a central role in the signalling pathway within 
renal afferent nerve endings (15). In vitro studies have shown that the basal activity of 
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TRPV1 is heightened and their responsiveness to activation is augmented during 
hypoxia (172). Therefore, we targeted intra-renal TRPV1 using capsaizepine followed 
by re-assessment of high-pressure (in cohort 2) and low-pressure baroreflex along with 
kidney function (in cohort 1). Blockade of TRPV1 channels caused potentiation in 
diuresis and natriuresis in CIH-exposed and sham groups. Renal excretory functions 
that were impaired in CIH-exposed rats were enhanced following TRPV1 blockade to 
comparable levels of sham rats. Therefore, we suggest that TRPV1 is involved in the 
impaired kidney functional responses to VE in CIH-exposed rats. However, since the 
RSNA inhibitory response to VE was not impaired in CIH-exposed rats and was not 
modulated by TRPV1 antagonism, we suggest that TRPV1 blockade increased 
diuresis and natriuresis in response to VE through a mechanism independent of RSNA. 
It is worth mentioning that stimulation of renal afferent nerves modulates the activity 
of neurons in the supraoptic nucleus (SON), the brain region that controls ADH release 
(50). However, we could not be conclusive about the effect of TRPV1 blockade on 
high-pressure baroreflex control of RSNA as it was not modulated in the second 
cohort, where rats exposed to CIH had modest hypertension without any modulation 
of the baroreflex gain curve. However, since the activation of TRPV1 in cohort 3 
induced an equivalent symptho-excitatory response in RSNA, it is likely that altered 
high-pressure baroreflex control is related to a mechanism that is independent of 
TRPV1, and the enhanced diuresis during TRPV1 antagonism is related to a 
mechanism independent of neural control of the kidney and/or the reno-renal reflex. 
This is further supported by the observation of no changes in the protein expression of 
TRPV1 in the kidney and the renal pelvic wall of CIH-exposed rats. 
Kidney inflammation and oxidative stress were not evident in CIH-exposed rats in this 
study indicating that the CIH paradigm used herein mimics a moderate stage of OSA. 
This notion is supported by studies in humans showing that OSA is associated with 
chronic kidney disease (CKD) (215). Similarly, rodent models of CIH showed 
proteinuria and renal structural changes (380). Interestingly, our results revealed that 
the development of hypertension in CIH-exposed rats was not associated with evident 
kidney inflammation or oxidative stress. However, the lack of pathological changes in 
the kidney does not exclude the possibility of early pathophysiological changes as 
indicated by decreased renal blood flow and cortical PO2, using the same model in 
another study from our laboratory (258). Moreover, the present study showed impaired 
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kidney function in CIH-exposed rats during fluid overload, indicating the emergence 
of renal dysfunction before the development of renal injury. In addition, it was shown 
previously that endothelial injury biomarkers such as intercellular adhesion molecule 
1 (ICAM) are upregulated within three days of CIH exposure (342, 380). Nevertheless, 
our findings propose that kidney injury occurs at a later stage after the development 
of hypertension in CIH (and perhaps OSA), suggesting that renal pathological changes 
are secondary to hypertension itself, or hypertension in combination with hypoxia. The 
lack of renal inflammation and oxidative stress despite sodium and water retention, 
supports our suggestion of the presence of an external defect that reveals impaired 
diuresis and natriuresis, such as suppressed humoral action. Therefore, there is a time 
lag between OSA and subsequent detrimental changes in the kidney if the individual 
does not have additional kidney complications or confounding stressors. This suggests 
that the treatment of OSA at a moderate stage could delay kidney deterioration and 
could be preventive to the development of kidney injury in individuals who are 
compliant with OSA treatment. A previous study has shown a correlation between the 
rate of decline in kidney function and the compliance of individuals in the use of 
continuous positive airway pressure (CPAP) during a 2 year follow-up period (285).   
Renal stenosis caused an increase in arterial blood pressure and peripheral 
vasoconstriction in cats, rats and rabbits, which were abolished by the denervation of 
the stenotic kidney (18, 44, 94, 295). Thus, the stimuli that cause activation of the SNA 
could be related to pressure and/or flow changes, hypoxaemia or hypercapnia (18). 
Rankin et al. (295) and Ashton et al. (18) have shown that the delivery of hypoxic 
blood into the kidney during constant pressure or flow causes an increase in the 
femoral perfusion pressure, which was not observed during the infusion of 
hypercapnic blood. Intra-renal infusion of aprotinin, an inhibitor of tissue kallikrein, 
during the infusion of hypoxic blood attenuated the increase in femoral perfusion 
pressure (18). In the same study, perfusion of the kidney with normoxaemic blood 
mixed with ischaemic mediators such as bradykinin resulted in ~ 19 mmHg increase 
in femoral perfusion pressure. This indicates that an acute decrease in renal PO2 causes 
the production of ischaemic metabolites, and the latter promote sensory signals out of 
the kidney, leading to reflex increases in the sympathetic outflow and blood pressure. 
Of note, a decrease in renal cortical PO2 was observed after exposure to CIH, similar 
to the protocol used in this study (258). Subsequently, we hypothesised that kallikrein-
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kinin system is altered following CIH exposure and involved in exacerbated 
sympatho-excitatory outcome and blood pressure elevation. Our findings illustrated 
that CIH exposure is associated with alteration in the renal kallikrein-kinin system, in 
particular, in the renal pelvis where bradykinin receptors are involved in the reno-renal 
reflex. This is represented by impaired increase in the contralateral RSNA and heart 
rate during the intra-renal pelvic infusion of bradykinin and decreased expression of 
BK2R in the renal pelvic wall of CIH-exposed rats. The lack of changes in the 
expression of BK1R is consistent with no signs of renal inflammation or oxidative 
stress, which are known to be involved in the upregulation of BK1R. However, the 
absence of any significant changes in the cardiovascular parameters and RSNA in 
CIH-exposed rats during the inhibition of BK1R and BK2R indicate that they do not 
contribute to the tonic reno-renal reflex whether of mechano- or chemo-sensory type. 
This is similar to findings in SHR that showed apparent changes in the renal kinin 
system, but with no change in the afferent renal nerve activity (ARNA) during BK2R 
antagonism in the renal pelvic wall (45, 190). Nevertheless, decreased sympatho-
excitatory response in CIH-exposed rats could be related to two mechanisms. First, 
the lack of increase in RSNA during the activation of bradykinin receptors may have 
been masked by the exacerbated sympatho-excitation in the resting state in CIH-
exposed rats. Second, we suggest the presence of increased renal levels of bradykinin 
that caused the decreased expression of BK2R; thus, decreased responses to activation 
in CIH. Indeed, increased levels of bradykinin was shown in ischaemia and was 
involved in the pathogenesis of hypertension in SHR (18, 45), through decreased 
degradation of bradykinin in the latter. Bradykinin is a pro-inflammatory mediator that 
mediates a protective mechanism in hypertension and ischaemia-reperfusion injury 
through vasodilation (347, 352, 367). Bradykinin increases renal medullary and 
papillary perfusion pressure, and induces pressure diuresis and natriuresis to 
counteract ischaemia (353). However, the renal kinin system activates the chemo-
sensory nerve endings and mediates a sympatho-excitatory effect (18, 29). While it 
was previously shown that the inhibition of BK2R restores the blunted baroreflex 
control of RSNA in rats with cisplatin-induced renal failure (3), the decreased 
sympatho-excitatory response to the activation of BK2R and no changes in the renal 
expression of BK1R in CIH, provide evidence that bradykinin receptors at a mild to 
moderate stage of the disease, do not contribute to RSNA sympatho-excitation and to 
the blunted baroreflex control of RSNA observed in cohort 1 of CIH exposure. 
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Moreover, it remains unresolved whether the presence of a blunted reno-renal reflex 
mechanism in CIH represents a protective physiological mechanism restraining 
sympatho-excitation and blood pressure elevation. 
This is the first study that examined the kallikrein-kinin system after exposure to CIH 
and further studies are required to investigate plasma and renal levels of bradykinin 
and downstream signalling pathways of BK2R. We hypothesized that exacerbated 
excitatory reno-renal reflex contributes to sympathetic over-activity and hypertension 
in CIH. However, our results reveal opposite findings with attenuation in the 
sympatho-excitatory response in CIH. We expect that prolonged or severe protocols 
of CIH would be associated with progressive and different changes in the kallikrein-
kinin system. It was shown that biomarkers of BK1R signalling pathway are 
overexpressed in the renal tissue of rats exposed to severe CIH such as MAPK and 
ERK (342, 380). Moreover, inflammatory mediators such as tumour necrosis factor-
alpha (TNF-α) and interleukin-6 (IL-6) are highly expressed in kidneys after exposure 
to severe or prolonged CIH, known to increase the expression of BK1R (131, 224, 
333, 335, 382). Therefore, the physiological consequences of changes in BK1R on the 
reno-renal reflex in CIH-exposed rats of other models are worth investigating. It was 
shown that increased expression of BK1R is associated with neuroinflammation, 
deleterious effects on kidney function and further elevation of blood pressure (286, 
335, 367). Therefore, we propose that local pathological renal changes through BK1R 
might appear due to inflammation and apoptosis at an advanced stage of CIH driving 
an excitatory reno-renal reflex.  
 
7.2. Limitations 
As in other scientific studies, this study has several limitations. The animal model of 
CIH mimics arterial hypoxaemia, a feature of OSA in humans, without modelling 
other features such as hypercapnia and intra-thoracic pressure changes. Studies have 
shown that hypoxaemia is the primary stimulus responsible for enhanced chemoreflex 
drive and sympathetic over-activity (318, 324, 417). However, central and peripheral 
chemoreceptors are activated by hypercapnia, a feature of apnoea that can contribute 
to sympatho-excitation, but was not included in our model. Moreover, phenotypes 
studied in animals, as in rats of the current study, do not necessarily translate to human. 
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In this study, similar to other CIH studies, we referred to the expression of the 
hypertensive phenotype as a consequence of hypoxia cycles. However, other than 
hypoxaemia caused by hypoxia exposure, rats may have been exposed to other 
ancillary stressors such as sleep fragmentation and acoustic stimuli during the infusion 
of nitrogen and oxygen into the chambers to manipulate environmental oxygen, which 
may have contributed to anxiety and blood pressure elevation in CIH-exposed rats. 
However, separate work by our group reported no change in plasma corticosterone 
concentration in rats exposed to CIH (257), revealing the manifestation of 
hypertension without a requirement for a persistent elevation in a key stress hormone. 
Furthermore, data were collected from anaesthetized rat preparations. As such, 
cardiovascular, renal, and autonomic-related outputs were altered compared with the 
conscious state. The use of anaesthesia such as urethane was shown to induce 
respiratory acidosis (404), which was observed in sham and CIH-exposed rats of 
cohorts 2 and 3. Nevertheless, respiratory acidosis was comparable between CIH-
exposed and sham rats in both cohorts. Sodium pentobarbital anaesthetic, which has a 
fast action and which was only used as part of the induction phase in this study was 
shown to blunt the autonomic nervous system in earlier reports (322, 377). Urethane 
anaesthetic which was utilized for induction and maintenance of anaesthesia in the 
present study, was shown to preserve the autonomic baroreflex control of RSNA 
(322). 
It is worth noting that I was not blinded to the identity of the experimental groups 
during surgical protocols. Furthermore, I was not blinded during ELISA, 
histopathological or immunofluorescence studies. However, I was fully blinded during 
the analysis of the in vivo data. I was also blinded during the capture and analysis of 
images for histology and immunofluorescence.  
ELISA was conducted on full kidney tissue homogenates rather than isolated renal 
pelvic wall. This is because the amount of protein extracted from whole renal pelvic 
wall is 2 to 3 times less than the amount of protein extracted from a fraction of full 
kidney tissue. Therefore, it was difficult to carry out a wide range of analyses of 
inflammatory and oxidative stress biomarkers on homogenates of renal pelvic wall. 
Rather, we were homogenized the middle part of the kidney which includes the renal 
pelvic wall along with cortex and medulla. This is considered a significant limitation, 
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as shown in the analysis of bradykinin receptors, where renal pelvic wall homogenates 
showed different outcomes from the same analysis in kidney tissue homogenates 
(Figure 5.5). In addition, we quantified relative area occupied by the positive 
immunofluorescence labelling of TRPV1, calcitonin gene-related peptide (CGRP) and 
neurokinin 1 (NK1) receptor, which shows protein abundance in the renal pelvic wall. 
However, we did not quantify protein expression in terms of integrated density of 
immunofluorescence because each image with z-stacks has a different threshold that 
is set manually and is therefore subjective. Thus, in addition to immunofluorescence, 
we carried out ELISA to accurately quantify protein expression of TRPV1 and 
bradykinin receptors, but this was mostly in kidney homogenates. 
Intra-renal administration of capsaizepine was unilateral, which might not reflect the 
full biological effect of TRPV1 antagonism. Unilateral infusion of drugs has been used 
effectively in other studies of baroreflex function (2, 3). In the present study, unilateral 
capsaizepine produced a decrease in basal blood pressure and produced changes in 
renal function suggesting efficacy; nevertheless, the effects of bilateral TPRV1 
inhibition is worthy of further investigation.  
Our study design involved the assessment of RSNA and renal excretory responses to 
VE in successive challenges, before and after intra-renal TRPV1 blockade. We 
acknowledge that restoration of renal excretory responses to VE in CIH-exposed rats, 
which was attributed to blockade of TRPV1 receptors, might relate to the performance 
of a second VE trial per se, independent of antagonism. Similarly, the attenuation in 
the RSNA response to 700 µM bradykinin during BK1R antagonism and further 
during the second phase of combined BK1R and BK2R antagonism, could be related 
to the sequential infusion of bradykinin and desensitization of receptors. For the 
assessment of dose-response relationships, we randomized the order of infusion of 
different concentrations of bradykinin to minimize the possible effect of 
desensitization. Our data regarding kidney function responses to intra-renal pelvic 
infusion of bradykinin and capsaicin is limited due to the short duration of infusion. 
Longer duration of infusion would allow assessment of contralateral sodium and water 
excretion responses at steady-state, and would facilitate greater urine volumes to be 
collected from a single kidney for the analysis of other parameters. In support of this, 
it was shown that renal stenosis induces peripheral vasoconstriction that displayed 
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onset latency of 28 seconds in rabbits and 38 seconds in rats (295, 298). We also 
acknowledge that sample size for the analysis of bradykinin receptors in the renal 
pelvic wall is small and therefore the data needs to be interpreted with caution. 
Our data on glomerular filtration rate (GFR) during VE should be viewed cautiously 
given that blood sampling was limited as we did not wish to interfere with blood 
pressure, and hence reflex control of RSNA, during VE challenges. As described in 
the methods, plasma samples were collected immediately before the start of VE (P2) 
and immediately at the end of VE (P3, when Uve5 was collected, 30 minutes of VE). 
Inulin concentration in the two blood samples were averaged and used to estimate 
GFR during the 30-minute challenge of VE. We did not collect plasma samples in the 
middle of urine collection phase i.e. during VE, although we acknowledge that it 
would be more accurate to do so. Altogether, we determined that it was more important 
to avoid manipulating blood pressure during VE challenge. On another hand, 
repetitive collection of blood samples during VE was associated with decreased 
haematocrit in CIH-exposed and sham rats before the start of the second VE phase 
(capsaizepine phase) (Table 8.4). We suggest that the decrease in haematocrit did not 
interfere with our results as the VE-induced haemodilution was comparable between 
the first and second VE challenges in CIH-exposed and sham rats, as shown in Figure 
8.4. 
Meanwhile, there are other limitations to the conclusions drawn from the study. We 
used a CIH paradigm that mimics mild-to-moderate OSA in humans to examine if 
baroreflex control of RSNA and heart rate, and kidney impairment contribute to the 
manifestation of hypertension. We were able to conclude that modulation of high- and 
low-pressure baroreflex control of RSNA are secondary to hypertension and are not 
associated with the development of hypertension in CIH. Moreover, renal function 
was altered in response to fluid overload despite no signs of oxidative stress or 
inflammation. This indicates that the kidney has an early response to hypoxia, but 
renal stress is not a major player in the development of hypertension in this model. 
However, since our model was associated with hypertension, the use of a shorter 
duration of CIH protocol to avoid the development of hypertension in rats, could be a 
useful model to test our hypothesis if renal impairment contributes to the manifestation 
of hypertension. Similar to other studies, studying the cardiorespiratory and autonomic 
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outputs after exposure to CIH at one time point shows only a snapshot of the whole 
spectrum of changes that manifest in response to exposure to CIH. As such, the lack 
of evidence of oxidative stress and inflammatory markers observed in this model 
illustrates an outcome after exposure to CIH for 14 days. However, the levels of these 
biomarkers could be oscillating at different time points before their measurement at 
day 15. In addition, we did not measure all oxidative stress markers and inflammatory 
cytokines; therefore, other markers could be altered within two weeks of exposure, as 
reported in other studies that showed elevation of endothelial dysfunction biomarkers 
within three days of exposure to severe CIH (30 cycles/hr) (277, 342). 
 
7.3. Future studies and knowledge gaps 
We studied baroreflex control in CIH-induced hypertension and concluded that 
baroreflex impairment does not contribute to the onset of hypertension. Moreover, we 
have seen that the activation of renal afferent nerves through bradykinin receptors 
reveals blunted sympatho-excitatory response in CIH and similar sympatho-excitation 
to sham rats in response to capsaicin. Therefore, it is less likely that renal afferent 
nerves increase sympathetic over-activity at the mild to moderate stage of CIH 
contributing to the onset of hypertension. However, it remains open to investigation if 
renal afferent nerves augment sympathetic over-activity in severe CIH and thus 
contribute to the exacerbation of hypertension. It would be interesting to determine if 
the excitatory reno-renal reflex contributes to the progression of hypertension in CIH-
exposed rats. One potential approach is the use of selective renal deafferentation using 
the capsaicin gauze technique (101) before CIH exposure. Following exposure to 
severe CIH, the measurement of cardiovascular, autonomic and renal parameters in 
denervated and non-denervated rats would illustrate if renal pelvic chemosensory 
mechanisms contribute to hypertension at a later stage of OSA in cooperation with the 
enhanced chemosensory activity of the carotid bodies. It would also be very interesting 
to use the same experimental design to study the cardiovascular, autonomic and renal 
outcomes in guinea pigs which are known to have insensitive carotid bodies to 
hypoxia, yet they develop hypertension in response to severe CIH. The latter 
experiment would determine if there are peripheral sensory inputs from the kidney 
and/or from other peripheral sites that contribute to the autonomic disruption observed 
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in CIH. Of note, exposure of guinea pigs to a mild protocol of CIH caused decreased 
bradycardic response to phenylephrine (225). Moreover, guinea-pigs-exposed to 30 
cycles/hr for 30 days was associated with hypertension and an increase in heart rate 
(84). These findings reveal a role for other peripheral sensory inputs or perhaps 
aberrant CNS plasticity that contributes to disrupted autonomic control of blood 
pressure and vascular tone despite the insensitivity of the guinea pig carotid bodies to 
hypoxia and evidence that there was no sensitization of the carotid bodies following 
CIH exposure (84). Therefore, renal deafferentation in guinea pigs prior to CIH 
exposure would determine if afferent sensory signals from the kidney are responsible 
for the disrupted autonomic control observed after CIH exposure.  
We found that the RSNA sympatho-inhibitory response to VE was not changed 
following exposure to CIH, showing preserved low-pressure baroreflex control. 
However, left ventricular hypertrophy and structural cardiac changes were evident in 
humans with OSA (21) and in animals exposed to severe or prolonged CIH protocols 
(396, 398). Therefore, low-pressure baroreflex might exacerbate hypertension at a 
later stage of disease progression. Ours is the first study to examine the low-pressure 
baroreflex in CIH model and it would be of value to conduct baroreflex assessment in 
other protocols of CIH that mimic severe OSA. It would be of interest to measure 
ADH and aldosterone during the assessment of the low-pressure baroreflex. Moreover, 
antagonism of renal TRPV1 enhanced diuresis and natriuresis in CIH-exposed and 
sham rats. Therefore, we suggested that TRPV1 might be involved in the impaired 
renal excretory response to VE in CIH-exposed rats and we recommended that this 
suggestion should be considered with caution because the antagonism of TRPV1 also 
enhanced diuresis and natriuresis in sham rats, and the activation of TRPV1 by 
capsaicin induced a similar excitatory RSNA response in CIH-exposed and sham rats. 
Therefore, it could be that TRPV1 caused diuresis and natriuresis through a local renal 
effect independent of the reno-renal reflex. To confirm the role of TRPV1 in CIH-
induced renal dysfunction, it would be interesting to use transgenic animals with a 
conditional knockout of renal TRPV1 channels to examine kidney functional 
responses to VE following exposure to CIH.  
Previous studies have shown that bradykinin receptors, as a part of the reno-renal 
reflex mechanism, modulate baroreflex control of RSNA and mediate a sympatho-
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excitatory effect (3, 18, 29). Bradykinin and bradykinin receptors were not previously 
studied in the CIH model. We showed that protein expression of bradykinin receptors 
in the kidney is not changed following CIH exposure. However, BK2R tends to be 
down-regulated in the renal pelvic wall of CIH-exposed rats along with suppressed 
increase in RSNA during the activation of bradykinin receptors. Further testing of a 
bigger sample size is required to confirm down-regulation of BK2R in the renal pelvic 
wall. Moreover, it would be interesting to determine whether the impaired RSNA 
response is physiologically related to suppressed sensory signalling or to other parts 
of the reno-renal reflex loop, such as modulation in the efferent sympathetic pathway. 
This can be investigated by direct recording of ARNA during bradykinin infusion to 
determine whether the afferent arm of the reno-renal reflex is compromised. In 
addition, an ex-vivo study of the renal pelvic wall to measure substance P release 
before and after the infusion of NK1 receptor blocker, BK2R agonist and 
phosphokinase C activator would illustrate if the sensory signalling pathway of BK2R 
is responsible for the impaired RSNA response to bradykinin infusion. It would also 
be interesting to further explore the putative role of BKR1. Following exposure to 
severe and prolonged CIH, it was shown that oxidative stress biomarkers and 
inflammatory cytokines accumulate in the kidney which are known to activate and up-
regulate BK1R (15, 131, 224, 333, 335, 382). Since BK1R are involved in pathological 
signalling at the level of renal tissue in hypertension, one expects exacerbated 
sympatho-excitation through BK1R in renal sensory nerve endings. Therefore, a study 
of the reno-renal reflex through BK1R is worthy of investigation to explore OSA-
related altered autonomic and cardiovascular outputs at a severe stage of the disease. 
 
7.4. Conclusions  
Moderate exposure to CIH resulted in hypertension and increased sympathetic 
outflow, with changes in kidney excretory function. CIH exposure, which caused renal 
sympatho-excitation in rats, was associated with enhanced basal diuresis and 
natriuresis. This suggests the presence of a compensatory mechanism that maintains 
basal sodium and water excretion at comparable levels to shams despite increased 
basal RSNA. Meanwhile, water and sodium retention were revealed in CIH-exposed 
rats in response to fluid overload, despite preserved RSNA sympatho-inhibitory 
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response to VE, associated with suppressed plasma [ANP]. This suggests altered 
humoral control of body fluid homeostasis contributing to renal excretory dysfunction 
during VE. Impaired diuresis and natriuresis in response to VE was alleviated 
following the inhibition of renal TRPV1 channels, suggesting that renal TRPV1 
receptors might contribute to sodium and water retention during fluid overload in CIH-
exposed rats, which requires further investigation. Mimicking an early stage of OSA, 
using a moderate protocol of CIH in this study, we showed that the high-pressure 
baroreflex control of RSNA and heart rate do not contribute to the onset of 
hypertension; rather, impaired baroreflex control of RSNA is secondary to 
hypertension. Moreover, renal histology and the analysis of biomarkers showed that 
kidney inflammation and oxidative stress were not essential for the development of 
hypertension in CIH, which is neurogenically-driven. Interestingly, the responsiveness 
of RSNA and heart rate to renal afferent nerve excitation, using the ischaemic 
metabolite, bradykinin, were blunted following CIH exposure. This was associated 
with decreased expression of BK2R in the renal pelvic wall with no change in the 
expression of BK1R. This suggests an attenuated excitatory reno-renal reflex at mild 
to moderate stage of the disease, suggesting a compensatory protective mechanism 
restraining the heightened efferent RSNA. Therefore, our findings indicate no 
pathological contribution of the reno-renal reflex at mild to moderate stage of CIH, 
suggesting it does not likely contribute to the onset of hypertension. Overall, sensory 
and local pathophysiological changes in the kidney are not obligatory for the 
development of hypertension in CIH, while further studies are required to examine the 
role of reno-renal reflex mechanisms in the progression of hypertension at later stages 
of the disease. This may have clinical implications in the consideration of OSA and 
CKD, indicating that early intervention to alleviate upper airway obstruction during 
sleep in hypertensive individuals with OSA might be required to prevent renal 
pathophysiological changes and progression to CKD, in the absence of other kidney-
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Figure 8.1. High-pressure baroreflex control of RSNA and HR using the five-
parameter model. Data (meanSE) are shown for RSNA (% of baseline, sham, n=9; 
CIH, n=9) or HR (sham, n=9; CIH, n=6) as a function of arterial blood pressure using 
the five-parameter model in the first cohort. Index of asymmetry was calculated using 
baroreflex parameters obtained from the five-parameter logistic equation and is 
expressed as mean±SD. A simple one-sample t-test was used to analyse if the index of 
asymmetry was not different from zero in CIH-exposed and sham rats. Data for 
baroreflex parameters are shown below in table 8.2. RSNA, renal sympathetic nerve 




















Table 8.2. High-pressure baroreflex parameters of RSNA and HR in sham and 
CIH-exposed rats of cohort 1. 




RSNA baroreflex  HR baroreflex 
A1 (% or beats 
min-1) 
85±33 103±36 0.317 85±33 103±36 1.000 
A2 
(mmHg-1) 
-0.18±0.14 -0.14±0.10 0.550 -0.18±0.14 -0.14±0.10 0.157 
A5 (mmHg-1) -0.16±0.13 -0.26±0.55 0.442 -0.16±0.13 -0.26±0.55 0.077 
A3 (mmHg) 106±5 113±13 0.188 106±5 113±13 0.480 
A4 (% or beats 
min-1) 
34±21 29±23 0.656 34±21 29±23 0.239 




-3.2±2.1 -4.2±5.4 0.798 -3.2±2.1 -4.2±5.4 0.239 
Data are expressed as mean±SD and represent baroreflex parameters of RSNA (sham, 
n=9; CIH, n=9) and HR (sham, n=9; CIH, n=6) of cohort 1 obtained from the five-
parameter equation. Data were analysed using independent samples t-test or Mann-
Whitney test. CIH, chronic intermittent hypoxia; RSNA, renal sympathetic nerve 
activity; HR, heart rate; A1, response range of RSNA; A2 and A5, gain (curvature) 
coefficients; A3, midpoint pressure of input; A4, the minimum response. Maximum 
gain was obtained by the calculation of the average of the two curvature parameters 






















Sham (surgical cohort 1)
CIH (surgical cohort 1)
Sham (cohort 3)
CIH (cohort 3)
Sham (surgical cohort 2)
CIH (surgical cohort 2)
Sham (surgical cohort 3)
CIH (surgical cohort 3)
 
 
Figure 8. 2. Body weights recorded during 14 days of CIH and normoxia (sham) 
exposure. Data are presented as mean in grams (g) of rats’ body weights on each day 
of cohort 1 (sham, n=10; CIH, n=10), cohort 2 (sham, n=12; CIH, n=10), cohort 3 




















Table 8. 3. Body weight gain parameters during 14 days of CIH and normoxia 
(sham) exposure. 
 












2.9±0.8 2.1±0.5* 0.021 3.3±0.4 2.4±0.6*** <0.0001 
% weight gain 
15.8±3.2 8.61±2.2*** <0.0001 15.6±2.1 12.3±2.2** 0.003 
Body weight 
after day 14 of 
exposure (g) 
319±32 320±17 0.805 321±19 312±28 0.419 
 












3.5±1.1 2.1±0.9 0.001 3.7±0.7 2.5±0.5** 0.002 
% weight gain 
17.8±6.5 10.1±5.8 0.002 12.2±2.6 19.4±3.1*** <0.0001 
Body weight 
after day 14 of 
exposure (g) 
320±30 293±32 0.028 330±29 298±18* 0.010 
Data are presented as mean±SD. Weight gain parameters are expressed as slope of 
body weight increase per day and percentage of weight gain after 14 days of exposure 
from basal body weight (day 0). Parameters were compared between sham and CIH 












Table 8. 4. Haematocrit and blood gases analysis of surgical cohort 1 and cohort 
2. 
 
Cohort 1   
 Saline CPZ   
 
Sham CIH p-value Sham CIH p-value 
pH 7.34±0.03 7.35±0.03 0.442 7.32±0.04 7.33±0.04 0.745 
PO2 (mmHg) 62.8±7.9 67.0±7.8 0.296 71.0±7.0 71.6±10.0 0.878 
PCO2 (mmHg) 35.6±5.7 36.8±6.2 0.699 33.9±2.8 35.4±4.6 0.405 
[HCO3-] (mmol L-1) 19.3±3.4 20.3±2.5 0.531 17.5±1.7 18.4±1.9 0.290 
Base excess (mEq L-1) -6.5±3.6 -5.4±2.3 0.500 -8.5±2.2 -7.6±2.1 0.405 
Haematocrit (%PCV) 40.6±5.0 42.6±2.8 0.239 36.5±4.8 37.1±3.2 0.757 
 Cohort 2   
 Saline CPZ   
 Sham  CIH  p-value Sham CIH p-value 
O2 supply (%) 29.3±1.1 27.8±0.3* 0.002 29.2±1.5 28.0±0.5* 0.013 
pH 7.27±0.01 7.30±0.03 0.021 7.29±0.03 7.30±0.04 0.482 
PO2 (mmHg) 91.1±8.6 95.4±6.9 0.252 90.5±7.1 94.0±10 0.586 
PCO2 (mmHg) 55.6±6.7 50.1±4.8 0.103 54.1±4.1 47.3±5.0* 0.003 
[HCO3-] (mmol L-1) 25.7±2.4 24.6±1.8 0.350 26.4±1.9 23.2±2.0* 0.003 
Base excess (mEq L-1) -1.3±2.3 -1.6±2.3 0.802 -0.3±2.1 -3.2±2.3* 0.013 
Haematocrit (%PCV) 43.6±1.4 44.3±2.6 0.360 42.7±2.6 42.1±3.1 0.762 
Data are presented as mean±SD and were compared using independent samples t-test. 
In cohort 1, blood samples were taken before the beginning of the saline and CPZ 
volume expansion challenges. In cohort 2, blood samples were taken before the 
injection of phenylephrine after the intra-renal infusion of saline and the intra-renal 
infusion of CPZ. In cohort 2, sham rats (n=10) were provided with a higher percentage 
of oxygen to reach an oxygen tension (PO2) above 80 mmHg compared with CIH-
exposed rats (n=10). O2 supply represents % of pure oxygen gas mixed with pure 
nitrogen gas. PO2, partial pressure of oxygen in arterial blood; PCO2, partial pressure 
of carbon dioxide in arterial blood; [HCO3
-], bicarbonate concentration in arterial 
blood; PCV, packed cell volume; CPZ, capsiazepine. * p<0.05 compared with 
corresponding value of sham group. 
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Table 8. 5. Haematocrit and blood gases analysis of surgical cohort 3. 
 
Cohort 3   
Before infusion of bradykinin Before infusion of capsaicin 
 
Sham CIH p-value Sham CIH p-value 
O2 supply (%) 27.2±1.6 25.8±2.1 0.082 27.3±1.6 24.4±2.5 0.289 
pH 7.31±0.04 7.35±0.04* 0.021 7.32±0.03 7.34±0.05 0.178 
PO2 (mmHg) 101±10 101.5±11.9 0.296 101±9 98±9 0.412 
PCO2 (mmHg) 52.8±5.7 48.6±4.3 0.059 49.0±5.9 47.7±7.8 0.673 
[HCO3-] (mmol L-1) 26.8±2.6 26.8±1.5 0.986 25.0±2.4 25.8±1.9 0.445 
Base excess (mEq L-1) 0.5±2.8 1.2±1.9 0.513 -1.2±2.6 0.0±1.9 0.269 
Haematocrit (%PCV) 43.3±3.8 45.8±2.3* 0.044 39.8±3.3 44.1±2.8* 0.006 
Data are presented as mean±SD and were compared using independent samples t-test 
or Mann-Whitney test. Blood gases were analysed before the infusion of bradykinin 
and another blood sample was analysed before the infusion of capsaicin. CIH-exposed 
rats (n=11) were less acidotic with elevated haematocrit compared with sham rats 
(n=12). O2 supply represents % of pure oxygen gas mixed with pure nitrogen gas. PO2, 
partial pressure of oxygen in arterial blood; PCO2, partial pressure of carbon dioxide 
in arterial blood; [HCO3
-], bicarbonate concentration in arterial blood; PCV, packed 












Table 8. 6. A comparison of basal cardiovascular parameters and RSNA between 
sham and CIH-exposed rats of cohort 1 and 2. 
After arterial cannulation (before renal surgical instrumentation)  
 MAP 
(mmHg) 
HR (beats min-1)    
Cohort 1  
Sham 124±13 432±28    
CIH 143±7 ɸ 461±39    
Cohort 2  
Sham 115±11 ɸ* 411±29*    
CIH 127±9 ɸ*    425±41*    
2X2 ANOVA      
Cohort P<0.001 P=0.010    
Exposure P<0.001 P=0.087    
Exposure X cohort P=0.222 P=0.630    
After stabilization (after renal surgical instrumentation)  
 MAP 
(mmHg) 
HR (beats min1) RSNA(% of max) RSNA (µV.s) 
Cohort 1 
Sham 84±9 400±52  17±7 0.66±0.30 
CIH 97±11 445±47 ɸ  36±15 ɸ 1.34±0.73 
Cohort 2 
Sham 103±12* 436±19  24±10 1.39±0.84  
CIH 107±18* 450±34 ɸ b
D32±18 
32±18 ɸ 1.67±0.65  
2X2 ANOVA     
Cohort P=0.002 P=0.121 P=0.789 P=0.486  
Exposure P=0.097 P=0.024   P=0.003 P=0.064  
Exposure X cohort P=0.437 P=0.276 P=0.204 P=0.163  
Data are presented as mean±SD and were collected from the first (sham, n=10; CIH-
exposed, n=9) and second cohorts (sham, n=13; CIH-exposed, n=10). Baseline 
cardiovascular parameters were recorded for 2 minutes after ~4-5 minutes of arterial 
cannulation i.e. before retroperitoneal incisions were performed to expose the kidneys. 
Cardiovascular parameters and RSNA were also recorded for 2 minutes after the 
stabilization period, 1 hour following renal surgical instrumentation. Parameters of 
sham and CIH-exposed rats were compared between the first and the second cohort 
using two-way ANOVA. ɸ p<0.05 compared with sham rats of the same cohort. * 
p<0.05 compared with the same exposure group of cohort 1. CIH, chronic intermittent 
hypoxia; MAP, mean arterial blood pressure; HR, heart rate; RSNA (% of max), renal 
sympathetic nerve activity normalized to maximum activity recorded during 






Figure 8.3. RSNA-MAP baroreflex curves of a sham and a CIH-exposed rat from 
cohort 1 and 2. Each figure shows RSNA (% of baseline) as a function of arterial 
blood pressure in a sham and a CIH-exposed rat of each cohort. RSNA (% of baseline) 
values were binned for every 5 mmHg change in mean arterial blood pressure. 
Therefore, each individual point represents the average of RSNA (% of baseline) 
during a 5 mmHg change in the mean arterial blood pressure. R-squared values show 
goodness of fit of data points around the sigmoidal regression line constructed by the 
four-parameter equation.  Graphs (a) and (b) show the baroreflex curve of a sham and 
a CIH-exposed rat from the first cohort. Graphs (c) and (d) show the baroreflex curve 
of a sham and a CIH-exposed rat from the second cohort. RSNA, renal sympathetic 





Figure 8. 4. Haematocrit changes during VE. Figure (a) shows box and whiskers 
plots where each individual point shows the haematocrit value of one rat either before 
(dark-coloured boxes) or at the end of VE (light-coloured boxes) during intra-renal 
infusion of saline and CPZ. Figure (b) shows box and whiskers plots representing the 
change in haematocrit during VE of sham (n=9) and CIH (n=9) groups during intra-
renal infusion of saline and CPZ. Each individual point represents the value resulting 
from the subtraction of haematocrit at the end of VE from haematocrit prior to VE in 
each rat in the group. All box and whiskers plots display median, first quartile, third 
quartile, interquartile range, minimum and maximum values.  PCV, packed cell 
volume; CPZ, capsaizepine; VE, volume expansion; CIH, chronic intermittent 
hypoxia. Delta changes in haematocrit during VE were analysed using repeated-
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